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Abstract 
 
Human papillomavirus type 16 (HPV16) is a causative agent of cervical cancer. In many 
HPV  induced  cancers  the  HPV  genome  is  present  integrated  into  the  cellular 
chromosomes. Integration of HPV DNA into that of the host promotes genomic instability 
and progression to cancer. Factors that promote integration remain to be fully identified. 
HPV replication during DNA damage is a factor that may promote viral DNA integration. 
HPV  origin  replication  is  investigated  in  the  presence  of  DNA  damaging  agents.  HPV 
replication produces double strand DNA breaks in the viral genome and DNA damaging 
agents such as etoposide will result in double strand breaks in genomic DNA therefore 
creating substrates for viral integration. HPV origin replication during DNA damage is not 
inhibited in vivo and in vitro. In contradiction to these results, replication initiated by the 
SV40 helicase, Large T antigen, is arrested in response to DNA damage and ATR is the 
candidate kinase for mediating the arrest. In order to carry out replication of the viral 
origin, the HPV genome encodes for the E1 protein. E1 forms a di-hexameric helicase 
complex that replicates the viral genome. The failure of E1 to be targeted by ATR/ATM 
allows HPV replication in the presence of DNA damaging agents. Such replication will 
result in double strand breaks in the viral genome ultimately promoting viral integration 
and progression of cervical cancer. 
 
Upon  activation of the DNA  damage  response cellular  DNA  replication  is  stalled.  The 
targets of the DNA damage pathways at the replication fork that result in the inhibition of 
DNA replication are not clearly defined. Evidence has shown that the MCM2-7 cellular 
helicase complex is targeted for phosphorylation by the ATR/ATM kinases and therefore 
LTAg helicase may also be targeted in a similar manner in response to DNA damage. The 
results presented in this thesis support the hypothesis that the replicative helicase is a 
direct target for phosphorylation by the DNA damaging signalling kinases. Using SV40 
replication as a model for eukaryotic DNA replication the results in this thesis show that XXII 
 
LTAg is targeted for phosphorylation by the DNA damage signalling kinases ATR/ATM in 
response  to  DNA  damage.  Large  T  Antigen  protein  levels  decrease  after  prolonged 
treatment  with  etoposide  suggesting that the degradation  may  inhibit  the  replication 
functions of this viral helicase.  
 
To carry out viral replication HPV encodes two proteins, E1 and E2, which interact with 
cellular factors to replicate the viral genome. E2 forms homodimers and binds to 12bp 
palindromic sequences adjacent to the viral origin and recruits the viral helicase, E1, to 
the origin. The regulatory consequences of the E1.E2 interaction have been controversial. 
The data in this thesis demonstrates the ability of E1 to stabilise E2 increasing E2 half life. 
Analysis using a mutant E2 that binds weakly to E1 demonstrates that the stabilisation is a 
consequence of a direct E1.E2 interaction. Furthermore this thesis also demonstrates that 
the presence of E1 results in the redistribution of HPV16 E2 by enhancing its affinity for 
chromatin.  The  E2  protein  tethers  the  viral  genome  onto  the  host  chromatin  during 
cellular mitosis thereby ensuring the distribution of viral episomes into both daughter 
cells. The redistribution of E2 onto chromatin suggests a role for E1 in enhancing HPV 
genome  segregation  functions  by  stabilising  the  association  of  E2  with  mitotic 
chromosomes. E2 also regulates transcription from the viral genome. The data in this 
thesis shows that the E1 protein enhances E2 transcription function in a manner that 
suggests the E1 protein itself can contribute to transcriptional regulation not simply by E2 
stabilisation but by a direct stimulation of E2-mediated transcription. E1 regulation of E2 
function is again dependent on a direct protein-protein interaction. Taken together these 
results suggest that co-expression of E1 with E2 can increase E2 stability, enhance its 
affinity with chromatin and enhance E2-mediated transcription. These consequences are 
discussed with relation to the virus life cycle. 
 Chapter 1: Introduction 
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Chapter 1 – Introduction 
 
1.1 Human papillomavirus 
Papillomaviridae  are  an  ancient  and  diverse  family  of  non-enveloped  DNA  viruses, 
collectively  known  as  papillomaviruses.  Papillomaviruses  infect  a  range  of  species 
including cattle, horses, birds, rabbit and humans causing persistent infections that are 
difficult to treat (Campo, 2002). The taxonomy of 120 papillomavirus has been described 
using sequence comparisons of the L1 open reading frame (de Villiers et al., 2002). There 
are  sixteen  genotypes  of  papillomavirus  categorised.  The  alpha  and  beta  genotypes 
contain the largest number of associated papillomavirus.  All human papillomavirus (HPV) 
have a special affinity for epithelial cells and infection persists in the dividing basal cells of 
the cutaneous or mucosal epithelium. The life cycle is closely linked to the differentiation 
status of epithelial cells. The small circular double-stranded DNA virus naturally exists 
episomally and has the ability to cause a wide range of lesions in humans (Table 1.1). 
 
1.2 Diseases associated with HPV 
There  are  over 120 types  of  papillomavirus  that  have been  identified  that  can  infect 
humans (de Villiers et al., 2004). Symptoms vary or may be absent.  Some types result in 
benign wart like growths on the skin typical of HPV types 1 and 2 (Table 1.1). Flat warts 
caused by HPV5 are most commonly found on the arms, face or forehead.  Abnormal 
immune  function  is  associated  with  the  development  of  a  cancer  called 
epidermodysplasia  verruciformis  (reviewed  by  Dubina  &  Goldenberg,  2009). 
Epidermodysplasia verruciformis (EV) is a rare chronic inherited disease believed to be 
associated with HPV and in particular types 5 and 8 (Majewski et al., 2002; Lane et al., 
2003).  Mutations  in  two  related  human  genes,  EVER1/TMC6  and  EVER2/TMC8,  are 
believed to result in a primary deficiency of intrinsic immunity against HPV types that Chapter 1: Introduction 
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would normally carry little oncogenic risk (Ramoz et al., 2002). HPV infections of the 
cutaneous epithelium are rarely fatal and carry a low oncogenic risk.  
 
Over forty types of HPV infect the mucosal epithelial lining of the anogenital tract and 
other mucosal areas of the body. Mucosal epithelial infection is associated with a range of 
disease from benign anogenital warts to  malignant carcinomas of the genital, oral or 
conjunctival mucosa. Of the types that infect the anogenital tract, two groups can be 
established based on the virus ability to cause malignancy. All of these types belong to 
the alpha genus (de Villiers et al., 2002). ‘High-risk’ (HR) sexually transmitted HPVs include 
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 (Muñoz et al., 2003).They may 
lead to the development of cervical intraepithelial neoplasia (CIN), vulva intraepithelial 
neoplasia  (VIN),  penile  intraepithelial  neoplasia  (PIN),  and/or  anal  intraepithelial 
neoplasia (AIN). The association of HPV and cervical cancer was first suggested by zur 
Hausen in 1975 (zur Hausen et al., 1975). It is now widely accepted that HPV16 and 18 are 
the causative agent of around 70% cervical cancer cases (Muñoz et al., 2004).  
 
The ‘low-risk’ (LR) HPV’s include types 6, 11, 40, 42, 43, 44, 53, 54, 61, 72 and 73. Types 6 
and 11 are the most common and are associated with 90% of genital warts and laryngeal 
papillomas (Gale et al., 1994; Brown et al., 1999; Gale, 2005; Gale & Zidar, 2006; Potocnik 
et al., 2007). Most HPV infections are cleared rapidly by the immune system and do not 
progress to cancer. Papillomas can form weeks to years after contact with HPV infected 
individual. Hosts that are asymptomatic may become unknown reservoirs of infection. Chapter 1: Introduction 
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Table 1.1  
HPV strain  Cell-type  Disease  Oncogenic Risk 
HPV1  Cutaneous epithelial    Common wart 
  Plantar Wart 
Low 
Low 
 
HPV3  Cutaneous epithelial    Flat wart  Low 
 
HPV6/11  Mucosal epithelial    Benign genital wart 
  Recurrent respiratory 
papillomatosis 
Low 
High 
 
 
 
HPV16  Mucosal epithelial    Cervical intraepithelial 
neoplasia 
  Cervical carcinoma 
  Head and neck cancers 
High 
 
High 
High 
 
HPV18  Mucosal epithelial    Cervical intraepithelial 
neoplasia 
  Cervical carcinoma 
  Head and neck cancers 
High 
 
High 
High 
HPV13/32  Mucosal epithelial    Focal epithelial 
hyperplasia (Heck 
disease) 
 
Low 
HPV5  Cutaneous epithelial    Epidermodysplasia 
verruciformis 
High in 
immunocompromised 
host 
Table 1.1 HPV type and associated diseases. Specific HPV types have been selected in 
table 1.1 to highlight the range of diseases the virus can cause in the human host.  
 
 
1.3 Life cycle 
 
HPV gains access to host cells through microabrasions in the epithelium. The target cell is 
the  basal  cells  of the  epithelium  (Egawa,  2003;  Schmitt  et al.,  1996). The basal  layer 
consists of basal epithelial cells including the stem cells of the epithelium. To initiate 
infection  the  viral  capsid  proteins  associate  with  the  primary  receptor,  membrane 
associated heparan sulphate (Giroglou et al., 2001; Joyce et al., 1999). The nature of the 
precise membrane-associated secondary receptor is controversial but there is evidence 
supporting  a  role  of  α6  integrin  (Joyce  et  al.,  1999;  Yoon  et  al.  2001).  Following 
attachment via L1 and L2, endocytosis has been shown to take many hours. The virus Chapter 1: Introduction 
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usually enters via clathrin coated pits or caveolar endocytosis depending on the type of 
papillomavirus (Smith et al., 2007; Hindmarsh et al., 2007).  
 
After exit from the endosome, L2 protein transports viral DNA into the nucleus where a 
complex is formed with promyelocytic leukaemia protein (PML) bodies (Day et al., 1998). 
PML bodies enhance early transcription of the papillomavirus genes (Day et al., 2004). 
Also located within the nucleus are the host cell transcription/replication factors. The 
papillomavirus genome is compact and therefore the virus utilizes its host enzymes for its 
own transcription and replication requirements. The life cycle requires three different 
modes  of  viral  DNA  replication.  The  different  modes  are  termed  ‘‘establishment’’, 
‘‘maintenance’’ and ‘‘amplification’’ (Reviewed in McBride, 2004). Expression of the E1 
and E2 proteins results in viral replication so that the infected cell contains around 20-50 
copies  of  the  episome.  After the  initial  amplification  step,  the  viral  genome  must  be 
maintained in the dividing basal cells to sustain a persistent infection. The virus exists 
episomally and replicates in synchrony with host cellular DNA (Evans et al., 2003).  
 
The  life  cycle  of  HPV  is  strictly  linked  to  the  differentiation  program  of  the  host 
keratinocyte. Infection within the basal layer generates a pool of infected cells. As basal 
cells  divide,  a  daughter  cell  is  produced  that  harbours  episomal  viral  DNA.  This  is  a 
consequence of the E2 protein tethering the viral episome to chromatin during mitosis 
(Skiadopoulos  &  McBride,  1998;  Oliveira  et  al.,  2006).  Post  mitosis,  one  infected  cell 
remains in the basal layer and the other migrates up through the suprabasal layers. The 
migrating cell begins a process of terminal differentiation. In an uninfected epithelium, 
the  migrating  cells  exit  the  cell  cycle.  However  papillomavirus  infected  cells  remain 
mitotically  active  and  they  can  undergo  some  differentiation.  Amplificational  (or 
vegetative) viral DNA replication permits viral genomes to be replicated to a high copy 
number destined to be packaged into the capsid to yield progeny virions (McBride, 2004). 
Some studies have reported that there is a switch in replication strategies of HPV in 
differentiated  cells  and  that  this  partially  explains  the  high  copy  plasmid  number 
detected.  The  switch  in  replication  mode  is  from  bidirectional  theta  replication 
encountered  in  basal  cells  to  a  rolling  circle  mode  in  differentiating  cells  (Flores  & 
Lambert, 1997; Rector et al., 2004).  Chapter 1: Introduction 
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Differentiated cells are withdrawn from the cell cycle therefore the virus relies on the 
proteins it encodes to maintain or induce a pseudo-S phase-like state in order to gain 
access to the cellular replication machinery. The E6 and E7 proteins modulate the cell 
cycle  through  associations  with  the  tumour  suppressors  p53  and  retinoblastoma  (Rb) 
proteins respectively (reviewed by Howley, 2006). The E1^E4 and E5 proteins are also 
translated in a differentiation dependent manner. It has been shown that E1^E4 inhibits 
G2 to M phase transition and that this arrest may play a role in creating an environment 
optimal for viral DNA replication (Davy et al., 2002; Davy et al., 2005). It has also been 
suggested  that  E5  contributes  to  cellular  proliferation  by  cooperating  with  E7.  E5 
enhances  E7-induced  mitogenic  response  and  this  contributes  to  viral  DNA  synthesis 
(Bouvard et al., 1994).  
 
The  L1  and  L2  capsid  proteins  undergo  expression  within  the  granular  layer  of  the 
epithelium (Barksdale & Baker, 1993). Restricting the synthesis of the L1 and L2 antigens 
to the upper layers of the epithelium may aid viral evasion from the immune response. 
The capsid proteins assemble into the icosahedral capsid via assistance from chaperone 
proteins such as heat shock protein 70 (Hsp70) (Chromy et al., 2003; Buck et al., 2005; 
Chromy et al., 2006).  Karyopherins may play a role in papillomavirus capsid assembly 
(Bird et al., 2008). It is unknown whether encapsidation of the viral episome takes place 
during or after capsid formation. The E1^E4 protein then interacts with cellular keratin 
networks to assist viral egression. The nature of the epithelium allows the virion to spread 
through the shedding of outer most cell layers (Figure 1.1). Chapter 1: Introduction 
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Figure 1.1 
 
 
Figure 1.1 HPV life cycle within the epithelium. The different replication modes of the 
virus and where they take place within the layers of the epithelium are highlighted. The 
E1 and E2 proteins are expressed in the establishment and maintenance stages of the 
virus infection within the basal epithelial cells. Within the upper layers of the epithelium 
amplificational  replication  takes  place  which  requires  increased  levels  of  E1  and  E2 
proteins.  The  E5,  E6  and  E7  oncoproteins  and  E1^E4  proteins  are  also  expressed. 
Differentiated epithelial cells exit the cell cycle however these viral proteins create an 
environment that supports amplificational replication of HPV DNA. Within the granular 
layers the L1 and L2 proteins are expressed and form the viral capsid. Papillomavirus 
virions are released through natural sloughing of the epidermis.  
 
 
1.4 HPV16 Genome 
 
Off all the HPV types, HPV16 has the most defined association with malignancy. HPV16 
DNA is not only detected in cancer of the cervix, but also in samples taken from oral and 
oropharyngeal cancer (reviewed in Marur et al., 2010). HPV16 has a 7.9kb circular double 
stranded DNA genome (Figure 1.2). The genome can be split into the three functional Chapter 1: Introduction 
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regions. The first region is a non-coding regulatory region which is known as the Long 
Control  Region  (LCR)  or  Upstream  Regulatory  Region  (URR).  The  LCR  contains  the 
sequences that are responsible for the regulation of HPV replication and transcription 
such as the p97 promoter (Desaintes & Demeret, 1996). The p97 promoter lies upstream 
of the HPV early oncogenes and is only functionally active in human keratinocytes (Cripe 
et al., 1990). The LCR also contains enhancer and silencer sequences as well as binding 
sites  for  cellular  transcription  factors  and  HPV  proteins  (Figure  1.2).  Examples  of  the 
cellular transcription factors that can interact with the LCR include nuclear factor 1 (NF1), 
activator protein 1 (AP1), specificity protein 1 (Sp1) and transcription factor II domain 
(TFIID) (Chong et al., 1990; Chan et al., 1990; Gloss & Bernard, 1990; Chong et al., 1991; 
Tan et al., 2003). The viral origin of replication is also contained within this region. Off all 
HPV ORFs, the LCR contains the least homology between different sub-types of HPV.  
 
The second region contains the ORF’s for the ‘Early’ proteins E6, E7, E1, E2, E4 and E5 and 
occupies over 50% of the virus genome (Zheng & Baker, 2006). The proteins expressed 
from these genes are responsible for viral replication, transcription, evasion of immune 
detection, control of cell cycle and oncogenesis. The third region contains the ‘Late’ ORF’s 
and codes for the L1 and L2 proteins. This region is responsible for the proteins that form 
the capsid of the virus. Directly after each coding region are the polyadenylation sites: 
early pA (pAE) and late pA (pAL). The pAE is situated around nucleotide 4215 (Somberg & 
Swatch, 2010). There are three possible pAL sites within the HPV16 genome situated at 
positions 7285, 7343 and 7680 (Kennedy et al., 1990) but only two are used (Milligan et 
al, 2007). 
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Figure 1.2  
 
 
 
 
Figure 1.2 Map of the HPV16 genome. This diagram represents the main features of the 
HPV16 genomic map. The known viral promoters are highlighted including p97, p542, 
p670, p3397 and p4062. The HPV16 ORFs are represented by open boxes. The pAE and 
pAL and 850 base pair LCR/URR are also indicated. This figure has been modified from 
Somberg & Schwartz, 2010.  
 
 
1.5 Transcription 
 
Transcription  involves  the  use  of  multiple  promoters  to  create  polycistronic  RNA 
transcripts that are capable of encoding the viral proteins at the correct time and place 
throughout the differentiation-dependent life cycle (Hebner & Laimins, 2006). Multiple 
viral mRNA species are created from one DNA strand through alternative splicing and 
alternative polyadenylation (Oberg et al., 2005; Rush et al., 2005). In the initial stages of 
the  HPV  life  cycle  lower  down  in  the  epithelium  layers,  the  early  viral  promoter  is 
activated to express the viral E1, E2, E6 and E7 genes [Hummel et al., 1992; Ozbun et al., 
1997). The multi-functional E2 protein interacts with four E2BSs in the long control region 
(LCR) of the HPV genome.  E2 interaction results in either the activation (at low levels of 
E2) or repression (at high concentrations of E2) of E6 and E7 transcription from the early 
promoter  (Bouvard  et  al.,  1994;  Steger&  Corbach,  1997).  E2  may  repress  the  E6/E7 
promoter by competing with cellular transcription factors or by preventing the assembly 
of a transcription complex on the viral chromatin (Demeret et al., 1994; Dong et al., 1994; 
Tan et al., 1994; Wu & Chiang, 2007).  
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Various promoters have been identified within the second region of HPV16 genome. A 
study  has  described  the  presence  of  a  promoter  in  the  HPV16  E6  ORF  at  nucleotide 
position 542 which controls the monocistronic expression of E7 (Glahder et al., 2003).  As 
HPV-positive cells differentiate, the late promoters are activated in the upper layers of 
the epithelium leading to the expression of the late genes (Hebner & Laimins, 2006). The 
transcripts initiated at and around p670 have a coding potential for the late genes, E1^E4 
protein and the E5 protein (Grassmann et al., 1996; Milligan et al., 2007).  A promoter 
located within the E4 ORF has been identified (Doorbar et al., 1990; Milligan et al., 2007). 
This  promoter in HPV31 has been shown to  regulate late gene expression (Ozbun & 
Meyers, 1997).  There is a promoter  within the 3’ end of the E5 ORF that has been 
suggested to have a role in the differentiation-dependent regulation of capsid protein 
expression (Geisen & Kahn, 1996; Milligane t al., 2007).  
 
The change in viral transcription also involves host cell transcription factors. The cellular 
bromodomain protein (Brd4) interaction with E2 has been shown to be required for both 
E2 transcriptional activation and repression of the viral E6/E7 promoter (Schweiger et al., 
2006; Nishimura et al., 2000; Goodwin et al., 1998). The CCAAT/enhancer-binding protein 
beta  (C/EBPβ)  is  a  key  transcription  factor  that  provokes  chromatin  opening  and  the 
terminal differentiation of keratinocytes. Within the differentiating epithelium it has been 
shown to inhibit transcription from the early p97 promoter and stimulate the p670 driven 
transcription of the HPV16 late genes (Kukimoto et al., 2006).  
 
 
1.6 HPV16 proteins 
 
The process of the transcription and translation of HPV proteins is a complicated and a 
not yet fully understood process. Activation of multiple promoters and alternative splicing 
are vital in order to guarantee the correct translation of viral proteins required during 
different stages on the virus life cycle. The proteins that are expressed from the eight HPV 
ORF’s can be grouped by the roles that they engage in the viral life cycle.  
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1.6.1 The Replication Proteins 
 
The episomal HPV DNA is replicated to different levels depending on the differentiation 
status  of  the  epithelial  cell.  To  support  PV  DNA  replication,  the  virus  encodes  two 
proteins; the replicative helicase E1 and the dimeric origin-binding protein E2. All other 
replication proteins and enzymes required for HPV replication are borrowed from the 
host cell replication machinery.  
 
1.6.1.1 E1 
 
The 68kDa E1 protein is an essential papillomavirus replication factor without which viral 
replication cannot take place (Sarver et al., 1984; Lusky & Botchan, 1985; Yang et al., 
1991; Ustav & Stenlund, 1991).  The E1 ORF retains the most conservation in sequence 
amongst the other papillomavirus ORF (Danos et al., 1983; Clertant & Seif 1984; Lusky & 
Fontaine, 1991; Campione-Piccardo et al., 1991). It is the viral helicase and belongs to the 
family  of  ATPases  associated  with  diverse  cellular  activities  (AAA+)  helicases.  The  E1 
helicase  shares  sequence  homology  and  similar  functional  motifs  with  other  AAA+ 
helicases including the Large T Antigen (LT) of SV40 virus (Park et al., 1994; Mansky et al., 
1997).  The  E1  protein  can  be  split  into  four  domains;  an  N  terminal  domain,  a  DNA 
binding domain, an oligomerization domain and a helicase domain at the C terminal.  
 
The DNA binding, oligomerization and helicase domains of E1 are essential to carry out 
HPV replication (Hughes & Romanos, 1993; Mendoza et al., 1995; Chen & Stenlund, 1998; 
Amin et al., 1999; Enemark et al., 2002). E1 alone possesses minimal DNA binding activity 
however in the presence of E2 the formation of E1-DNA complexes increases (Lu et al., 
1993; Frattini & Laimins, 1994; Sun et al., 1996; Dixon et al., 2000). E2 is the viral helicase 
loading factor. The N terminal domain of E2 binds to the helicase domain of E1 and this 
facilitates E1 interaction with the E1BS within the viral origin of replication (Sarafi and 
McBride, 1995; Yasugi et al. 1997; Sedman et al., 1997) (Figure 1.3 (b)). The E1BS consist 
of an 18bp palindromic sequence that contains multiple overlapping ATTGTT recognition Chapter 1: Introduction 
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sequences for the E1 protein (Holt et al., 1994; Chen and Stenlund, 2001; Titolo et al., 
2003; Auster and Joshua-Tor, 2004). E1 binds to DNA as a dimer (Auster & Joshua-Tor, 
2004). Three closely spaced E2BS that are in close proximity to the E1BS facilitate the 
interaction of the E2 dimers with the E1 dimer (Figure 1.3(a)). Together, they have been 
shown to induce a loop in the supercoiled viral DNA. The extra twist in the DNA creates 
torsional stress that is relieved by denaturing of the AT-rich sequence in the origin (Sim et 
al., 2008). The denatured viral DNA alpha helicase may aid the loading of the E1 proteins 
into a functional hexameric complex. In BPV1 it has been shown that once E1 is recruited 
to the origin the E2 dimers displace from E2BS that are proximal to the E1BS (Sanders & 
Stenlund, 1998). Distal E2BS may continue to act as a reservoir for E1 proteins until the 
formation of the dihexameric complex is complete. 
 
E1 alone possesses a weak affinity for the viral origin. Studies in the Broker and Chow lab 
reveal an interaction between E1 and the chaperone proteins Heat Shock Protein 40 and 
70  (HSP40/70)  (Liu  et  al.,  1998;  Lin  et  al.,  2002).  Using  electrophoretic  mobility  shift 
assays  this  group  identified  that  HSP40  and  HSP70  independently  and  additively 
enhanced E1 binding to the origin of replication. The HSP70 and E1 interaction resulted in 
E1  hexamer  formation  whereas  HSP40  bound  to  E1  resulted  in  the  formation  of  a 
dihexameric E1 complex.  In vitro, HPV11 replication assays where HSP40/70 was also 
expressed  show  an  increase  in  replicated  origin  plasmid  DNA  compared  to  extracts 
without  the  chaperones  (Liu  et  al.,  1998).  Further  investigations  into  the  role  of 
chaperone proteins on the formation of papillomavirus pre-replication complex found 
that E2 partially inhibits E1-mediated DNA origin unwinding. E2 is displaced from an E1-
origin complex by the addition of HSP70 and results in an increase in DNA unwinding. 
These studies suggest that the HSPs play a role in the assembly and activation of the 
unwinding activity of the E1 replicative helicase. Chapter 1: Introduction 
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Figure 1.3  
 
(a) 
 
 
(b) 
 
Figure 1.3 Initiation of E1-E2 mediated replication. (a) Map of E1BS (green box) and E2BS 
(red boxes) within the HPV16 LCR. Part of the L1 and E6 ORF are also indicated on this 
figure. The distances are approximate and not to scale. (b) The E2 dimer binds to E2BSs 
within the viral origin. The N terminal domain of E2 then interacts with the C terminal of 
an E1 dimer. This interaction recruits E1 to E1BS. E2 is displaced, and the hexameric 
helicase  is  assembled.  As  a  result  the  DNA  melts,  unwinds  and  viral  replication  can 
commence (Modified from Hickman & Dyda, 2005). 
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The viral helicase melts and unwinds the alpha helix structure of the viral DNA. In order to 
do this E1 has further activity as an ATPase. E1 hydrolyses adenosine triphosphate (ATP) 
into  adenosine  diphosphate  (ADP)  and  a  free  phosphate  ion.  The  dephosphorylation 
releases energy which then drives the function of the helicase (Enemark & Joshua-Tor, 
2006). The E1 complex can function on a variety of DNA substrates such as linear/circular 
single/double stranded DNA (Yang et al., 1993; Seo et al., 1993) but has a preference for 
‘tailed’ DNA strands, like those seen at replication forks. Each helicase subunit contains a 
beta-hairpin  that  is  projected  into  a  central  channel  formed  when  the  protein 
oligomerizes (Enemark & Joshua-Tor, 2006) (Figure 1.4). This structure is also conserved 
in Large T Antigen helicase complexes (Reviewed by Hickman & Dyda, 2005). The hairpin 
prises apart the DNA strands and makes contact with adjacent nucleotides in a sequential 
matter. Upon ATP hydrolysis each hexamer then translocates bidirectionally by feeding 
the DNA through the central channel with 3’ to 5’ polarity. This results in DNA unwinding 
and gives the cellular replication/transcription machinery access to the viral DNA. Chapter 1: Introduction 
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 Figure 1.4  
 
 
 
Figure 1.4 Structure of the E1 hexameric helicase in complex with DNA and ADP. Ribbon 
representations of two E1 helicase hexamers viewed perpendicular (a) and parallel (b) to 
the channels. (a) The oligomerization domains form a rigid collar, located between the 
AAA+ domains in (a) and projected towards the reader in (b) The DNA in the central 
channel and the ADP molecules at subunit interfaces are depicted in stick representation. 
Each  individual  E1  oligomerization  domain  has  been  lettered  from  A-L.  Images  were 
prepared with Bobscript34 and Raster3D (Enemark & Joshua-Tor, 2006) Chapter 1: Introduction 
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The N terminal domain of E1 spans approximately the first 200 amino acids (Abbate et al., 
2004). Multiple mutagenesis studies using transient replication assays to study the HPV11 
and BPV1 E1 proteins reveal that replication is greatly reduced when the N terminal 
domain is missing (Ferran & McBride, 1998; Sun et al., 1998; Amin et al., 2000). Therefore 
the N terminal domain enhances papillomavirus replication. Further studies have 
suggested that the N terminal domain is involved in the regulation of papillomavirus 
replication. E1 interacts with multiple cellular cyclin/cdks and this interaction requires an 
RXL motif. An RXL motif is a docking site on a protein that recruits cyclin-cdk complexes to 
facilitate the phosphorylation of close proximity Ser/Thr phosphorylation sites (Chen et 
al., 1996). The RXL motif is located within the N terminal domain of the E1 protein (Ma et 
al., 1999). There are four cdk phosphorylation sites within E1 and three of which lie in the 
N terminal domain. Studies on HPV11 E1 have shown that E1 is targeted by cyclins E/cdk 
at cdk phosphorylation sites and that mutations at the sites greatly reduce the efficiency 
of E1 and E2 mediated replication (Deng et al., 2004; Ma et al., 1998).   
 
The N terminal domain contains a conserved nuclear export signal  (NES) (Deng et al., 
2004; Rosas-Acosta & Wilson 2008). The exact role cytoplasmic E1 plays in the viral life 
cycle  is  still  unclear.  Work  from  the  Archambault  laboratory  investigated  the 
phosphorylation of NES sites in regard to E1 cellular location. They used mutagenesis 
studies to show that two cyclin E/A-cdk 2 phosphorylation sites located in and close to 
the NES of HPV31 E1 are phosphorylated and this inhibits nuclear export of E1 (Fradet-
Turcotte et al., 2010). Cyclin E/A-cdk2 kinases are required for S phase entry and cell cycle 
progress (Lees et al., 1992; Dulic et al., 1992). Therefore nuclear import and export of E1 
may restrict HPV replication to that of S phase of the cell cycle. 
 
E1  has  also  been  shown  to  interact  with  chromatin  remodelling  complexes.  This 
potentially alters nucleosome positioning and would allow for efficient procession of the 
replication fork or transcription of viral RNA transcripts.  The N terminal of E1 can to bind 
to  histone  1  (H1).  H1  is  a  linker  histone  that  binds  to  regions  of  DNA  between 
nucleosomes therefore condensing the chromatin into a tightly ordered structure (Thoma 
et al., 1979). H1 bound to viral DNA was displaced by the E1 protein (Swindle & Engler, 
1998). The removal of H1 suggests that E1 alters the structure of nucleosome at the viral Chapter 1: Introduction 
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origin and this may be critical for recognition by the E1-E2 complex in order to initiate 
replication. E1 has also been associated with alterations of chromatin in other studies. 
The switching deficient/sucrose non-fermentable (SWI/SNF) protein complex alters the 
structure  of  chromatin  in  order  to  transcriptionally  activate  genes.  SWI/SNF  disrupts 
chromatin  structure  at  promoters  to  allow  increased  access  to  the  transcription 
machinery (Peterson & Herskowitz, 1992; Travers, 1992). HPV18 E1 has been shown to 
interact  with  SNF  proteins  (Inil/hSNF5)  and  a  consequence  of  this  is  enhanced  viral 
replication seen in transient replication assays (Lee et al., 1999). Therefore E1 may play a 
role in chromatin modifications by recruiting proteins that can alter chromatin structure 
potentially enhancing viral replication or transcription of the viral ORF’s.   
 
The  HPV  genome  is  small  and  therefore  limited  in  its  capacity  to  synthesis  proteins 
capable of carrying out essential functions. Therefore HPV has evolved to hijacks the 
cellular replication machinery in order to mediate it own replication. In order to do this E1 
interacts with a variety of host cellular replication proteins that are involved in eukaryotic 
DNA replication. These include DNA polymerase α primase (polα-primase), replication 
protein  A  (RPA),  topoisomerase  1  (topo  1)  proliferating  cell  nuclear  antigen  (PCNA), 
replication factor C (RFC) and polymerase δ (polδ). (Park et al., 1994; Conger et al., 1999; 
Loo & Melendy., 2004; Clower et al., 2006; Melendy et al., 1995; Podust et al., 1995). 
Polymerase α primase has been shown to interact with E1 protein from BPV1 and HPV6 
and this interaction is essential for viral replication (Park et al., 1994). The amino terminal 
of E1 forms a complex with the p180 polymerase subunit and recruits the protein to the 
viral origin allowing viral replication during in vitro studies. Later work with HPV16 also 
shows an interaction between the N terminal of E1 with polα-primase. The p68 subunit of 
polα-primase  binds  to  amino  acids  438-623  of  HPV16  E1  and  is  competitive  with  E2 
interaction  (Masterson  et  al.,  1998).  These  data  support  evidence  of  sequential 
interaction during the initiation of papillomavirus replication. The E1 protein of HPV11 
interacts with the p180 and p70 subunits of polα-primase and is also essential for HPV 
replication. The p70 subunit competes with E2 for E1 interaction (Conger et al., 1999). 
Another  protein  that  E1  recruits  to  the  viral  origin  is  the  RPA.  Work  from  Loo  and 
Melendy has shown that BPV1 and HPV11 E1 interact with 70kDa subunit of RPA (Han et 
al.,  1999;  Loo  &  Melendy,  2004).  Further  studies  from  this  group  also  identified  the Chapter 1: Introduction 
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interaction between BPV1 and HPV11 E1 and the topo 1 protein (Clower et al., 2006). An 
interaction within the N terminal DNA binding domain and C terminal helicase domain 
stimulates the activity of topoI. The replication factors RPA, RFC, PCNA, polα-primase and 
polδ are essential for BPV1 E1 and E2 mediated replication  during in vitro replication 
assays  (Melendy  et  al.,  1994).  Further  to  this  polymerase  δ  and  RPA  can  efficiently 
cooperate with BPV1 E1 in virus replication studies (Podust et al., 1995). These studies 
highlight the  dependence  of papillomavirus for  cellular  replication  factors  in order  to 
carry out viral replication.  
 
 
1.6.2 E2 
 
The  E2  proteins  of  papillomavirus  function  as  dimers  within  the  virus  life  cycle.  The 
structure of E2 is prototypic of a transcription factor as it is divided into 3 functional 
domains (reviewed in McBride et al., 1991) (Figure 1.5). The N terminal transactivation 
domain is well conserved and it is within this domain that the multi-functional E2 protein 
can regulate viral transcription and replication (McBride and Myers, 1997). The central 
hinge region varies in sequence size and is not well conserved across varying HPV types. 
Little is known about the functions of this region but it has been shown as having a role in 
E2 protein turnover and nuclear localisation (Lai et al., 1999; Penrose & McBride, 2000; 
Zou et al., 2000). The C terminal domain is important for dimerization of the E2 protein, 
DNA  binding  at  12bp  palindromic  sites,  interaction  with  the  viral  helicase  E1  and 
interaction with the transcriptional protein TBP (reviewed in McBride. 2008).   Chapter 1: Introduction 
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Figure 1.5 
 
 
 
 
 
Figure 1.5 Structure of the E2 dimer. The three domains of E2 are highlighted. The N 
terminal domain is associated with the transactivation functions of the E2 dimer, and the 
C terminal domain is associated with DNA binding and E2 dimerization.  
 
 
E2 is involved in the regulation of viral DNA replication through its association with E1. E2 
interacts with DNA as a functional dimer at E2 binding sites within the viral LCR (Figure 
1.6 (a)) (Mohr et al., 1990; Ustav & Stenlund, 1991; Ustav et al., 1991). The DNA binding 
domain of the E2 proteins forms a dimeric structure that positions two alpha helices to 
recognize  and  contact  the  E2  binding  site  (Hedge  et  al.,  1992).  The  HPV16  E2  dimer 
interacts with 12bp palindromic sequences and has a high affinity for the DNA sequence: 
ACCGN4CGGT (Bedrosian & Bastia, 1990). There are four E2BS within the HPV16 LCR that 
are used in functions such as viral replication, transcriptional regulation and viral genome 
partitioning.  As mentioned in Chapter 1.6.1.1, the amino terminal domain of E2 recruits 
the  ATP  dependent  viral  helicase  E1,  via  its  C  terminus,  to  the  viral  origin  therefore 
initiating E1/E2-mediated HPV DNA replication (Masterson et al, 1998) (Figure 1.6 (b)). E2 
interacts with E1 at arginine 454 in the helicase domain of E1 (Abbate et al., 2004). A 
mutation  of  the  glutamic  acid  residue  at  position  39  of  HPV16  E2  to  alanine  (E39A) 
disrupts  its  E1  interaction  activity  and  its  replication  function  without  affecting  its 
transcriptional function (Sakai et al., 1996; Kasukawa et al., 1998).  E2 bound to E2BS 
loads the E1 helicase onto the E1BS and increases the specificity of E1 DNA binding. The Chapter 1: Introduction 
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E1.E2 interaction reveals specific DNA binding activity intrinsic to the E1 DNA binding 
domain (Stenlund, 2003). After E1 recognition of the origin E2 is displaced in an ATP 
dependent manner to facilitate the formation of the E1 dihexameric complex, therefore 
generating  larger  complexes  that  can  modify  the  origin  structure  (Lusky  et  al.,  1994; 
Hughes & Ramanos, 1993; Sedman & Stenlund, 1998). E2 also recruits cellular replication 
factors to the viral origin. The E2 protein from BPV1 interacts with RPA and this facilitates 
opening of closed DNA structures (Li & Botchan, 1993).  
 
Figure 1.6 
(a) 
                        
(b) 
                               Chapter 1: Introduction 
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Figure 1.6 Functional interaction domains of the E2 dimer. (a)E2-DNA complex viewed 
from pdb file 2BOP. The BPV1 E2 (326-410) dimer (red/blue) is bound to its DNA target 
(grey) (Hedge et al., 1992). (b) Ribbon structure of two independent HPV16 E2 monomers 
are shown in blue and green. Side chains of glutamine 39 are highlighted in purple. This 
amino acid is essential for E2 interaction with E1 (modified from Anston et al., 2000).  
 
The E2 protein can regulate viral gene transcription. The E2 gene can code for three E2 
proteins that are the products of multiple transcription initiation sites and alternative 
splicing (Lambert et al., 1987; Vaillancourt et al., 1990; Sherman & Alloul, 1992). The full 
length E2 protein is called E2-Transactivator (E2-TA). Within the LCR the E2 dimer binds to 
the E2 specific enhancers (12bp palindromic sequence of ACCGNNNNCGGT). Several E2 
dimers interact with the palindromic sequences in cooperation with cellular transcription 
factors such as p300, AP1 and NFK/1 factor (Gauthier et al., 1991; Kruppel et al., 2008)  
This allows E2 to regulate viral transcription. There is evidence of a complex interplay 
between  E2  and  cellular  transcription  factors  within  the  LCR  that  indicates  dose-
dependent regulation, i.e. at lower concentrations of E2, E6 and E7 viral transcription is 
stimulated from the p97 promoter and at higher levels of E2, transcription is repressed 
(Bouvard et al., 1994; Steger& Corbach, 1997). It is possible that at high concentrations, 
E2 sterically hinders the cellular transcription factors interaction at the viral promoter 
elements such as Sp1 binding sites and the TATA box (Cripe et al., 1987; Thierry and 
Yaniv, 1987). The areas within the transactivation  domain required for transcriptional 
regulation are different from those required for replication. The E2 residues arginine 37 
and  isoleucine  73  within  the  N  terminal  section  of  the  transactivation  domain  are 
important for transcriptional regulation (Sakai et al., 1995; Antson et al., 2000) (Figure 
1.7). Mutations at these residues severely repress E2 transcriptional activation from E2 
reporter plasmids. E2 has also been shown to regulate a number of cellular promoters. 
This  allows  the  virus  to  express/downregulate  cellular  proteins  that  may  be  required 
during different stages of the virus life cycle. HPV18 E2 protein downregulates the cellular 
human  telomerase  reverse  transcriptase  (hTERT)  by  interacting  with  Sp1  (Lee  et  al., 
2002). E2 interaction with Sp1 has been shown to transactivate p21 expression (Steger et 
al., 2002).  HPV16 E2 transactivation domain can transactivate the alternative splicing 
factor/splicing factor 2 (ASF/ SF2) promoter (Mole at al., 2009).  Chapter 1: Introduction 
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Figure 1.7 
 
 
Figure 1.7 Structure of the transactivation domain of E2. Stereo diagram showing the 
distribution of conserved residues within the HPV18 E2 monomer. Side chains of internal 
structural residues are shown in yellow, those in the interface between the two domains 
are shown in green and those exposed on the surface with are shown in aquamarine. The 
structure  is  overlaid  with  that  of  the  backbone  HPV18  E2  (blue).  Highlighted  are  the 
residues essential for transcriptional activation (green circle) and E1 interaction (yellow 
circle). Image generated with BOBSCRIPT27 and Raster3D (modified from Anton, 2000). Chapter 1: Introduction 
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At the basal layer of the epithelium, cell division results in one daughter cell remaining in 
the basal layer and one daughter cell migrating up to the suprabasal layers to begin the 
differentiating  process.  E2  ensures  that  viral  episomes  are  distributed  into  both  new 
daughter cells and therefore maintains a source of HPV DNA for persistent infection. To 
achieve this, E2 either interacts directly with the chromatin or indirectly through cellular 
factors that tether the viral genome to the cellular chromatin (Skiadopoulos and McBride, 
1998; Zheng et al., 2005). E2 can bind to mitotic chromosomes through a direct protein-
protein interaction. The DNA binding domain binds to the E2BS within the viral LCR and 
tethers the viral genome to the condensed chromosomes via its transactivation domain 
(Bastien and McBride, 2000; Ilves et al., 1999). 
 
The  factors  used  by  E2  to  tether  the  viral  chromatin  during  mitosis  vary  between 
papillomavirus type. For example HPV11 E2 has been shown to bind HPV origin plasmids 
directly to the mitotic spindle (Van Tine et al., 2004) (Dai et al, 2006). HPV8 E2 targets the 
short arms of acrocentric mitotic chromosomes, in particular the repeated ribosomal DNA 
genes  (Poddar,  2009).  Brd4  is  a  member  of  the  BET  family  of  double  bromodomain 
proteins which interacts histones H3 and H4 and can bind to chromatin through mitosis 
(Florence and Faller, 2001; Dey et al., 2003). BPV1 E2 and HPV16 E2 have been shown to 
utilize Brd4 as an accessory factor in viral genome tethering and the complex on mitotic 
chromosomes (You et al 2004; Baxter et al 2005; Schweiger et al., 2006). Two highly 
conserved  residues  arginine  37  and  isoleucine  73  in  the  N  terminal  section  of  the 
transactivation domain are critical for Brd4 binding (Baxter et al., 2005; McPhillips et al., 
2006;  Senechal  et  al.,  2007).  These  residues  are  also  essential  for  E2  transactivation 
function. The N terminal domains of the E2 dimer interact with two Brd4 peptides within 
the Brd4 C terminal (Abbate et al., 2006).  
 
ChLR1, a DNA helicase that plays a role in sister chromatid cohesion, has been shown to 
interact with BPV E2 at early mitosis as a possible loading factor (Parish et al, 2006). E2 
interacts with and co-localises with ChLR1, but only at early stages of mitosis. E2 protein 
that does not interact with ChLR1 cannot tether viral DNA to cellular chromatin. The viral 
genome is lost when ChLR1 expression is inhibited. Work carried out in this laboratory 
suggests that Topoisomerase binding protein 1 (TopBP1) could be the mitotic chromatin Chapter 1: Introduction 
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receptor for HPV16 E2 in late mitosis (Donaldson et al 2007). E2 was shown to associate 
with the mitotic spindle via co-localisation with TopBP1 suggesting that this protein could 
be the mitotic chromatin receptor for HPV16 E2. The E2 protein of HPV8 has been shown 
to interact with the pericentromeric region of mitotic chromosomes. The precise target is 
the  ribosomal  RNA  gene  loci  that  are  situated  on  the  short  arms  of  acrocentric 
chromosomes (Oliveira et al., 2006; Poddar et al., 2008). 
 
Asides from  its roles  in  viral  replication,  viral genome  partitioning  at cell  mitosis  and 
regulation of viral gene expression, E2 also has a role in the regulation of cell proliferation 
and apoptosis. A characteristic of HPV-induced cervical cancer is the loss of episomal HPV 
DNA and integration of the HPV genome into that of the host cell (Cooper et al., 1991; 
Kristiansen et al., 1994; Alazawi et al., 2002; Peitsaro et al., 2002; Arias-Pulido et al., 2006; 
Pett  et  al.,  2006).  This  integration  often  results  in  a  loss  of  the  E2  ORF  leading  to 
derepression of viral oncoprotein expression resulting in a growth advantage in the cells 
(Romanczuk et al., 1990; Romanczuk & Howley, 1992; Jeon et al., 1995). The E2 protein 
was  first  described  as  having  apoptotic  properties  by  an  investigation  of  BPV1  E2 
introduction into a range of cervical cancer cell lines. The presence of E2 was shown to 
inhibit  cellular  proliferation  in  HeLa  (human  epithelial  carcinoma  cell  line  containing 
HPV18 integrated DNA), C-4I (squamous cell carcinoma cell line of the cervix containing 
integrated HPV18 DNA), MS751 (squamous cell cervical carcinoma cell line containing 
HPV18 DNA) and HT-3 (HPV-negative p53 mutated cervical carcinoma cell line) (Hwang et 
al.,  1992).  Due  to the use  of  HT-3  cells,  this  study  also  suggests that  the  E2  protein 
appears to exert a growth-inhibitory effect that is independent of its effects on HPV gene 
expression. A separate study has shown that cell lines containing episomal HPV31 DNA 
have a higher rate of apoptosis after long term interferon (IFN-β) treatment compared to 
HPV-negative  cell  lines.  Induced  E2  expression  resulted  in  a  significant  increase  in 
apoptotic cells compared to non-induced cells, therefore supporting evidence of E2 pro-
apoptotic effects (Chang et al., 2002). 
 
Other  studies  have  been  carried  out  investigating  the  effects  of  HR-HPV  E2  on  cell 
proliferation. Multiple studies by the Gaston group have focused on the role of HPV16 E2 
and its pro-apoptotic properties (Sanchez-Perez et al., 1997; Webster et al., 2000; Parish Chapter 1: Introduction 
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et al., 2006). Their work, focusing on p53 mediated apoptosis, shows that E2 induces 
apoptosis  in  both  HPV-transformed  and  non  HPV-transformed  cell  lines  via  two 
independent pathways. In non HPV-transformed cells, mutations in E2 that abrogate its 
interaction with p53 inhibit E2-induced apoptosis (Webster et al., 2000). In contrast, E2 
mutants that do not interact with p53 do not inhibit E2 mediated cell apoptosis in HPV 
transformed cell lines (Parish et al., 2006). The results from HPV-transformed cell lines 
suggest that E2 regulates cell proliferation by interfering with the expression of the anti-
apoptotic viral proteins E6 and E7. The E6 and E7 proteins alter the cellular proliferation 
by negatively interfering with two regulatory proteins of the cell cycle, p53 and pRb (see 
Chapter 1.6.2.1 – 1.6.2.2). Investigations carried out in the Thierry lab on HPV18 show 
that E2 is able to cause apoptosis in Hela cells and has a negative effect of E6 and E7 
transcription  (Thierry  &  Howley,  1991;  Desaintes  el  al.,  1997; Desaintes  et  al., 1999). 
However, Saos-2 cells that are deficient in p53 function and are non HPV-transformed 
show that E2-mediated apoptosis is activated independently of viral functions, suggesting 
the use of the extrinsic apoptosis pathway (Demeret et al., 2003). Therefore the pathways 
with which E2 is able to activate apoptosis are still highly debatable and differences in 
results may be accountable to the type of papillomavirus used. Loss of E2 expression in 
cell lines containing integrated DNA most certainly contributes to cell immortality. 
 
 
1.6.2 Oncoproteins 
 
The  association  between  HPV  infection  and  cervical  cancer  was  first  reported  three 
decades ago. It is widely accepted nowadays that HPVs are the causative agent of cervical 
cancer. Over 99% of cervical lesions and 40% of oral cancers are found to contain HPV 
DNA from ‘high risk’ strains of the virus (Walboomers et al., 1999; Parkin & Bray, 2006).  
The viral oncoproteins are well documented for their contribution in the development of 
cervical  cancer.  The  E7  and  E6  proteins  support  each  other’s  function  and  have 
transforming capabilities. More recent work has also indicated a role for E5 protein in 
contributing towards cancer development.  
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1.6.2.1 E7  
 
The  17kDa  HPV16  E7  protein  is  located  primarily  in  the  nucleus.  Within  the  amino 
terminal of E7, there is a conserved LXCXE motif. The motif is the site where E7 interacts 
with the Rb tumour suppressor protein and related family members p107 and p130 and 
targets them for degradation (Dyson et al., 1989; Munger et al., 1989). ‘High risk’ E7 
proteins have been shown to bind with the Rb family members with much higher affinity 
than proteins from ‘low risk’ HPV’s and this may contribute to their oncogenicity (Gage et 
al., 1990).  
 
The Rb family of proteins control G1-S phase transition of the cell cycle by regulating the 
activity of the E2F family of transcription factors (reviewed by Dyson, 1998). The eight 
members  of  the  E2F  family  are  involved  in  the  regulation  of  transcription  of  genes 
involved in cell cycle progression, differentiation, mitosis and apoptosis. Therefore E2F 
binding sites are found in the promoters of genes involved in these functions. In non HPV 
infected cells, Rb proteins inhibit transcription of E2F dependent promoters by directly 
interacting with the E2F transactivation domain (reviewed by Harbour & Dean, 2000). In 
HPV infected cells however, the E7 protein disrupts Rb-E2F interaction by binding to Rb 
protein. This interaction results in the expression of E2F responsive genes such as cyclin A 
and  cyclin  E  and  consequently  promotes  premature  S  phase  progression  and  DNA 
synthesis (Chellappan et al., 1992). The E7 and E2F-6 interaction therefore maintains an S 
phase environment that is required for amplificational replication in differentiating cells 
(McLaughlin-Drubin  et  al.,  2008).  The  HR-HPV  E7  also  target  Rb  family  members  for 
degradation through ubiquitination (Boyer et al., 1996).  
 
The  expression  of  E7  has  also  been  associated  with  abnormal  chromosome  numbers 
(Duensing & Münger, 2003a; Duensing & Münger, 2003b). E7 rapidly induces centrosome 
amplification by the formation of multiple immature centrioles from a single maternal 
centriole (Duensing et al., 2001; Duensing et al., 2007). Centrosome abnormalities have 
the  potential  to  lead  to  genomic  instability.  Therefore  E7  proteins  from  HR-HPVs, 
contribute to the development of cervical cancer through targeting members of the Rb Chapter 1: Introduction 
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family for degradation, activating E2F transcription factors that drive the expression of S 
phase genes and inducing centrosome abnormalities in HPV infected cells.  
 
 
1.6.2.2 E6 
 
The previously described interaction between E7 and Rb family of proteins can lead to 
inhibited cell growth and apoptosis through the activation of p53 dependent pathways 
(Jones et al., 1997; Eichten et al., 2004). To counter this, HPV expresses the E6 protein. E6 
interferes with p53 functions by multiple mechanisms. E6 recruits the E3-ubiquitin ligase 
E6 associated protein (E6AP) and results in ubiquitylation and consequential proteasomal 
degradation of p53 (Scheffner et al., 1993; Lechner & Laimins, 1994). E6 can also alter p53 
function by decreasing its stability. The histone acetylases p300 and CREB binding protein 
(CBP) have been shown to increase p53 stability through acetylation. HPV16 E6 binds to 
p300  and  CBP  therefore  inhibiting  their  ability  to  stabilise  p53  (Patel  et  al.,  1999; 
Zimmermann et al., 1999).  
 
E6 contributes to cell immortalisation through the activation of telomerase. Telomerase 
enzyme  is  often  activated  in  many  cancers  and  is  important  for  replicating  the  DNA 
sequences  at  the  end  of  chromosomes.  HPV16  E6  can  activate  the  transcription  of 
telomerase  reverse  transcriptase  (TERT)  and  increases  its  protein  levels  by  directly 
associating with the nuclear transcription factor X-123 (Katzenellenbogen et al., 2007). 
 
E6 interferes with the effects of a number of growth inhibitory cytokines in order to 
regulate cellular proliferation. When the virus first enters the cell a potent inhibitor of 
keratinocyte proliferation, the tumour necrosis factor alpha (TNF-α), is synthesised (Basile 
et  al.,  2001).  Inflammatory  cytokines  such  as  TNF-α  activate  the  extrinsic  apoptotic 
pathways such as those belonging to the TNF receptor family. Members of this family 
include TNFR-1, FAS and TNF-related apoptosis-inducing ligand (TRAIL). HPV16 E6 inhibits 
TNF-α  induced  apoptosis  by  interacting  with  TNFR1  (Fillippova  et  al.,  2002).  This 
interaction inhibits the formation of the Death Inducing Cellular complex (DISC) resulting Chapter 1: Introduction 
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in inhibition of apoptosis. HPV16 E6 also interacts with the Fas-associated death domain 
(FADD) and caspase-8, therefore protecting cells from Fas associated apoptosis (Fillippova 
et al., 2004; Garnett et al., 2006).  
 
The  human  homologue  of  the  Drosophila  discs  large  tumour  suppressor  gene  (hDlg) 
protein  is  a  PDZ  domain  containing  protein  that  is  involved  in  the  regulation  of  cell 
polarity and negative proliferation control. The HPV16 E6 protein has been shown to 
target  hDlg  for  proteasomal  degradation  therefore  enhancing  morphological 
transformation of the cell (Gardiol et al. 1999; Watson et al., 2002). Prior to degradation 
mediated by E6, hDlg is phosphorylated by either Cdk1 or Cdk2 and a result of this is 
accumulation of hDlg in the cell nucleus. It is within the nucleus where hDlg encounters 
E6-induced degradation (Massimi et al., 2006; Narayan et al., 2009). E6 contributes to cell 
transformation through a number of mechanisms including targeting p53 and hDlg for 
degradation, activation of telomerase and preventing HPV induced cellular apoptosis.  
 
 
1.6.2.3 E5 
HPVs are known to cause long term persistent infections. Viral persistence is caused by a 
number of factors. The papillomavirus life cycle takes place exclusively in epithelial cells 
and therefore can go undetected by the immune cells of the dermis. Papillomavirus do 
not initiate an inflammatory response because they do not cause lysis of the host cell. 
Viral  proteins  inhibit  activation  of  the  host  cell  immune  response.  The  hydrophobic 
membrane bound HPV E5 protein contributes to viral persistence by down-regulating the 
host cell immune defence. The Major Histocompatibility Complex class I (MHC class I) 
expression increases presentation of viral antigens to cytotoxic T cells. E5 protein down 
regulates MHC class I in HPV infected cells (Ashrafi et al., 2005; Campo et al., 2010).  This 
is achieved by recruiting the MHC complex to the golgi apparatus as opposed to the cell 
surface where it would be recognised by CD8+ T cells (Ashrafi et al., 2006; Cortese et al., 
2010).  The  accumulation  of  the  MHC  in  the  golgi  is  a  consequence  of  E5  induced 
alkalinisation of the golgi membrane (Schapiro et al., 2000).  
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Malignant transformation by HPV can also be attributed to the E5 protein. The role of 
HPV16 E5 has been suggested mostly in early stage of cervical carcinogenesis. Evaluation 
of E5 expression levels by immunohistochemistry has shown that E5 is detectable in 80% 
of  HPV  infected  low  grade  squamous  intraepithelial  lesions  and  that  this  percentage 
drops to around 60% in cervical carcinoma tissue (Chang et al., 2001). Further evidence 
supporting the role of E5 as a transforming protein is by its interaction with the epidermal 
growth factor receptor (EGFR) signalling pathway (Straight et al., 1993; Genther Williams 
et al., 2005; DiMaio & Mattoon, 2001). The downstream effects of EGFR are an increase in 
DNA  synthesis  and  cell  proliferation.  Over  expression  of  EGFR  signalling  has  been 
correlated with a large number of cancers (reviewed in Zhang et al., 2007). E5 increases 
EGFR  signalling  by  interfering  with  its  degradation  and  by  increasing  the  number  of 
receptors expressed on the cell surface.  
 
HPV16 E5 is capable of enhancing cell proliferation by interfering with tumour suppressor 
proteins p21 and p27. E5 proteins of HPV11 and HPV16 have been shown to repress p21 
gene expression and this might be one of the mechanisms by which E5 stimulates cell 
proliferation (Tsao et al., 1996). The half life of p27 (Kip1) decreases in the presence of E5 
favouring an S phase environment (Pedroza-Saavedra et al., 2010).  
 
Resistance to apoptosis is a hallmark of many cancers. HPV16 E5 is reported to impair 
apoptotic  pathways  in  HaCaT  cells.  E5  weakens  FasL  and  TRAIL  mediated  apoptotic 
pathways by down regulating Fas expression involved in FasL signalling and altering the 
formation of the death-inducing signalling complex involved in TRAIL signalling (Kabsch & 
Alonso,  2002).  Therefore,  apart  from  its  role  in  avoidance  of  the  host  immune 
surveillance, E5 is a potential oncogene through interaction with the EGFR, interfering 
with tumour suppressor protein expression and by inhibiting HPV activated apoptotic 
pathways.  Chapter 1: Introduction 
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1.6.3 Proteins expressed in the upper epithelial layers 
 
1.6.3.1 E1^E4 
 
The E4 protein is expressed from a spliced mRNA species as E1^E4. Spliced transcripts are 
formed between the N terminal of the E1 ORF and an almost complete E4 ORF (Nasseri et 
al., 1987). E1^E4 accumulates to high levels in the mid layers of the epithelium. The E1^E4 
roles in the viral life cycle are a little unclear, however when this protein is lost it results in 
severe and adverse effects on viral genome amplification of HPV types 16, 18 and 31 
(Nakahara et al., 2005; Wilson et al., 2005; Wilson et al., 2007). The cottontail rabbit 
papillomavirus, E1^E4 is essential for completion of the vegetative stage of the virus life 
cycle (Peh et al., 2004). Therefore one of the key roles for the E1^E4 protein in the upper 
epithelial layers appears to support vegetative replication. 
 
E1^E4 may be involved in vegetative replication by inhibiting mitotic progression and 
inducing DNA re-replication (Knight et al., 2004). Inhibiting cellular replication could allow 
for the recruitment of the cell replication factors to the viral origin of replication. In the 
presence of the replication licensing factor cdc6 the HPV1 E4 protein inhibits the initiation 
of cellular DNA replication. E4 blocks  cellular replication by preventing the loading of 
Mcm2 and Mcm7 onto cellular chromatin (Roberts et al., 2008).  
 
E1^E4 has also been associated with having a fundamental role in viral egress. E1^E4 
diminishes the integrity of the keratinocyte by disrupting the keratin cytoskeleton and 
cornified envelope formation (Doorbar et al., 1991; Roberts et al., 1993; Bryan & Brown, 
2000; McIntosh et al., 2010). E1^E4 induces apoptosis through alteration of mitochondrial 
function (Raj et al., 2004). Therefore through breaking down the cell architecture, E1^E4 
expression in the upper layers of the epithelium is able to assist HPV capsid release.  
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1.6.3.2 The capsid proteins: L1 & L2 
 
The 55nm diameter HPV capsid is non-enveloped, has T=7 icosahedral symmetry and is 
formed  from  two  HPV  structural  proteins,  L1  and  L2.  Within  the  capsid  is  the  7.9kb 
circular genome that is associated with cellular histones to form chromatin like structures 
(Larsen et al., 1987; reviewed in Doorbar, 2005). There are 72 pentamers of L1 that make 
up the viral coat and they are associated with L2. The stoichiometry of L1:L2 in purified
 
L1+L2  complexes  is  5:1  indicating  that  a  single  molecule  of
  L2  interacts  with  an  L1 
pentamer (Finnen et al., 2003) .The capsid proteins are essential for viral entry, and are 
only  expressed  in  terminally  differentiated  keratinocytes  demonstrating  their  role  in 
capsid formation and egress (Barksdale & Baker, 1993).  
 
The L1 protein is evolutionary conserved. Interaction between the viral capsid and the cell 
surface receptor relies primarily on L1. There has been speculation regarding what cell 
surface  receptor  L1  interacts  with  to  fulfil  capsid  attachment  to  the  cell.  
Glycosaminoglycans (GAG’s) are the suggested initial attachment receptors, in particular 
heparin sulphate (Joyce et al. 1999; Giroglou et al., 2001; Combita et al., 2001; Drobni et 
al., 2003). Another potential candidate for L1 attachment is syndecan1. Heparin sulphate 
proteoglycans  (HSPG)  are  frequently  located  on  cell  surfaces  and  in  the  extracellular 
matrix. Syndecans are the predominant HSPG in epithelial cells. Syndecan1 may therefore 
serve as the primary attachment receptor due to its high expression level in epithelial 
cells (Sapp & Day, 2009; Shafti-Keramat et al., 2003).  
 
L1 expressed alone is sufficient to produce synthetic papillomavirus particles. Formation 
of non-infectious viral like particles is highly immunogenic. This is why L1 is used as a 
preventive vaccination against HPV types. Two HPV vaccines are currently on the market: 
Gardasil and Cervarix (reviewed by Harper, 2009). Both vaccines protect against two HR-
HPV types, 16 and 18. Gardasil also protects against the two LR-HPV types, 6 and 11. 
 
HPV binding and entry into the host cell is complex and involves virus attachment to 
multiple  receptors.  The  multifunctional  L2  minor  capsid  protein  is  internally  located 
within the capsid. Initial low specificity binding of the L1 major capsid with HSPG results in Chapter 1: Introduction 
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a conformational change in the viral capsid and subsequent exposure of the L2 N terminal 
(Roden et al., 2001; Yang et al., 2003; Sapp & Day, 2009). L2 interacts with the C terminal 
domain  of  L1.  Proteolytic  cleavage  of  L2  N  terminal  domain  by  furin  is  essential  for 
successful HPV infection (Day et al., 2008). The cleavage site is conserved amongst all 
papillomaviruses and it is otherwise inaccessible at the surface of the virion (Richards et 
al., 2006). The location of this essential cleavage site helps prevents an immune response 
against L2 (Sapp & Day, 2009). Furin cleavage of L2 results in an additional conformational 
change that exposes a site on L2 for a yet undetermined secondary receptor.  Interaction 
with the secondary receptor facilitates the release of a L2/genome complex into the host 
cytosol via endocytosis.  
 
Aside from its role in virion attachment and endocytosis, L2 is responsible for the nuclear 
import of the viral genome. L2 interacts with syntaxin 18 facilitating the movement of the 
viral genome to a perinuclear complex (Bossis et al., 2005; Richards et al., 2006). The 
amino terminal of L2 contains a nuclear localisation site (Fay et al., 2004; Bordeaux et al., 
2006). L2 may therefore translocate the viral genome into the nucleus, exposing it to the 
cellular  transcription  and  replication  machinery.    L2  also  plays  a  role  in  viral  DNA 
encapsidation using the HPV E2 proteins (Heino et al., 2000; Gu et al., 2004; Holmgren et 
al., 2005).  
 
 
1.7 HPV episomal integration 
 
Failure of the immune system to detect and clear high-risk HPV infections can result in 
the development of cancerous cells, a process that may take several decades. Episomal 
viral DNA can be detected in precancerous lesions. However DNA from the HR-HPV types 
16 and 18 are frequently found integrated into host cell DNA in high grade squamous 
intraepithelial lesions (SIL) and squamous cell carcinomas (Cooper et al., 1991; Kristiansen 
et al., 1994; Alazawi et al., 2002; Peitsaro et al., 2002; Arias-Pulido et al., 2006; Pett et al., 
2006). HPV integration often occurs in a naturally occurring region of genomic instability. 
Integration  is  an  accidental  but  critical  event  in  the  development  of  carcinomas.    In Chapter 1: Introduction 
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cervical  malignancies,  over  half  of  HPV16-positive  and  nearly  all  of  HPV18-positive 
malignancies contain integrated HPV genomes (reviewed in Pett & Coleman, 2007). There 
is also evidence of HPV16 integration in HPV-positive head and neck cancers. A study has 
found that 61% of head and neck cancers are HPV DNA positive. HPV16 was accountable 
for 84% of the malignancies and was found integrated in 50% of the samples (Koskinen et 
al., 2003). This supports evidence from other studies that have also detected integrated 
HPV DNA in HPV-positive head and neck cancer cells (Hafkamp et al., 2003). Other factors 
that must be taken into consideration are alcohol intake and whether the individual is a 
smoker, however this evidence suggests that head and neck cancers may also have viral 
integration aetiology.  
 
In a HPV episomal infection, the E2 protein regulates the expression of the E6 and E7 
oncoproteins. Viral integration normally results in loss of E2 expression and deregulated 
expression of the viral oncoproteins (Figure 1.8). Deregulated expression of E6 and E7 can 
contribute to cellular proliferation and transformation. Integration of HR-HPV DNA also 
correlates with a selective growth advantage of cells for clonal expansion (Jeon et al., 
1995; Romanczuk & Howley, 1992; Romanczuk et al., 1990).  Chapter 1: Introduction 
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Figure 1.8 
 
 
Figure  1.8  HPV  episomal  integration.  In  the  course  of  cancer  development  the  HPV 
episome frequently becomes integrated into host cell DNA. The episome is most often 
opened within the E2 ORF therefore the E2 gene is lost. E4, E5 and part of L2 ORF are 
often deleted after integration (partial genes are denoted by an asterisk). The E6 and E7 
ORF are present and transcription is enhanced by flanking host-cell promoters (modified 
from zur Hausen, 2002). 
 
Episomal  HPV  DNA  is  lost  over  time  in  HPV-integrated  cells.  However  early  on  in 
malignant progression, episomal and integrated viral DNA exists within the host cell. It 
has been suggested that episomal E1 and E2 are able to stimulate viral replication from 
an integrated origin of replication. This would result in amplification of the integrated 
HPV origin and flanking sequences (Kadaja et al., 2009). A consequence of this replication 
may be local rearrangements within the DNA backbone (Figure 1.9). The theory of an 
‘onion  skin’  method  of  replication  during  S  phase  of  the  cell  cycle  would  result  in 
chromosomal  abnormalities  that  could  drive  malignant  progression.  Replication  of 
integrated HPV activates the DNA damage checkpoints which can cause chromosomal 
abnormalities through non homologous end joining (NHEJ) repair.  Chapter 1: Introduction 
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Figure 1.9 
 
 
Figure 1.9 E1 and E2 expressed from episomal DNA can cause replication of integrated 
DNA. If the HPV episome is present in cells harbouring integrated HPV, DNA re-replication 
from the integrated HPV origin is initiated. The chromosomal abnormalities encountered 
may be further exasperated by ‘onion skin’ methods of replication (modified from Kadaja 
et al., 2009).  
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1.8 DNA replication and the cell cycle 
 
The  fundamental  features  and  components  of  DNA  replication  are  well  conserved 
throughout evolution from viruses to mammals. Every cycling cell is required to duplicate 
its genome in a coordinated manner before it leaves the cell cycle and enters cytokinesis.  
 
1.8.1 G1 
 
There are four stages of the cell cycle prior to cytokinesis. The G1 phase is marked by 
synthesis of various enzymes that are required in S phase, mainly those needed for DNA 
replication. It is within this phase that the pre-replication complexes are formed (Figure 
1.10). The DNA double helix must be opened to allow access of the components required 
to copy each strand. DNA is opened up at the origins of replication. The assembly of the 
prereplication complex (pre-RC) takes place at the origins (Kelly & Brown, 2000; Bell & 
Dutta, 2002). In eukaryotic cells the primary factor that initiates the formation of the pre-
RC is the origin recognition complex (ORC) (reviewed in Méchali, 2010). The ORC is a 
heterohexamer with DNA dependent ATPase activity. The ORC then recruits cdc6 and 
CDT1. These proteins load the ‘inactive’ mini chromosome maintenance (MCM) complex 
onto the DNA strands (Cook et al., 2003). The MCM2-7 complex is a group of proteins that 
belong to the AAA+ ATPase family of proteins. Other members of this family include the 
HPV E1 protein and the SV40 Large T Antigen protein. The heterohexamer complex has 
DNA helicase activity and forms a ring around the origin. Once the helicase is bound to 
the DNA, the origin is deemed licensed for activation.  
 
In  order  to  activate  origin  firing,  cellular  factors  including  cdc45  protein,  the  GINS 
complex, Cdc7-DBf4, geminin and Cdk2 are recruited (Mailand & Diffley, 2005; Moyer et 
al., 2006; De Marco et al., 2009; Ilves et al., 2010; Balestrini et al., 2010) . The cdc6 and 
ORC become degraded. CDT1 is negatively regulated by Geminin in order to restrict origin 
firing to once per cell cycle. In the presence of geminin, CDT1 interaction with DNA is 
inhibited leading to the initiation of DNA replication.  
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Figure 1.10 
 
 
 
 
Figure  1.10  Assembly  of  the  pre-replication  complex  at  DNA  replication  origins  In 
eukaryotes,  ORC  directly  recognizes  an  origin of  replication.  Cdc6 and  CDT1  are then 
recruited to load the MCM2–7 complex onto the replication origin. Once the helicase is 
bound to the DNA, the origins are ‘licensed’ marking the end of pre-replication complex 
(preRC) assembly. CDT1 is a major regulator of this reaction, as it is negatively regulated 
by Geminin to restrict licensing to only once per cell cycle. The preRC is further activated 
by Cdc45, GINS complex, CDC7–DBF4 and Cdk2. As cells enter S phase, CDT1 is inactivated 
by  both  its  release from  the  origin  by  Geminin  and  by its degradation.  These  events 
enable the association of the DNA polymerase machinery and MCM2–7 to travel ahead of 
the replication fork to open the double-stranded DNA and allow the synthesis of the 
complementary strand. 
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1.8.2 S phase 
 
The S phase of the cell cycle starts with the onset of DNA replication and continues until 
all chromosomes have been replicated. DNA replication takes place at an activated origin 
of replication. Replication of genomic DNA requires a number of factors (Figure 1.11).  
Briefly, the MCM2-7 complex unwinds the DNA double helix, the topoisomerase enzyme 
is recruited to remove DNA supercoiling ahead of the MCM2-7 helicase, RPA coats the 
single  strands  to  prevent  the  DNA  from  re-annealing  to  itself  and  DNA  primase 
synthesizes  the  short  RNA  primers  for  the  initiation  of  complimentary  DNA  synthesis 
(Maniar et al., 1997; Iftode et al., 1999). Preventing the rebinding of the MCM complex to 
DNA is key to avoiding re-replication (Blow & Dutta, 2005). DNA polymerase delta and 
alpha (for the leading and lagging strand respectively) copy the DNA strands starting at 
the 3’ end of the RNA primer and RNAse H degrades the RNA on the lagging strand. 
Okazaki fragments on the lagging are joined together by DNA ligase. At the core of the 
replication complex is the sliding clamp, PCNA  (Sporbert et al., 2002; Sporbert et al., 
2005).  The  clamp  is  loaded  onto  the  separated  DNA  strands  by  the  clamp  loading 
complex, RFC. The sliding clamp helps hold this DNA polymerase onto the DNA as the 
DNA moves through the replication machinery 
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Figure 1.11 
 
 
 
Figure 1.11 DNA replication fork. Two DNA polymerase molecules (delta and alpha) are 
active at the fork. Pol. δ produces the new DNA molecule on the leading strand, whereas 
Pol. α produces a series of short 'Okazaki DNA fragments' on the lagging strand. Both 
polymerases are anchored to their template by PCNA and RFC. MCM2-7 opens the DNA 
helix ahead of the replication fork. DNA topoisomerase aids DNA helix unwinding. Pol. α 
requires the action of a DNA primase. Single-stranded regions of DNA at the fork are 
coated with RPA that holds the DNA template strands open with their bases exposed 
(modified from Alberts, 2003). 
 
 
1.8.3 G2 
 
G2 phase follows successful completion of chromosomal replication and is the last stage in 
interphase prior to cell entry into mitosis. Within this phase the cell undergoes a period of 
rapid growth and produces new proteins in preparation for mitosis. The G2 phase can be 
considered as a safety gap during which the cell can ensure that the correct duplication of 
its DNA prior to entering mitosis.  
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1.8.4 M phase 
 
The completion of interphase allows the cell cycle to enter mitosis. M phase permits the 
equal  segregation  of  the  genome  into  two  daughter  cells.  Mitosis  occurs  in  different 
stages:  prophase,  prometaphase,  metaphase,  anaphase  and  telophase.  As  discussed 
previously, the E2 protein tethers the viral genome to the cell chromatin during mitosis.  
 
 
1.8.5 Cytokinesis 
 
The cytoplasm of a eukaryotic cell is divided to form two daughter cells. A contractile ring 
made up from myosin II and actin filaments forms in the middle of the cell at the cell 
cortex. Using the free energy released from ATP hydrolysis, myosin moves along the actin 
filaments (reviewed in Pollard & Wu, 2010). This causes the cell to pucker, a process 
called furrowing. The cleavage furrow begins to move inwards. Ingression continues until 
the process of abscission physically cleaves the cell into two and the process of cellular 
division is complete. 
 
 
1.9 Regulation of the cell cycle 
 
DNA  checkpoint  mechanisms  have  evolved  that  monitor  the  completion  of  cell  cycle 
events. If DNA is damaged or DNA replication is blocked a signal transduction pathway is 
activated to maintain genome integrity. There are three regulatory checkpoints within 
interphase of the cell cycle: the G1/S, intra-S and G2/M (Abraham, 2001; Bartek & Lukas, 
2003; Harper & Elledge, 2007). The G1/S checkpoint determines whether the cell should 
divide,  delay  division,  or  enter  a  resting  stage  (G0).  The  intra-S  checkpoint  will  stall 
ongoing  replication  and  initiation  of  late  firing  replication  origins  if  DNA  damage  is 
detected  during  S  phase.  The  G2/M  checkpoint  ensures  that  DNA  has  been  correctly 
duplicated prior to entry into mitosis.  
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Signal transduction pathways consisting of many factors that are involved in checkpoint 
regulation  (Harper  &  Elledge,  2007).  These  proteins  include  DNA  damage  sensors, 
amplifying mediators, transducers and effectors. Their ultimate goal is to arrest the cell 
cycle, activate transcription of the DNA repair machinery and repair the damaged DNA or 
activate apoptosis  if damage is too severe (Table 1.2). In parallel to cell cycle arrest, 
checkpoint signalling mediates the recruitment of DNA repair proteins.  
 
There  are  two  major  branches  of  the  kinase  signalling  cascade  that  are  vital  to 
chromosome  integrity.  The  ataxia  telangiectasia  mutated  (ATM)  and  ATM  and  Rad3-
related  (ATR)  protein  kinases  are  positioned  at  the  apex  of  the  DNA  damage  signal 
transduction pathway (Abraham, 2001; Harper & Elledge, 2007; Kastan & Bartek, 2004; 
Shiloh, 2003). Both of these proteins belong to a structurally unique family of serine-
threonine  kinases  characterized  by  a  C  terminal  catalytic  motif  containing  a 
phosphatidylinositol 3-kinase domain called PIKK proteins (phosphatidylinositol 3-kinase-
related  kinase).  The  other  member  of  this  family  is  DNA-dependent  protein  kinase 
catalytic subunit (DNA-PK). Although ATM and ATR appear to phosphorylate many of the 
same cellular substrates,
 they are generally activated by distinct types of DNA damage. Chapter 1: Introduction 
 
41 
 
 
 
Table 1.2 
 
DNA Damage Response  Signal Transduction Protein 
Sensors  RFC 
RPA 
PCNA 
9-1-1 
Pol alpha 
TopBP1 
Amplifying mediator  Rad9 
Claspin 
Transducers 
Primary: 
 
 
Secondary: 
 
ATM 
ATR 
 
Chk2 
Chk1 
Effector  P53 
Cdc25 
Targets  Cdks/cyclin complex 
Table 1.2 Functional role of cellular factors involved in DNA damage signal transduction 
pathways. 
 
 
1.9.1 ATM activation 
 
The 370kDa ATM protein is activated in response to double strand DNA breaks. Activation 
requires  the  recruitment  of  the  MRN  (Mre11,  Rad50,  Nbs1)  mediator  complex  and 
phosphorylated  H2AX  histone  (Fernandez-Capetillo  et  al.,  2004;  Celeste  et  al.,  2003). 
Together they act as a signal amplifier that can recruit other factors to the dsDNA lesion. 
Nbs1  of  the  MRN  complex  is  responsible  for  ATM  activation.  Under  normal  cellular 
conditions ATM exists as a multimer. Upon DNA damage, the protein dissociates into Chapter 1: Introduction 
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active  monomers  (Bakkenist  et  al.,  2003).  ATM  activation  is  regulated  by  post 
translational  modifications.  ATM  has  been  shown  to  be  phosphorylated  at  S1981  in 
response  to  damage  sourced  from  ionizing  radiation  (IR).  Separate  studies  have  also 
found that ATM is acetylated at lysine 3016 in response to IR and this is essential for its 
activation (Sun et al., 2005; Sun et al., 2007). Activated ATM phosphorylates the variant 
histone H2AX at S139 to synthesise γH2AX (Harper & Elledge, 2007; Fernandez-Capetillo 
et al., 2004). This phosphorylation facilitates γH2AX interaction with the BRCT motif of the 
mediator of DNA damage checkpoint 1 protein (MDC1). In return, ATM phosphorylates 
MDC1, promoting tighter binding of the MRN complex and ATM at the site of the double 
strand break.  
 
 
1.9.2 ATR activation 
 
The 317kDa ATR protein  is a serine/threonine-specific kinase that is involved in sensing 
DNA damage and activating the DNA damage checkpoint resulting in a cell cycle arrest.  
ATR is activated in response to persistent single-stranded DNA. Single strand DNA breaks  
are commonly formed during DNA damage detection and repair. Should the replication 
fork stall during DNA synthesis, the MCM helicase continues to unwind the DNA template 
upstream of the replication fork. This exposes single stranded DNA (ssDNA) coated with 
RPA. RPA acts as a sensor to DNA damage (Byun et al., 2005). It recruits ATR to stalled 
replication forks through a direct interaction with ATR Interacting Protein (ATRIP) (Zou & 
Elledge, 2003). ATRIP regulates the localization of ATR to stretches of RPA coated ssDNA 
at stalled replication forks. ATRIP is also essential for ATR signalling (Cortez et al., 2001; 
Zou & Elledge, 2003; Ball & Cortez, 2005).  
 
The precise method for ATR activation however involves not only ATR-ATRIP complex but 
also a DNA associated complex involving Rad9-Rad1-Hus1 (9-1-1) complex and TopBP1 
(Kumangai et al., 2006; Majka et al., 2006; Mordes et al., 2008; Lee & Dunphy 2010). The 
9-1-1 complex serves as a heterotrimeric clamp that encircles DNA in a similar manner to 
PCNA. The complex is loaded onto DNA by a clamp loader consisting of Rad17 and four 
subunits  of  RFC.  TopBP1  is  then  recruited  in  a  phosphorylation  dependent  manner Chapter 1: Introduction 
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(Parrilla-Castellar et al., 2004). As a result, the 9-1-1 complex facilitates the interaction 
between TopBP1 and the ATR-ATRIP complex. TopBP1 belongs to a family of evolutionary 
conserved  proteins  containing  multiple  BRCT  domains  which  interact  with  phospho-
proteins (Manke et al., 2003; Yu et al., 2003). TopBP1 contains a region between the sixth 
and  seventh  BRCT  domains  called  the  ATR  Activation  Domain  (AAD).  When  TopBP1 
interacts with ATR-ATRIP, it activates ATR kinase activity (Kumagai et al., 2006; Mordes et 
al., 2008).  
 
The  polymerase  alpha  protein  also  has  a  role  in  sensing  stalled  replication  forks  and 
activation of ATR (Muzi-Falconi et al., 2003; Michael et al., 2000). The DNA structure that 
the Rad17-RFC clamp recognises is an RPA coated 5’DNA single strand. Polymerase alpha 
can synthesis primers that produce the 5’DNA substrates and therefore may have a direct 
role in the recruitment of the 9-1-1 complex to stalled replication forks. Polymerase alpha 
has also been shown to accumulate on DNA at stalled replication forks to levels in excess 
over  what  is  observed during  normal  DNA  replication.  TopBP1  depletion  is  shown  to 
inhibit the hyper loading of polymerase alpha at these sites on the chromatin (Yan et al., 
2009).  Therefore  TopBP1  may  have  a  role  in  recruiting  polymerase  alpha  to  stalled 
replication forks.  
 
ATM, ATR kinases belong to a series of primary transducers that can activate secondary 
kinases or directly target effector proteins. Two well known secondary signal transducer 
include Chk1 and Chk2. 
 
 
1.9.3 Chk2 
 
 The checkpoint kinase 2 protein (Chk2) is a common target of ATM and DNA-PK. Chk2 
exists as inactive monomers in unperturbed cells. Oligomerization of Chk2 during DNA 
damage  is  believed  to  increase  the  protein  kinase  activity  (Ahn  et  al.,  2004).  In  the 
presence  of  DNA  damage,  Chk2  undergoes  multiple  intermolecular  phosphorylations. 
ATM phosphorylates Chk2 in a serine/threonine cluster at threonine 68 in response to IR 
treatment.  Active  Chk2  phosphorylates  p53  at  Serine20  and  blocks  p53-MDM2 Chapter 1: Introduction 
 
44 
 
interaction consequently stabilizing p53. Similarly, BRCA1 phosphorylates p53 efficiently 
at serine 15 after activation by ATM (Schwarz et al., 2003; Melchionna et al., 2000; Ahn et 
al., 2000).  
 
1.9.4 Chk1 
 
The Chk1 kinase is one of the best studied ATR substrates. Its activation by ATR-mediated 
phosphorylation  requires  the  presence  of  the  mediator  protein  claspin  (Kumagai  A, 
Dunphy, 2000; Kumagai et al., 2004; Liu, 2006). Phosphorylation of Chk1 by ATR takes 
place at serine residues 317 and 345 and results in a marked increase in kinase activity 
(Zhao & Piwnica-Worms, 2001).  
 
 
1.9.5 Direct targets of ATR/ATM 
 
The effector kinases are so named due to the effect they produce on the cell. These 
effects include DNA replication inhibition, recruitment of the DNA repair machinery or 
apoptosis. Active ATM phosphorylates downstream targets including p53, MDM2, BRCA1, 
and 53BP1. The p53 protein is stabilized and activated after being phosphorylated on 
multiple serine residues. Phosphorylation at serine 9 and serine 15 inhibits binding to 
MDM2. Phosphorylation at serine 20 and 46 has important consequences for apoptotic 
activity.  ATM-mediated  phosphorylation  of  MDM2,  a  negative  regulator  of  the  p53 
tumour suppressor, increases MDM2 auto-ubiquitination. ATR has been implicated in the 
late phosphorylation of p53 at serine 15 after treatment with IR (Shiloh, 2001).  
 
 
1.10 Cdc25 Phosphatases 
 
The ATR/Chk1 and ATM/Chk2 pathways converge to inactivate members of the Cdc25 
family of phosphatases (Donzelli & Draetta, 2003). The ability of cells to divide is mainly 
attributed  to  the  presence  of  two  classes  of  molecules,  a  family  of  serine/threonine 
kinases called the cyclin-dependent kinases (Cdks) and their binding partners the cyclins. Chapter 1: Introduction 
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Cdks are highly conserved and become activated once associated with their regulatory 
cyclin subunits (Nurse, 2000). Cdk-cyclin complexes vary and are activated at different 
stages within the cell cycle (Table 1.3) 
 
Table 1.3 
 
Cdk  Cyclin Partner  Activation Phase 
Cdk3  cyclin C  G0/G1 
Cdk4 
Cdk2 
cyclin D 
cyclin E 
mid-late G1 
 
Cdk2  cyclin A  S phase 
Cdk1 
Cdk2 
cyclin A 
cyclin B 
late G2-mitosis 
 
Table 1.3 Regulatory partners of Cdk kinases (Sherr, 2000; Sage, 2004). 
 
 
Cdk activity during the cell cycle is tightly controlled in order to ensure the integrity of 
DNA sequence and coordination of mitotic events. The regulation of Cdks  is, in part, 
controlled  by  a  family  of  proteins  called  the  cell-division  cycle  25  (Cdc25).  Cdc25 
phosphatases are conserved amongst all eukaryotic cells. In mammalian cells there are 
three Cdc25 genes (Cdc25A/B/C) (Galaktionov & Beach, 1991; Sadhu et al., 1990; Nagata 
et al., 1991). In unperturbed cells, Cdc25B activates the Cdk1/cyclin B complex at the 
centrosome therefore initiating mitosis (Jackman et al., 2003). The G1/S phase transition 
is predominantly controlled by Cdc25A. Cdc25A is activated prior to S phase initiation and 
a result of this is activation of the Cdk2/cyclin E complex (Jinno et al., 1994; Blomberg & 
Hoffmann,  1999).  During  S  phase,  Cdc25A  also  activates  the  Cdk2/cyclin  A  complex 
driving the synthesis of DNA replication.  
 
In response to damaged DNA, Chk1 and Chk2 delay cell cycle progression by targeting and 
inhibiting the Cdc25 proteins (Donzelli M, Draetta, 2003). Cdc25A is a critical substrate for 
activated Chk1 and Chk2. Chk1 phosphorylates Cdc25A at serine 76,124,178,279,293 and 
threonine 507. Chk2 protein also phosphorylates Cdc25A at serine 124, 178,279 and 293 Chapter 1: Introduction 
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(reviewed in Kiyokawa & Ray, 2008). Chk1Phosphorylation of Cdc25A at serine 76 serves 
as an initiation event to promote subsequent Cdc25A phosphorylation at serines 82 and 
88. This subsequent phosphorylation facilitates the recognition of βTrCP ubiquitin ligase 
complex  (Busino  et  al.,  2003).  Polyubiquitnated  Cdc25A  is  then  recruited  to  the 
proteosome for degradation thus arresting the cell cycle (Jin et al., 2003).  
 
Cdc25B and C also undergo similar phosphorylation by Chk1 and Chk2. During interphase 
of the cell cycle, Chk1 negatively regulates Cdc25B and therefore prevents mitotic entry 
(Kramer et al., 2004; Loffler et al., 2006). Chk2 phosphorylates Cdc25C at serine 216 and 
assists  binding  with  the  14-3-3  complex.  Interaction  with  the  14-3-3  complex 
consequently  sequesters  Cdc25C  to  the  cytoplasm  therefore  hindering  cell  cycle 
progression (Kiyokawa & Ray, 2008).  
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1.11 DNA repair - double stranded breaks 
 
Double-strand breaks are hazardous to the cell. If left unrepaired they can lead to a loss 
of heterozygosity, mutations, deletions, genomic rearrangements and chromosome loss. 
These  factors  contribute  to  cancer  and  genetic  disease.  Mechanisms  exist  to  repair 
double-strand  breaks  (DSBs)  including  non-homologous  end  joining  (NHEJ),  and 
homologous recombination (HR). 
 
1.11.1 Non homologous end joining 
 
Non homologous end joining is referred to as "non-homologous" because the break ends 
are directly ligated without the need for a homologous template. In contrast, homologous 
recombination requires a homologous sequence to guide repair. A DSB within the DNA is 
recognized by the Ku dimer (Ku70–Ku80). The two DNA ends are brought together by 
DNA-PKcs.  DNA-PKcs/MRN  and  Artemis  are  phosphorylated,  and  the  DNA  ends  are 
processed by a protein complex consisting of XLF, XRCC4 and DNA ligase IV (reviewed in 
Lieber et al., 2010). The DNA ends are ligated by DNA ligase IV, and the DNA-repair factors 
dissociate (Figure 1.12). Major themes of NHEJ include flexibility in handling diverse DNA 
end configurations by the nuclease, polymerase, and ligase activities and also repetitive 
processing of each DNA end (Lieber et al., 2010).   
 
HPV DNA integration into that of the host genome is believed to occur through HNEJ. 
Studies into the pathogenic role of genomic integration of HPV16, HPV18 and HPV31 
genomes  have  analysed  integration  sites  in  anogenital  precancerous  and  cancerous 
lesions. At many integration sites, a short overlap between HPV and genomic sequences 
is observed. These data suggests that the integration of HPV genomes is mediated by 
HNEJ (Ziegert et al., 2003).  
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Figure 1.12 
 
 
Figure 1.12 DNA damage repair: NHEJ. A DSB is recognized by the Ku dimer (Ku70–Ku80) 
and DNA-PKcs.  The  two  DNA ends  are  then bridged together.  DNA-PKcs  and  Artemis 
become phosphorylated and this results in the formation of the ligase complex (XRCC4-
like complex, XRCC4, DNA ligase IV and Artemis). Upon activation, the DNA ends are 
ligated by DNA ligase IV, and the DNA-repair factors dissociate (modified from Downs et 
al., 2007). 
 
1.11.2 Homologous recombination 
 
Homologous recombination (HR) repairs DNA breaks without loss of genetic information 
(reviewed in van den Bosch et al., 2002). Homologous recombination uses a homologous 
DNA template and is therefore highly accurate (whereas NHEJ rejoins the broken ends 
without using a template and is often accompanied by loss of some nucleotides).  
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1.12 DNA repair – single stranded breaks 
 
When  only  one  of  the  two  strands  of  a  double  helix  encounters  a  DNA  break,  the 
undamaged strand can be used as a template to guide the correction of the damaged 
strand. A number of excision repair mechanisms that remove the damaged nucleotide 
and  replace  it  with  an  undamaged  nucleotide  complementary  to  that  found  in  the 
undamaged DNA strand exist.  
 
 
1.12.1 Mismatch repair 
 
The  main  role  of  mismatch  repair  (MMR)  is  to  remove  base  mismatches  and  small 
insertion/deletion  loops  (IDLs)  that  can  sometimes  occur  during  replication.  Most 
knowledge of MMR stems from research carried out in Escherichia coli (E.coli) (reviewed 
in Kolodner, 1996). The main proteins involved in E.coli MMR are MutS, MutL and MutH 
(Modrich, 1991).  
 
 
1.12.2 Nucleotide excision repair 
 
Nucleotide excision repair (NER) is the most flexible of the DNA repair pathways due to 
the diversity of DNA lesions it acts upon. These include pyrimidine dimers, bulky chemical 
adducts, DNA intrastrand crosslinks and forms of oxidative damage. The NER process 
requires  the  action  of  damage  recognition,  opening  of  the  DNA  helicase  around  the 
lesion, dual incision of the damaged strand, gap repair synthesis, and  strand ligation. 
There  two  distinct  forms  of  NER.  Global  genomic  NER  (GG-NER)  repairs  damage  at 
transcriptionaly  silent  parts  of  the  genome  and  transcription  coupled  NER  (TC-NER), 
repairs damage at transcriptionaly active genes (reviewed in Schuck et al., 2008). 
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1 .12.3 Base excision repair 
 
The base excision repair (BER) is the main cellular defence pathway against endogenous 
DNA damage. The rate of endogenous DNA damage is estimated to be at least 20,000 
lesions  per  cell  per  day  (Lindahl,  1993;  Sung  &  Demple,  2006).  The  BER  pathway  is 
activated in response to damage including abasic sites, oxidative lesions, alkylated and 
alternative bases. There are two major BER repair pathways: short and long patch repair 
(Klungland & Lindahl, 1997; McCullough et al., 1999; Matsumotoet al., 1999). 
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1.13 Research Aims 
 
DNA from the high risk HPVs 16/18 is frequently found integrated into host cell DNA in 
high grade squamous intraepithelial lesions (SIL) and squamous cell carcinomas (Cooper 
et al., 1991; Kristiansen et al., 1994; Alazawi et al., 2002; Peitsaro et al., 2002; Arias-Pulido 
et al., 2006; Pett et al., 2006). In cervical malignancies, over half of HPV16-positive and 
nearly all of HPV18-positive malignancies contain integrated HPV genomes (reviewed in 
Pett & Coleman, 2007). Factors that may promote integration include viral replication 
during DNA damage. Replication of the HPV episome will create substrates for NHEJ and 
this may promote HPV integration.  
 
E2  is  a  multifunctional  protein  and  it  is  involved  in  viral  replication,  transcription 
regulation and long term maintenance of the viral episome. Factors that promote E2's 
stability will affect the virus life cycle and may reveal antiviral therapeutic targets. The 
rate  at  which  HPV  DNA  is  replicated  varies  as  part  of  the  viral  life  cycle.  Vegetative 
replication, where viral genomes are amplified to a high copy number, is triggered in 
differentiated epithelial cells. This may be due to an increase in the levels of the viral 
replication proteins. The levels of BPV1 E2 protein is greatly increased in BPV1 cells that 
undergo  spontaneous  amplification  of  the  viral  genome  suggesting  that  increased  E2 
protein levels may account for amplificational replication (Burnett et al., 1990; Penrose 
and McBride, 2000). The E1 and E2 proteins are known to interact during the viral life 
cycle however the consequences of this interaction on E2 stability and function remains 
controversial.  
 
The activation of DNA damage pathways is well described in the literature however the 
downstream target proteins at the replication fork are not as well defined. There is some 
evidence to suggest that the MCM2-7 cellular helicase is phosphorylated by the DNA 
damage response (Cortez et al., 2004; Ishimi et al., 2003a). SV40 DNA replication control 
mimics that of cellular DNA replication (Miao et al., 2003). The LTAg protein forms a 
dihexameric complex that is able to replicate the SV40 origin in a bidirectional manner Chapter 1: Introduction 
 
52 
 
similar to the MCM2-7 and E1 helicase complexes. Therefore SV40 DNA replication is 
often used as a model for eukaryotic DNA replication.  
 
Based on this knowledge, the following hypotheses were made: 
 
  A factor that may promote HPV integration is the ability of HPV E1 and E2 mediated 
DNA replication to go unregulated by the DNA damage response pathways 
 
  The SV40 LTAg viral helicase is targeted by an activated DNA damage response  
 
  The interaction between the HPV E2 and E1 proteins will alter E2 protein stability and 
function. 
 
 
This thesis has three main aims: 
 
(i) To assess HPV E1/E2 mediated replication in the presence of DNA damage and an 
activated cellular DNA damage response. 
 
This was investigated using transient in vivo replication assays. E1 and E2 expressed from 
transfected plasmids were used to study the replication of HPV origin plasmids in the 
presence and absence of DNA damaging agents.  
 
(ii) To identify the downstream targets of the DNA damage response pathways. 
 
This aim was investigated using the SV40 Large T Antigen viral helicase as a model for 
eukaryotic DNA replication. The phosphorylation of the viral helicase by ATR/ATM during 
DNA damage was studied using co-immunoprecipitation techniques. An antibody that 
detects  phosphorylated  targets  of  ATR  and  ATM  was  used  to  identify  LTAg  pulldown 
during an activated DNA damage response indicating that this protein is being targeted by 
the DNA damage response pathways.  
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 (iii) To assess the regulatory and functional consequences of the E1.E2 interaction. 
  
This was examined using a plasmid that expressed wild type HPV16 E2 and a plasmid that 
expressed an E2 mutant that did not interact with E1. The stability of the E2 protein was 
measured by calculating protein half life in the presence and absence of an E1 expressing 
plasmid. The transcriptional function of E2 was also assessed in the presence and absence 
of an E1 expressing plasmid using an E2 responsive reporter plasmid containing six E2 
binding sites. For all experiments the E2 wild type protein was compared to E2 mutant 
that did not interact with E1.  
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Chapter 2 – Materials and Methods 
 
2.1 Materials 
 
2.1.1 Antibodies 
 
Abcam plc. (Cambridge, United Kingdom) 
Rabbit polyclonal to ATR 
Catalogue Number: ab10312 
Rabbit monoclonal to Chk1 
Catalogue Number: ab40866 
 
Covance Inc. (Princeton, USA) 
HA.11 Clone 16B12 Monoclonal Antibody 
Catalogue Number: MMS-101R 
 
Dr. Merilyn Hibma (University of Otago, New Zealand) 
The TVG 261, Human Papilloma Virus-16 early protein 2 (HPV16-E2) Antibody was a kind 
gift from Dr. Merilyn Hibma (University of Otago) 
 
Dr. Thomas Melendy (University of Buffalo, USA) 
pAb101, SV40 Large T Antigen Monoclonal Antibody was a kind gift from Dr. Thomas 
Melendy (University of Buffalo). The pAb101 recognizes a C terminal epitope within the 
last 190 amino acids of LTAg. Chapter 2: Materials and Methods 
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pAb419, SV40 Large T Antigen Monoclonal Antibody was a kind gift from Dr. Thomas 
Melendy (University of Buffalo). The epitope is contained between amino acids 1 and 82 
of LTAg.  
 
New England Biolabs Ltd. (Herts, United Kingdom) 
Phospho-Chk1/2 Antibody Sampler Kit 
Catalogue Number: 9931 
Phospho-(Ser/Thr) ATM/ATR Substrate Antibody) 
Catalogue Number: 2851 
 
Sigma-Aldrich Company Ltd. (Dorset, United Kingdom) 
Anti-Mouse IgG (whole molecule) - peroxidase antibody produced in goat 
Catalogue Number: A4416 
Anti-Rabbit IgG (whole molecule) peroxidase developed in goat 
Catalogue Number: A6154 
GTU-88, Monoclonal Anti-γ-Tubulin antibody produced in mouse 
Catalogue Number: T6557 
 
TopBP1 Antibody 
TopBP1 polyclonal antibody R1180 against amino acids 861-1287 was raised in a rabbit, 
method  of  preparation  of  the  antibody  and  the  preimmune  have  been  described 
previously (Boner et al 2002). 
 
 
2.1.2 Bacteriology 
 
Bibby Sterlin Ltd (Staffordshire, United Kingdom) 
90mm bacteriology petri dishes - Catalogue Number: 502014 
 
Invitrogen Ltd. (Paisley, United Kingdom) 
S.O.C. medium - Catalogue Number: 15544-034 
Subcloning efficiency DH5α competent cells - Catalogue Number: 18265-017 Chapter 2: Materials and Methods 
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Sigma-Aldrich Company Ltd. (Dorset, United Kingdom) 
Ampicillin - Catalogue Number: 10047 
LB-Agar- Catalogue Number: L2897 
LB-Broth -Catalogue Number: L3022 
 
 
2.1.3 Cell lines 
 
C33A cells are derived from a HPV negative cervical carcinoma and are defective for both 
p53 and Rb function. 
 
Human Embryonic Kidney 293 (293) are a specific cell line originally derived from human 
embryonic kidney cells grown in tissue culture 
 
Human Embryonic Kidney 293T (HEK293T) derived from the 293 cell line in which the 
SV40 T-antigen was inserted. 
 
 
2.1.4 Chemicals 
 
Amersham International PLC (Buckinghamshire, United Kingdom) 
Enhanced chemiluminescence (ECLplus) detection substrate - Catalogue Number: PRPN2132 
Hyperfilm X-ray film - Catalogue Number: 93184 
 
Applied Biosystems (Warrington, United Kingdom) 
Hi-Di™ Formamide - Catalogue Number: 4336697 
 
Bio-Rad Laboratories Ltd. (Hertfordshire, United Kingdom) 
Bio-Rad protein assay dye (Bradford) reagent concentrate (5X) – Catalogue Number: 500-0006 
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Merck Chemicals Ltd. (Nottingham, United Kingdom) 
Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132) – Catalogue Number: 474791 
3,8-Diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridiniumdiiodide 
(Propidium Iodide) – Catalogue Number: JA1654 
 
Roche Biosystems (Basel, Switzerland) 
Complete protease inhibitor cocktail tablets - Catalogue Number: 04 693 159 001 
 
Sigma-Aldrich Company Ltd. (Dorset, United Kingdom) 
3,8-Diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium  diiodide 
(Propidium Iodide) – Catalogue Number: 81845 
3-Hydroxy-4-(2-sulfo-4-[4-sulfophenylazo]  phenylazo)-2,  7-naphthalenedisulfonic  acid 
sodium salt (Ponceau S) - Catalogue Number: P7170 
4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) - Catalogue Number: H4034 
4’-Demethylepipodophyllotoxin  9-(4,6-O-ethylidene-β-D-glucopyranoside)  (Etoposide)  – 
Catalogue Number: E1383 
Acetic acid sodium salt (Sodium acetate) - Catalogue Number: S2889 
Aphidicolin – Catalogue Number: A0781 
Bovine serum albumin protein standard - Catalogue Number: P0834 
Caffeine 99% tissue culture grade - Catalogue Number: C8960 
Calcium chloride solution, 1M - Catalogue Number: 21115 
Camptothecin – Catalogue Number: C9911 
Cycloheximide - Catalogue Number: C4859 
D-(+)-Glucose (Dextrose) - Catalogue Number: G8270 
Magnesium chloride (MgCl2) anhydrous beads - Catalogue Number: 449172 
Nonident P-40 (NP40) - Catalogue Number: I8896 
Phenol: chloroform: isoamyl alcohol (25:24:1) - Catalogue Number: P3803 
Phosphate buffered saline - Catalogue Number: P4417 
Potassium chloride - Catalogue Number: P3911 
Propan-2-ol (Isopropanol) - Catalogue Number: 24137 
Ribonuclease 3’- pyrimidinooligonucleotidohydrolase (Ribonuclease A) – Catalogue Number: 
R4642 Chapter 2: Materials and Methods 
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Sodium chloride - Catalogue Number: S7653 
Sodium dodecyl sulphate (SDS) AnalaR® - Catalogue Number: L4509 
Tris base (2-Amino-2-(hydroxymethyl)-1, 3-propanediol) - Catalogue Number: T6066 
Tween 20 (polyoxethylene sorbitan nonolaurate) - Catalogue Number: P1379 
 
University of Glasgow (University of Glasgow Stores) 
Crude Ethanol 
Crude Methanol 
 
VWR International Ltd. (Leicestershire, UK) 
Absolute 99.7-100% AnalaR® ethanol - Catalogue Number: 10107EP 
Acetic acid AnalaR® - Catalogue Number: 10001CU 
Crystal Violet - Catalogue Number:  340245L 
Disodium hydrogen phosphate (Na2HPO4) AnalaR® - Catalogue Number: 102494C 
Dimethyl sulfoxide (DMSO) - Catalogue Number:  8029122500 
Ethylenediaminetetraacetic acid (EDTA) AnalaR® - Catalogue Number: 100938B 
Hydrochloric acid - Catalogue Number: 101254H 
Methanol AnalaR® - Catalogue Number: 10158FK 
Sodium Hydroxide Pellets AnalaR - Catalogue Number: 102527R 
 
 
2.1.5 Enzymes 
 
New England Biolabs Ltd. (Herts, United Kingdom) 
DpnI – Catalogue Number: R0176L 
Exonuclease III (E.coli) - Catalogue Number: M0206L 
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2.1.6 Kits 
 
Applied Biosystems (Warrington, United Kingdom) 
ABI Prism® BigDye®Terminator v3.1 Cycle Sequencing Kits – Catalogue Number: 4337436  
DNA-free™ - Catalogue Number: AM1906 
RNaseZap - Catalogue Number: AM9780 
 
Invitrogen Ltd. (Paisley, United Kingdom) 
NuPAGE® 4-12% Bis-Tris 10 well 1.0 mm gels - Catalogue Number: NP0321 
NuPAGE® 4-12% Bis-Tris 12 well 1.0 mm gels - Catalogue Number: NP0322 
NuPAGE® Antioxidant  - Catalogue Number: NP0005 
NuPAGE® LDS Sample Buffer – Catalogue Number: NP0007 
NuPAGE® MES SDS Running Buffer (20X) - Catalogue Number: NP0002 
NuPAGE® Sample Reducing Agent (10X) - Catalogue Number: NP0009 
NuPAGE® Transfer Buffer (20X) - Catalogue Number: NP0006-1 
Purelink® plasmid maxiprep kit - Catalogue Number: K2100-07 
SeeBlue Plus2 prestained standard - Catalogue Number: LC5925 
SuperScript® III first-strand synthesis system for RT-PCR - Catalogue Number: 18080-051 
 
Agilent Technologies UK Limited. (Cheshire, United Kingdom) 
AffinityScript QPCR cDNA synthesis kit – Catalogue Number: 600559 
Brilliant® QPCR master mix – Catalogue Number: 600549 
 
© Merck KGaA (Darmstadt, Germany) 
KOD Hot Start DNA polymerase – Catalogue Number: 71086 
 
Promega UK Ltd. (Southampton, United Kingdom) 
Luciferase assay substrate – Catalogue Number: E151A 
Reporter lysis buffer 5X – Catalogue Number: E397A 
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Qiagen Ltd. (West Sussex, United Kingdom) 
RNeasy mini kit – Catalogue Number: 74104 
QIAshredder – Catalogue Number: 79654 
 
 
Sigma-Aldrich Company Ltd. (Dorset, United Kingdom) 
Protein A-Sepharose
® 4B, fast flow from Staphylococcus aureus – Catalogue Number: P9424 
Protein G  Sepharose
®,  fast  flow  recombinant  expressed  in  Escherichia  coli  –  Catalogue 
Number: P3296 
 
 
2.1.7 Cell culture 
 
Corning Incorporated (Leicestershire, United Kingdom) 
100mm x 20mm non-pyrogenic cell culture dishes - Catalogue Number: 430167 
60mm x 15mm non-pyrogenic cell culture dishes - Catalogue Number: 430166 
25ml disposable serological polystyrene pipettes - Catalogue Number: 4251 
10ml disposable serological polystyrene pipettes - Catalogue Number: 4101 
5ml disposable serological polystyrene pipettes - Catalogue Number: 4051 
Cell scraper - Catalogue Number: 3010 
 
Invitrogen Ltd. (Paisley, United Kingdom) 
0.05% Trypsin-EDTA 1X – Catalogue Number: 25300 
DMEM + GlutaMAX™ Dulbeccos Modified Eagle Medium – Catalogue Number: 31966 
Fetal calf serum – Catalogue Number: 16101 
Lipofectamine™ 2000 Transfection Reagent – Catalogue Number: 11668027  
Opti-MEM® reduced serum media – Catalogue Number: 31985 
Penicillin/streptomycin solution – Catalogue Number: 15140 
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Greiner Bio-One Ltd. (Gloucestershire) 
15ml polypropylene centrifuge tubes - Catalogue Number: 188261 
50ml polypropylene centrifuge tubes - Catalogue Number: 210201 
Tissue culture flasks 175cm
2 – Catalogue Number: 660160 
Tissue culture flasks 75cm
2 – Catalogue Number: 658170 
 
 
© Merck KGaA (Darmstadt, Germany) 
GeneJuice
® Transfection Reagent – Catalogue Number: 70967 
 
 
2.1.8 Miscellaneous 
 
BD Biosciences (Oxford, United Kingdom) 
5ml falcon tube - Catalogue Number: 352052 
 
Elkay International (Basingstoke, United Kingdom) 
1.5ml microcentrifuge tubes with attached cap - Catalogue Number: MICR050 
0.5ml microcentrifuge tubes with attached cap - Catalogue Number: MICR051 
Plastic pasteur pipettes - Catalogue Number: P511 
 
VWR International Ltd. (Leicestershire, United Kingdom) 
Cuvet – Catalogue Number: 634-2501 
 
STARLAB (UK), Ltd. (Milton Keynes, United Kingdom) 
TipONE 1-20µL Bevelled Filter Tips - Catalogue Number: S1120-1810 
TipONE 1-100µL Graduated Filter Tips - Catalogue Number: S1120-8810 
TipONE 101-1000µL Extended Length Filter Tips - Catalogue Number: S1122-1834 
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Thermo Fisher Scientific Inc. (Hertfordshire, United Kingdom) 
0.5ml thermo PCR tube - Catalogue Number: AB-0350 
Thermo fast 96 well PCR plate - Catalogue Number: AB-0600 
Optical 8-cap strip - Catalogue Number: 4323032 
 
Thermo Labsytems Corporation (Warwickshire, United Kingdom) 
Luminoskan Acsent Luminometer and Ascent software (version 2.4.2) 
 
Global Medical Instrumentation, Inc. 
MJ Research PTC-200 Thermo Cycler 
Leica Microsystems (UK) Ltd. (Milton Keynes, UK) 
Illumination Leica DM IL LED Microscope 
Invitrogen Ltd. (Paisley, United Kingdom) 
iBlot® Dry Blotting System 
 
 
Wm Morrison Supermarkets plc (Anniesland, UK) 
Marvel dried skimmed milk 
 
Kimberley Clark (Brighton, United Kingdom)  
Safeskin Disposable Purple Nitrile Exam Gloves - Catalogue Number: 014602 
 
 
2.1.9 Plasmids 
 
pGL3 control contains SV40 promoter and enhancer sequences driving the expression of firefly 
luciferase (Promega Ltd Southampton, United Kingdom). 
 
pGL3  basic  lacks  SV40  promoter  and  enhancer  sequences  but  contains  the  firefly 
luciferase (Promega Ltd Southampton, United Kingdom). Chapter 2: Materials and Methods 
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ptk6E2luc  contains  the  thymidine  kinase  promoter  from  HSV-1  cloned  into  the  pGL3 
luciferase vector upstream of 6 HPV16 E2 binding sites (Vance et al. 1999). 
 
pCMV-E2 contains the entire HPV16 E2 open reading frame. cloned into XbaI-SmaI sites 
of  the  cytomegalovirus  immediate-early  promoter/enhancer-based  expression  vector 
pCMV4 (Sakai et al, 1995). 
 
pCMV-E39A E39A contains HPV16 E2 ORF that had been mutated at amino acid position 
39 by replacing a glutamic acid with alanine. The mutation was synthesised in the pCMV 
E2 vector.  
 
pCMV-E1  (E1-Rep)  was constructed  by  inserting  the  HPV16 DNA  fragment  (nt  865 to 
2813), into XbaI-SmaI sites of pCMV4 (Sakai et al, 1995) 
 
pMH1-16E1HA was constructed by inserting E1 ORFs from HPV -16 (83–2814 nt) into 
pMH1. The major splice donor site (AGGT) at the beginning of E1 ORFs was disrupted by 
inserting influenza hemagglutinin epitope tag (HA) in-frame into the E1 coding sequence. 
The inserted HA tag had no effect on the E1 protein activities (Kadaja et al 2007). This 
plasmid was a kind gift from Mart Ustav, University of Tartu. 
 
pMH1-11E1HA  was  constructed  as  described  above.  Additional  point  mutation  was 
introduced into the splicing acceptor site of HPV11 E1 ORF (2622 nt), (ACA → ACC), and 
this  did  not  change  the  coding  capacity.  This  plasmid  was  a  kind  from  Mart  Ustav, 
University of Tartu. 
 
pOri16M is a modified version of pOri16 described (Sakai et al., 1996). The HPV16 Ori (nt 
7838–139) was PCR amplified from pOri16 with a primer containing a point mutation at 
nt 115 (C to T) of the HPV16 genome creating a DpnI site (GATC). The PCR fragment was 
cloned as an EcoRI/BamHI fragment into pSKII (−) 
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pLT contains the entire SV40 LTAg open reading frame. 
 
pLTAg-S120A contains SV40 LTAg ORF that had been mutated at amino acid position 120 
by replacing a serine amino acid with alanine. The mutation was synthesised in the pLT 
vector. 
 
pLTAg-T517A contains SV40 LTAg ORF that had been mutated at amino acid position 517 
by replacing a threonine amino acid with alanine. The mutation was synthesised in the 
pLT vector. 
 
pLTAg-S639A contains SV40 LTAg ORF that had been mutated at amino acid position 639 
by replacing a serine amino acid with alanine. The mutation was synthesised in the pLT 
vector. 
 
pLTAg-S664,666A contains SV40 LTAg ORF that had been mutated at amino acid positions 
664  and  666  by  replacing  a  serine  amino  acid  with  alanine.  The  mutations  were 
synthesised in the pLT vector. 
 
pLTAg-S676A contains SV40 LTAg ORF that had been mutated at amino acid position 676 
by replacing a serine amino acid with alanine. The mutation was synthesised in the pLT 
vector. 
 
pcDNA 3.1 contains CMV promoter and was used as a carrier plasmid, Invitrogen Ltd. 
(Paisley, United Kingdom) 
 
pCMV E2 (b) contains HPV16 E2 ORF and was a kind gift from Peter Howley. 
 
pCMV R37A  contains the HPV16 E2 ORF with mutation at  amino acid position 37 by 
replacing an arginine for an alanine. This plasmid was a kind gift from Peter Howley.  
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pTM1-E1 contains the full length HPV11 E1 ORF inserted into pTM1. This plasmid was a 
kind gift from Jacques Archambault. 
 
pCR3-E2 contains the full length HPV11 E2 ORF inserted into pCR. This plasmid was a kind 
gift from Jacques Archambault. 
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2.1.10 Oligonucleotides 
 
2.1.10.1 Real-Time PCR analysis 
Eurogentec Ltd. (Southampton, United Kingdom) 
 
Table 2.1 Oligonucleotide for RT-PCR analysis 
Oligonucleotide  Sequence Written 5’ to 3’ 
Beta actin probe  ATTTCCCGCTCGGCCGTGGT 
Beta actin FWD  AGCGCGGCTACAGCTTCA 
Beta actin REV  CGTAGCACAGCTTCTCCTTAATGTC 
HPV16 E1 probe  ATGATAATGATTATTTAACACAGGCAGAAACAGAGACAGC 
HPV16 E1 FWD  CGAGAACGAAAATGAACAGTGATACA 
HPV16 E1 REV  TTTTGGTTCCTGTGCAGTAAACA 
HPV16 E2 probe  CAACCACCCCGCCGCGA 
HPV16 E2 FWD  CCTGAAATTATTAGGCAGCACTTG 
HPV16 E2 REV  GCGACGGCTTTGGTATGG 
HPV ori probe  ACCAAAAGAGAACTGCAATGTTTCAGGATCC 
HPV ori FWD  ATCGGTTGAACCGAAACCG 
HPV ori REV  TAACTTCTGGGTCGCTCCTG 
Large T Antigen probe  AAGCAACTCCAGCCATCCATTCTTCTATGTC 
Large T Antigen FWD  TTTGGGCAACAAACAGTGTAGC 
Large T Antigen REV  AATGTTTGGTTCTACAGGCTCTGC 
Luciferase probe  CACTGATCATGAACTCCTCTGGATCTACTGGTC 
Luciferase FWD  TCCTTCGATAGGGACAAGACAATT 
Luciferase REV  GGCAGAGCGACACCTTTAGG 
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2.1.10.2 Site directed mutagenesis 
VH Bio Ltd. (Gateshead, United Kingdom) 
 
Table 2.2 Oligonucleotides for site directed mutagenesis 
Oligonucleotide  Sequence 5’ to 3’ 
LTAg: S120A   
FWD  GATGAGGCTACTGCTGACGCTCAACATTCTACTCCTCCAAAAAAG 
REV  CTTTTTTGGAGGAGTAGAATGTTGAGCGTCAGCAGTAGCCTCATC 
LTAg: T517A   
FWD  AAACACCTAAATAAAAGAGCTCAAATATTTCCCCCTGGAATAG 
REV  CTATTCCAGGGGGAAATATTTGAGCTCTTTTATTTAGGTGTTT 
LTAg: S639A   
FWD  GATGATGATGATGAAGACGCCCAGGAAAATGCTGATAAAAATGAAG 
REV  CTTCATTTTTATCAGCATTTTCCTGGGCGTCTTCATCATCATCATC 
LTAg: S664,666A   
FWD  GAAACAGGCATTGATGCACAGGCCCAAGGCTCATTTCAGGCC 
REV  GGCCTGAAATGAGCCTTGGGCCTGTGCATCAATGCCTGTTTC 
LTAg: S676A   
FWD  TTTCAGGCCCCTCAGTCCGCACAGTCTGTTCATGATCATAATC 
REV  GATTATGATCATGAACAGACTGTGCGGACTGAGGGGCCTGAAA 
E2: E39A   
FWD  TATTGGAAACACATGCGCCTAGCATGTGCTATTTATTACAAGGCC 
REV  GGCCTTGTAATAAATAGCACATGCTAGGCGCATGTGTTTCCAATA 
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2.1.10.3 siRNA knockdown 
Dharmacon Inc. (Leicestershire, United Kingdom) 
 
Table 2.3 Oligonucleotides for siRNA knockdown 
Oligonucleotide  Target Sequence 
siATR  CCCGCGUUGGCGUGGUUGAdTdT 
siLuciferase  CGUACGCGGAAUACUUCGAdTdT 
siTopBP1  GUGGUUGUAACAGCGCAUCdTdT 
 
 
2.1.10.4 Sequencing 
VH Bio Ltd. (Gateshead, United Kingdom) 
 
Table 2.4 Oligonucleotides for DNA sequencing 
Oligonucleotide  Sequence 5’ to 3’ 
LTAg S120A  GGAACTGATGAATGGGAG 
LTAg T517A  GATTTGCCTTCAGGTCAG 
LTAg S639A  GAGAGATTGGACAAAGAG 
LTAg S664,666A  GAGAGATTGGACAAAGAG 
LTAg S676A  GAGAGATTGGACAAAGAG 
E2 E39A  CGTGGATCCGAGACTCTTTGC 
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2.2 Methods 
 
The protocols used in this thesis are described in the following section. The manufacturer 
and distributor details for the materials used are given in the previous section. 
 
2.2.1 Cell culture methodology 
 
 
2.2.1.1 General growth 
 
All cell culture experiments were carried out in a tissue culture laboratory and under strict 
aseptic conditions. All cell culture procedures were carried out in a Class II laminar flow 
hood (BioMAT 2, MAT, Derby, U.K.). The 293T, 293 and C33A cell lines were grown in 
DMEM+GlutaMAX with 10% (v/v) foetal calf serum and 1% (v/v) penicillin/streptomycin 
mixture (Invitrogen) at 37 °C in a 5% CO2/95% air atmosphere (LEEC GA2000 Cell Culture 
Research Incubator, LEEC Ltd.). Cell lines were passaged at least twice a week. The cells 
were harvested by trypsonisation 
 
 
2.2.1.2 Calcium phosphate transient transfection 
 
Cells were transiently transfected using the calcium phosphate precipitation technique. 
Cells were counted and were plated out onto sterile plates with 5mls of media for 60mm
2 
plates or 10ml of media for 100mm
2 plates and left over night in the incubator to adhere. 
The following day, the plasmid DNA of interest was mixed with distilled water to a final 
volume of 375μl. 125μl of 1M CaCl2 was then added to the mix. This 500μl solution was 
then added drop wise to 2X HEPES buffered saline (50mM HEPES, 280mM NaCl, and 
1.5mM Na2HPO4.2H2O to pH 7.0). The solution was left at room temperature until the 
formation of an opaque precipitate could be seen.  The precipitate was then added to 
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16 hours. The cell monolayer was then washed twice with PBS and fresh medium was 
added before an additional 24 hour incubation. 
 
 
2.2.1.3 GeneJuice transient transfection 
 
293  cells  were  transfected  with  pLTAg  mutated  using  the  GeneJuice®  method  of 
transfection (Novagene). Briefly 1x10
6 293 cells were plated out in normal growth media 
onto 100mm dishes (so as to achieve around 80% confluence at harvest) and incubated at 
37°C (5% CO2) overnight. For each dish to be transfected, 800μl of Opti-MEM® was placed 
into a sterile tube. GeneJuice® was then added drop wise to the serum free media and 
incubated at room temperature for 5 minutes. The volume of GeneJuice® used was 2μl 
per μg of plasmid DNA being transfected. (i.e. 2μg of pLTAg
mutated with 4μl of GeneJuiceﾮ). 
After incubating, the plasmid DNA was added to the mix and gently mixed by pippeting. 
The GeneJuice/DNA mixture was incubated at room temperature for 15  minutes. The 
entire volume of GeneJuice/DNA mixture was added dropwise to the dish whilst gently 
rocking motion to ensure equal distribution. Cells were incubated for 24-48 hours and 
harvested for protein extraction.  
 
 
2.2.1.4 Lipofectamine 2000™ transfection 
 
For  siRNA  knockdown  experiments,  siRNA  oligonucleotides  against  ATR,  TopBP1  and 
luciferase were designed (Dharmacon). Two transfections solutions were prepared; firstly 
2.5µl of a 75μM stock of the desired oligonucleotide was added to 497.5µl Opti-MEM® 
(Invitrogen), and secondly 15µl Lipofectamine 2000™ was added to 485µl Opti-MEM®. 
These two separate cocktails were incubated at room temperature for 5 minutes before 
being mixed and incubated for a further 20 minutes at room temperature. Following the 
incubation  0.5  x  10
6  293T  cells  were  added  to  the  Lipofectamine/oligo  solution  and  
plated  out  onto  a  60mm  tissue  culture  plate  incubated  at  37°C  (5%  CO2)  (v/v).  The Chapter 2: Materials and Methods 
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following day, media was replaced with fresh media and cells were harvested 24 hours 
later.  
 
 
2.2.1.5 Cell count assay 
 
2x10
6  293T  cells  were  plated  onto  100mm  plates.  The  following  day  the  cells  were 
transfected  with  oligonucleotides  for  siATR/siTopBP1/siLuciferase  using  the 
Lipofectamine  2000  protocol  (2.2.1.4).  Forty  eight  hours  post  transfection,  cell  were 
harvested as normal with trypsin, washed and counted. 2x10
5 cells were plated onto 
60mm  plates  (in  triplicate).  The  remaining  unused  cells  were  checked  for  successful 
knockdown using the western blot technique. Every 2-3 days, the cells were harvested 
and recounted and 2x10
5 cells were replated onto 60mm plates (in triplicate). A running 
cell total is calculated for data analysis. 
 
 
2.2.1.6 Colony survival assay 
 
3 x 10
5  293T cells per 100mm culture dish were plated out in 7ml DMEM (containing 10% 
foetal  calf  serum  and  penicillin),  and  siRNA  treated  with  siATR/TopBP1/Luciferase  as 
described (2.2.1.4). 48 hours later the cells were trypsinised, counted and 2000 cells per 
100mm culture dish were plated out in 7ml DMEM (containing 10% foetal calf serum and 
penicillin). 12 days later the medium was removed and the cells washed twice with 5ml 
PBS.  The  surviving  colonies  were  visualised  by  staining  with  2mls  0.5%  crystal  violet 
solution (25% methanol, ddH2O) for 20 minutes at room temperature with gentle shaking. 
The plates were washed with tap water until the solution ran clear, dried overnight at 
room temperature before the colonies were counted. 
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2.2.1.7 Luciferase assay 
 
2.5x10
5 cells were plated onto 60mm
2 plates and transfected using the calcium phosphate 
precipitation protocol as described (2.2.1.2). The total volume of the calcium phosphate 
(CaPO4) mixture was 1ml but it contained plasmid DNA for two reactions. At transfection 
therefore, 500µl of CaPO4 and DNA mixture was transfected onto each plate. Twenty four 
hours later the plates were removed from incubation and the medium removed. The 
tissue culture dishes were gently washed twice with 4ml of PBS. At the final wash all 
excess PBS was removed by pipetting. 300μl of 1x Reporter Lysis Buffer (Promega) was 
added to each plate and left to incubate for 15 minutes at room temperature. The cell 
lysate was scraped using a sterile plate scraper into a clean microcentrifuge tube. The 
samples were centrifuged at 14000g for 10 minutes at 4˚C. To measure luciferase activity, 
80μl of each sample was added into a 96 well plate. The luminescence was measured 
using the Luciferase Assay System (Promega) at a 1 in 3 dilution and a Luminoskan Ascent 
plate reader (Thermo Labsystems).  
 
 
2.2.1.8 Drug treatments 
 
Prior to drug treatment the media was removed from the plates and any excess was 
removed by a pipette. A master mix of drug and medium was made up separately so that 
each plate received the same concentration of drug. The following concentration of each 
drug was used, unless otherwise stated; etoposide (50µM), aphidicolin (2.5µg/ml) MG132 
(30µM),  cycloheximide  (100µM)  hydroxyurea  (3mM)  and  camptothecin  (10μM). 
Treatment times are indicated in the results section.  
 
 
2.2.1.9 Preparation of protein extract 
 
Cells were grown and transfected so as to achieve around 80% confluence at harvest. The 
medium was removed and the cells were washed once with PBS. 1ml trypsin was added Chapter 2: Materials and Methods 
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to each plate and incubated at 37°C until the cells detached from the plate. Medium was 
then  added  to  the  mix  (at  least  3mls).  The  cells  were  then  transferred  to  a  15ml 
centrifuge tube and centrifuged at 1000g for 5 minutes. The resultant cell pellet was 
washed in 5ml PBS and centrifuged for a second time. After the PBS was removed by 
pippeting, the cell pellet was lysed in NP40 lysis buffer (0.5% NP40, 150mM NaCl, 50mM 
Tris pH 8.0 (containing 1 in 10 volume protease inhibitor cocktail tablet), and incubated 
on ice for 30 minutes. The lysate was then centrifuged at 14000g for 30 minutes at 4°C. 
The protein extract was stored at -80°C until required.  Chapter 2: Materials and Methods 
 
  74 
2.2.2 Molecular methods 
 
 
2.2.2.1 DNA purification using phenol chloroform 
 
DNA samples were purified using phenol:chloroform to remove all residual contaminants. 
Sample volumes were typically completed to 500μl prior to extraction. An equal volume 
of phenol: chloroform: isoamyl alcohol (24:25:1 v/v/v) was added to each sample. After a 
thorough  vortex  the  samples  were  centrifuged  at  14000g  for  10  minutes  at  room 
temperature.  The  top  aqueous  layer  was  gently  removed  and  put  into  fresh 
microcentrifuge tube. The procedure was repeated for a second time.  
 
 
2.2.2.2 Ethanol precipitation  
 
Following  purification  of  DNA  samples  using  phenol:chloroform  (2.2.2.1)  DNA  was 
precipitated  using  ethanol  precipitation.  1/10th  of  the  sample  volume  of  3M  sodium 
acetate, pH 5.2 and 2x the sample volume 100% ethanol, was added to the sample. The 
samples were vortexed and left to incubate at –20˚C for 1-24 hours. The samples were 
centrifuged at 14000g at 4˚C for 30 minutes. The ethanol was removed gently. 1x sample 
volume of 70% ethanol was used to wash the resulting DNA pellet. The samples were 
centrifuged at 14,000g for 15 minutes at 4˚C. The ethanol was carefully removed with a 
pipette. The pellet was dried either by the use of a heating block or at room temperature 
until no ethanol remained. The precipitated DNA was then resuspended in distilled H20. 
 
 
2.2.2.3 Oligonucleotide synthesis  
 
Oligonucleotides used as primers in RT PCR reactions were synthesised by Eurogentec Inc. 
Each  oligonucleotide  probe  was  dual  labelled  (5’FAM,  3’TAMRA)  and  purified  using Chapter 2: Materials and Methods 
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Reversed Phase High-performance liquid chromatography (HPLC-RP).  The primers were 
purified using SePOP (Selective Precipitation Optimized Process). SePOP desalting is based 
on a differential precipitation process. It increases the purity level of the deprotected and 
desalted Oligonucleotides from 15 to 80 bases. All purification was done by Eurogentec. 
The  oligonucleotides  arrived  lyophilised  and  were  re-suspended  in  ddH2O  to  a 
concentration of 100μM and stored at -20°C until required.  
Oligonucleotides used as primers for site directed mutagenesis and sequencing protocols 
were synthesised by VH Bio Ltd. The primers were purified by RP-Column at VH Bio and 
arrived  lyophilised.  The  oligos  were  resuspended  in  water  so  as  to  achieve  a  stock 
concentration of 100μM and stored at -20°C until required.  
RNA oligonucleotides used during siRNA experiments were synthesised by Dharmacon. 
The siRNA duplex is provided in the 2’-deprotected and desalted form. Upon arrival, the 
lyophilised form was resuspended in siRNA Buffer (20mM KCl, 6mM HEPES-KOH pH 7.5, 
0.2mM MgCl2) to make a stock of 75μM and stored at -20°C until required. 
 
 
2.2.2.4 Real-Time PCR detection for transient DNA replication assay 
 
A description of each probe and primer set is described in Table 2.1. For HPV E1 and E2 
mediated replication, the primer set chosen amplifies a 99bp region of the HPV16 origin 
which has been cloned into pOriM. For SV40 Large T antigen mediated replication, the 
primer set chosen amplifies the luciferase gene found in pGL3 plasmids. To differentiate 
between replicated and input plasmid DNA, 25μl of each sample was digested with Dpn1 
overnight  followed  by  1  hour  digest  with  Exonuclease  III  (ExoIII).  ExoIII  was  heat 
inactivated by heating each sample for 30 minutes at 70°C.  
 
5μl of each sample was analysed in triplicate using real time PCR. Quantification was 
performed using a standard curve from pOri16M (HPV replication) or pGL3-Control/Basic 
(SV40  replication)  dilutions  of  100pg  to  10
-5pg.  Standard  curves  were  prepared  in Chapter 2: Materials and Methods 
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duplicate. A non DNA control (ddH2O) was prepared in quadruplicate. Five microlitres of 
each sample was prepared in a solution containing 12.5µl of Mastermix (Stratagene), 
900nM of each primer, 100nM of probe, 0.5µl of reference dye (supplied with Mastermix) 
and 6µl of ddH2O so that the final volume was 25µl. Triplicates were prepared in a single 
tube to eliminate a source of variability. 25µl was pipetted into each well in a 96-well real-
time PCR plate. To measure the quantity of pOri16M or pGL3-Control, DNA was detected 
by assaying the real-time PCR plate on an ABI Prism 7500 using the universal real-time 
PCR conditions (95°C 10 minutes ‘hot-start’, 95°C for 30 seconds and 60°C for 1 minute in 
40  cycles).  Data  was  analysed  using  the  7500  System  Software.  This  calculates  the 
standard curve and the quantity of DNA for each individual sample well. The average 
signal  for  each  sample  was  calculated  from  the  sample  repeats.  The  undigested 
pOri16M/pGL3-C represents the freshly replicated molecules.  
 
 
2.2.2.5 In vitro DNA replication assay 
 
Viral in vitro DNA replication assays were performed by John Fisk at the University of 
Buffalo.  Thirty  nanograms  of  template  DNA  containing  the  SV40  or  HPV  origins  of 
replication  (pSV011  or  p7974-99)  was  incubated  with  200ng  of  SV40  TAg  or  40ng  of 
HPV11  E1  and  20  ng  of  HPV11  E2,  replication  buffer  (30mM  HEPES  (pH  7.5),  40mM 
creatine  phosphate,  7mM  MgCl2,  0.5mM  DTT,  4mM  ATP,  200μM  CTP,  200μM  UTP, 
200μM GTP, 100μM dCTP, 100μM dGTP, 100μM dTTP, 25μM dATP, 0.1mg/ml acetylated 
BSA, 0.625μg creatine phosphokinase (Sigma), 1μCi α
32P dATP, and 30–50ng of HEK 293 
cell extract in 10μl reactions. Reactions were carried out for one hour at 37 °C and were 
terminated  by  addition  of  stop  buffer  (20mM  Tris  (pH  7.5),  10mM  EDTA  (pH  8.0), 
0.1%SDS, 1 μg/μl proteinase K) for twenty minutes at 37 °C. Replication was evaluated by 
resolution  of  replication  products  on  0.8%  agarose  gels  followed  by  phosphorimager 
autoradiography. 
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2.2.2.6 In vitro checkpoint kinase assay 
 
In  vitro  checkpoint  kinase  assays  were  carried  out  by  John  Fisk  at  the  University  of 
Buffalo.  To  determine  the  effect  of  the  kinase  inhibitors  wortmannin,  NU7026,  and 
KU55933, either dimethylsulfoxide (DMSO) or the inhibitor dissolved in DMSO was first 
incubated with cellular extracts for 5 minutes on ice prior to assembly of the replication 
reaction.  Non-template  plasmid  added  to  the  reactions  (pUC19)  was  isolated  using 
standard protocols, and then either added directly or first digested with the restriction 
enzyme RsaI to completion, and then phenol:chloroform extracted and precipitated prior 
to addition. Several restrictions enzymes, with varying termini (3′ overhand, 5′ overhang, 
and blunt ended) were also used and all types of ends produced very similar results (data 
not shown). Quantification of DNA replication activity was by phosphorimager analysis; 
incorporation of isotope from the top of the replication intermediates all the way through 
Form I DNA was quantified, background from an unused lane was subtracted, and the 
results were compared to the DMSO only positive control lane (set to 100%). 
 
2.2.2.7 Bradford assay 
 
Prior to western blotting and immunoprecipitation, protein extracts were analysed for 
protein concentration so as to ensure that equal amounts of protein were used in each 
experiment. Bovine serum albumin (BSA) protein standard solutions were made up at the 
following concentrations from a stock of 2mg/ml (Invitrogen); 2, 1, 0.4, 0.2, 0.1mg/ml. 5μl 
of  each  protein  extract  was  added  to  995μl  of  Bio-Rad  Protein  Assay  Dye  (Bradford) 
Reagent  Concentrate  (5X)  in  a  cuvet.    The  Bradford  reagent  was  diluted  to  a 
concentration of 1x with distilled water. Samples were shaken to mix and absorbance was 
measured  on  a  spectrophotometer  (O.D  595).  The  absorbance  readings  for  the  BSA 
standards were used to derive a standard curve, from which the sample concentrations 
were calculated. 
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2.2.2.8 Immunoprecipitation 
 
In preparation for immunoprecipitation (IP) experiments, protein A/G sepharose beads 
were washed 5 times in lysis buffer (0.5% NP40, 150mM NaCl, 50mM Tris pH 8.0)and 
were resuspended after the final wash at a bead:slurry ratio 1:1 (v/v).The concentration 
of protein lysate used for coimmunprecipitation was 300μg.  
 
For IPs involving the phospho - (Ser/Thr) ATM/ATR substrate antibody, protein lysate and 
antibody (1/20) were incubated in a 1.5ml eppendorf tube on a spinning rotor overnight 
at 4 °C. The following morning 20μl of protein G sepharose beads were added to the 
lysate and incubated for 1 h at 4 °C on the rotor.  
 
For IPs involving the HA antibody, protein lysate and antibody (1/200) were incubated in a 
1.5ml eppendorf tube on a spinning rotor overnight at 4 °C. The following day 20μl of 
protein  A  sepharose  beads  was  added  to  each  sample  in  a  post-clearing  step.  The 
incubation  was  for  1-2  hours  on  a  spinning  rotor  at  4°C.  The  eppendorf  tube  was 
centrifuged briefly at 3000g and the lysate was transferred to a fresh eppendorf tube. 
20μl of protein A sepharose was added to the samples for a second overnight incubation.  
 
For IPs involving the LTAg antibody; pAb419, protein lysate and antibody (1/100) were 
incubated  in  a  1.5ml  eppendorf  tube  whilst  spinning  at  4°C  for  1-2hours.  Protein  A 
sepharose beads (20μl) were added to the mixture for 1 hour under the same conditions. 
The complexes containing the antibody-protein A/G sepharose-cell lysate were pelleted 
by centrifugation and washed five times with 500μl of lysis buffer. The beads were boiled 
in  15μl  of  LDS  buffer  (Invitrogen)  and  5μl  of  sample  reducing  agent  (Invitrogen)  for 
10minutes at 70°C. Protein inputs (10%) were mixed with 5 μl of LDS buffer and 2 μl of 
sample  reducing  agent  and  boiled  under  the  same  conditions.  Both  the  beads  and 
supernatant were electrophoresed using SDS-PAGE system and subjected to western blot.  
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2.2.2.9 Western blotting 
 
Protein concentrations were determined using a Bradford assay as described in chapter 
2.2.2.7. Equal amounts of protein (20-30ng) were added to 2l NuPage® 
 sample reducing 
agent (10X) and 5l NuPAGE
 sample buffer (4x) (Invitrogen) and heated to 70C for 10 
minutes. The pre-cast gels (either 10/12 well) were placed into the gel tank filled with 1x 
MES  running  buffer.  500l  10X  antioxidant  was  added  to  the  running  buffer  before 
loading the sample. 10l See-Blue® kDa marker (Invitrogen) was also loaded as marker 
using fine pipette tips. SDS-Page gels were electrophoresed for 1 hour at 200V.  The 
buffer was discarded and the gel cast was carefully cracked open and the top plate peeled 
off to leave the gel in place. The gel was soaked in transfer buffer NuPAGE® (1X) for 10 
minutes  prior  to  transfer.  The  wells  were  removed  and  the  gel  was  transferred  to  a 
nitrocellulose  membrane  using  the dry  Invitrogen  i-blot transfer  system  following  the 
manufacturer’s  instructions.  Following  transfer  the  nitrocellulose  membrane  was 
incubated with 5% milk PBS-T (1 x PBS 0.1% Tween) on a mechanical shaker for either 1 
hour at room temperature or overnight at 4°C. Following blocking, the membrane was 
incubated with the primary antibody in 5% milk PBS-T using the following concentrations: 
ATR (1:1000), Chk1 (1:1000), HA.11 (1:2000), TVG 261 (1:250), pAb101 (1:1000), pAb419 
(1:1000), phospho-Chk1/2 antibodies (1:1000). For 1-2 hour incubations the membranes 
were  gently  shaken  at room  temperature.  For  overnight  incubations, the membranes 
were  gently  shaken  in  a  4°C  cold  room.  The  antibody  was  then  removed  and  the 
membrane was washed  in PBS-T  for 3 x 5 minutes at room temperature with gentle 
agitation. The secondary antibody was then added diluted in 5% milk PBS-T and incubated 
at room temperature for 1 hour with gentle agitation. The secondary antibodies were 
used at the following concentrations: anti-rabbit IgG (1:10000), anti-mouse IgG (1:10000) 
and GTU-88 (1:10000). The antibody was then removed and the wash steps repeated. The 
proteins were detected using ECLplus (GE Healthcare) according to the manufacturer’s 
instructions. Briefly 1ml detection reagent A and 25µl detection reagent B was mixed and 
added to the membrane and incubated at room temperature for 5 minutes. The excess 
was  removed  and  the  membrane  placed  into  a  cassette  and  developed  with  X-ray 
Hyperfilm (Amersham).   Chapter 2: Materials and Methods 
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2.2.2.10 Stripping of nitrocellulose membrane 
 
Membranes  were  washed  in  PBS-T  for  3x  5  minutes  whilst  gently  shaking  therefore 
removing any excess ECL reagent. Membranes were incubated on the shaker in 0.1M 
NaOH for 10-15 minutes. The NaOH was removed and membrane washing steps were 
performed (3 x 5 minutes in PBS-T whilst gently shaking). The membranes were then 
blocked with 5% milk PBS-T for 1 hour at room temperature in preparation for incubation 
with the primary antibody.  
 
2.2.2.11 Site directed mutagenesis 
 
The site directed point mutagenesis was carried out using KOD Hot Start Polymerase kit 
according  to  the  manufacturer’s  instructions.  The  primers  used  to  generate  point 
mutations in SV40 large T antigen and HPV16 E2 are described in Table 2.2. Primers were 
designed to be around 25-45 nucleotides long and have a melting temperature (Tm) value 
>65°C. The Tm of each primer was calculated using the formula: Tm (°C) = 2(NA + NT) + 
4(NG + NC). For each mutation generated 1ul pLTAg/E2 (100ng/μl) was mixed with 5ul 10x 
KOD buffer, 15μl of 2mM dNTPs, 4μl of 25mM  MgCl2, 1μl DMSO, 1μl of 10μM Primer 1, 
1μl  of  10μM  Primer  2,  1μl  KOD  polymerase  and  31μl  ddH2O.  PCR  amplification  was 
carried out using an MJ Research PTC-200 Thermo Cycler. Samples were heated to 94°C 
for 5 minutes (polymerase activation), 94°C for 15 seconds (denature), lowest primer Tm 
for  30  seconds  (annealing)  and  72°C  for  20  seconds/kb  (extension).  The  cycle  of 
denaturing,  annealing  and  extension  was  repeated  another  17  times.  To  finish,  the 
samples remained at 72°C for 5 minutes then were cooled to 4°C. Non mutated template 
DNA was then digested using 1μl of DpnI for 1 hour at 37°C. The mutated plasmids were 
cleaned up using phenol chloroform extraction and ethanol precipitation techniques. The 
mutated plasmid DNA was transformed into DH5 cells and grown up for DNA miniprep. 
The DNA was then sequenced to check for mutations. Chapter 2: Materials and Methods 
 
  81 
2.2.2.12 DNA sequencing 
 
To check plasmids for mutation they were sequenced using an Applied Biosystems 3100 
automated  sequencer.  The  region  of  interest  was  sequenced  using  a  primer 
complementary to the appropriate region (Table 2.4). Reactions were carried out in 0.5ml 
PCR tubes and contained around 250ng/μl of plasmid DNA, 2μl of 5x Big Dye buffer, 
3.2pmol primer, 4μl of Big Dye Terminator Reaction mix made up to 20μl with ddH2O. 
Samples were heated to 96˚C for 10 seconds, 50˚C for 5 seconds, and 60˚C for 4 minutes. 
This cycle was repeated 25 times and the sequencing reaction held at 4˚C till required. 
PCR reactions were purified using phenol:chloroform ethanol precipitation (as described 
in  2.2.2.1).  Following  purification  the  reactions  were  resuspended  in  25μl  Hi-Di 
formamide and analysed using an ABI Prism 300 automatic sequencer. 
 
 
2.2.2.13 DNA/RNA concentration determination 
 
The concentration of plasmid DNA was measured using an absorbance measurement at 
260nm (Biotech spectrophotometer -model UV1101). An optical density reading (OD) of 1 
is equivalent to 50μg/ml of double stranded DNA. RNA concentration was determined 
similarly and OD of 1 is equivalent to 40μg/ml RNA. A 260nm/280nm absorbance ratio 
was  measured  for  all  plasmid  preparations,  a  reading  of  between  1.8  and  2.1  being 
indicative of a pure sample. 
 
 
2.2.2.14 Transformation of chemically competent bacterial cells 
 
Transformation  of  DH5α  competent  bacterial  cells  took  placed  prior  to  large  scale 
preparation of DNA.  10ng of plasmid DNA was added to 50μl DH5α cells and incubated 
on ice for 30 minutes. Cells were immediately heat shocked at 42˚C for 45 seconds and 
placed back on ice for 2 minutes. Each sample was gently mixed with 100μl SOC medium Chapter 2: Materials and Methods 
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(25ml bactotryptone, 0.5% yeast extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM 
MgSO4 and 20mM glucose). The samples were incubated at 37˚C whilst shaking (225rpm) 
for 1 hour.  The samples were aseptically plated out on to Ampicillin containing agar 
plates. The plates were then left inverted and incubated overnight at 37˚C. Colonies were 
picked the following day and grown in 5ml L-broth, 50mg/ml Ampicillin, overnight at 37˚C 
with shaking (225rpm) prior to both small and large scale preparations of plasmid DNA. 
 
2.2.2.15 RNA extraction 
 
RNA was extracted from cells using the Qiagen RNeasy kit. Cells were washed twice with 
PBS and trypsinised and pelleted into a 1.5ml Eppendorf tube. Pellets were lysed in 750μl 
of RTL buffer. The lysate was transferred into a QIAshredder spin column then centrifuged 
to homogenise the sample. An equal volume of 70% ethanol was added to the lysate and 
the  sample  was  transferred  to  an  RNeasy  mini  column  by  centrifugation.  The  flow 
through was discarded and the column was washed with 700μl RW1 once, and twice with 
500 μl of RPE buffer by centrifugation. Purified RNA was eluted from the column by 100μl 
of RNase-free H2O. RNA concentration was measured as described (2.2.2.12). 
 
 
2.2.2.16 DNase treatment 
 
Following  RNA  extraction,  0.1  volume  10X  DNase  I  buffer  and  1μL  rDNase  I  (Applied 
Biosystems) were added to the RNA, and mixed gently. The sample was incubated at 37°C 
for 30 minutes. DNase Inactivation Reagent (typically 0.1 volume) was added to each 
reaction and mixed well. The reaction was incubated for 2 minutes at room temperature 
mixing occasionally. The samples were then centrifuged at 10000g for 1.5 minutes and 
the RNA was transferred to a fresh tube for cDNA synthesis. 
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2.2.2.17 Synthesis of complementary DNA  
 
RNA  was  converted  to  cDNA  using  the  SuperScript  III  Reverse  Transcriptase  kit  from 
Invitrogen. In sterile 0.2μl PCR tubes, 1-500ng of RNA, 50–250ng of random primers, 1μl 
of 10mM dNTP Mix (10mM each dATP, dGTP, dCTP and dTTP at neutral pH) and sterile 
ddH2O (to 13 μl) were mixed, incubated at 65°C for 5 minutes and then were placed on 
ice for 1 minute. Prior to PCR, 4 μl of First Strand Buffer (5X), 1 μl of 0.1M DTT and 1 μl of 
the SuperScript III enzyme were added to the reaction. First strand cDNA synthesis was 
carried out using a MJ Research PTC-200 gradient cycler. Samples were incubated at 25°C 
for 5 minutes, heated to 50°C for 1 hour and terminated at 70°C for 5 minutes. The 
samples were stored at -20°C until required.  
 
 
2.2.2.18 Large scale preparation of plasmid DNA (maxiprep) 
 
1ml  of  a  5ml  overnight  bacterial  culture  was  used  to  inoculate  500ml  of  L-broth 
containing  antibiotic.  The  culture  was  incubated  overnight  in  a  2L  conical  flask  with 
vigorous shaking. The following day, the culture was poured into 50ml tubes and cells 
were pelleted by centrifugation at 3500g for 10 minutes at 4°C. The supernatant was 
discarded. The bacterial pellet was resuspended in 10ml resuspension buffer (50mM Tris-
Cl pH 8.0, 10mM EDTA, 100μg/ml RNase A) by vortexing and pipetting. 10ml of lysis 
buffer (200mM NaOH, 1% SDS) was added by gentle inversion 5 times. The lysed pellets 
were incubated for 5 minutes at room temperature. 10ml of precipitation buffer (3.0M 
potassium acetate pH 5.0) was then added and mixed gently to homogenize the sample. 
The precipitated sample was centrifuged at 3500g for 10 minutes at 4°C. To prepare the 
extraction columns for the sample, 15ml of equilibration buffer (750mM NaCl, 50mM 
MOPS, pH 7.0, 15% isopropanol (v/v) and 0.15% Triton r X-100 (v/v)) was added directly 
into the top. The buffer was allowed to drain through.  
 
Following centrifugation the supernatant was filtered to remove the precipitate and the 
clear lysate was added to the extraction column. The lysate was left to drain by gravity Chapter 2: Materials and Methods 
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flow.  60ml of wash buffer (1.0M NaCl, 50mM MOPS pH 7.0, 15% isopropanol) was added 
and left to  drain by gravity flow. The DNA  was eluted by adding 15ml elution buffer 
(1.25M  NaCl,  50mM  Tris-Cl  (pH  8.5)  and  15%  isopropanol),  and  collected  into  50ml 
centrifuge tubes. 10.5ml of isopropanol was then added to the eluted DNA. The sample 
was centrifuged at 3500g at 4˚C for 1 hour. The resulting supernatant was removed and 
the DNA pellet was washed in 10ml 70% ethanol before centrifugation at 3500g for 15 
minutes at 4˚C. The pellets were allowed to air dry before being resuspended in 300μl of 
TE Buffer, and stored at –20˚C until required. 
 
 
2.2.2.19 Propidium iodide staining and flow cytometry analysis 
 
Cells were plated out in duplicate onto 100mm plates so as to achieve a confluence of 
80% at harvest. Forty eight hours post transfection, cells were harvested, and washed 
twice with ice cold PBS (centrifuged at 1000 rpm, for 10 minutes at 4°C between each 
wash). After the final wash, the pellet was resuspended in 0.5ml of residual PBS. Samples 
were kept cool on ice. On a vortex at a low speed, 4.5ml of ice cold 70% ethanol was 
added dropwise to each sample. If the samples were being used straight away, they were 
left on ice for 30 minutes. If samples were being stored to use on a separate day, they 
were stored at -20°C. Each sample was washed twice in ice cold PBS following the same 
conditions prior to fixing. Each pellet was resuspended in 0.5ml of fresh PBS, 10µg/ml of 
Propidium Iodide and 1µl of ribonuclease A. The staining was carried out for at least 3h at 
4 °C. The samples were analysed using the EXPO32ADCXL4 Colour program on a Beckman 
Coulter Epics XL-MCL machine. 
 
 
2.2.2.20 Salt extraction 
 
Cells were lysed in CSK buffer (10nM PIPES pH6.8, 100mM NaCl, 300mM sucrose, 3mM 
MgCl2, 1mM EGTA) containing 0.5% Triton X-100, and the insoluble material was pelleted 
by centrifugation. The pellet was then serially extracted with increasing concentrations of Chapter 2: Materials and Methods 
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NaCl in CSK (0.15/0.2/0.4/0.6/0.8/1.0M salt). The first extraction (0.15M) was incubated 
on ice for 15 minutes then centrifuged at 14000g for 30 minutes at 4 °C. For the following 
extractions  (0.2-1.0M),  the  pellet  was  incubated  on  ice  for  20  minutes  before  being 
centrifuged at 14000g for 30 minutes at 4 °C. Lysates were then prepared for western blot 
analysis.  
 
 
2.2.2.21 DNA plasmid miniprep using alkaline lysis 
 
Three to five mls of  E.coli culture containing the plasmid were grown overnight. The 
culture  was  centrifuged  in  a  1.5ml  Eppendorf  tube  at  14000g.  The  supernatant  was 
removed and the pellet was resuspended in 300μl of buffer 1 (50mM Tris-HCl pH 8.0, 
10mM EDTA, 100µg/ml RNase A). Buffer 1 is stored at 4°C. To lyse the pellet, 300μl of 
buffer 2 (200mM NaOH 1% SDS) was added and the eppendorf tube was inverted 5 times 
and incubated for 5  minutes at room temperature. 300μl of ice cold buffer 3 (3.0 M 
potassium acetate pH 5.5) was added and the tube inverted 5 times. The sample was then 
incubated on ice for at least 5 minutes and then centrifuged at 14000g for 10 minutes. 
The  supernatant  was  transferred  to  a  new  tube,  phenol:chloroform  extracted  and 
centrifuged  at  14000g  for  5  minutes.  The  aqueous  phase  was  transferred  to  a  fresh 
eppendorf  tube.  0.7  volumes  of  Isopropanol  was  added,  mixed  by  inversion  and 
centrifuged  at  14000g  for  15  minutes  at  4˚C.  The  pellet  was  washed  by  ethanol 
precipitation and resuspended in TE buffer. 
 
 
2.2.2.22 Harvesting low molecular weight DNA 
 
Low molecular weight DNA was harvested for real time PCR analysis as part of the in vivo 
transient replication assays. 3 x 10
5 293T cells were counted, plated onto 100mm
2 cell 
culture dishes and incubated for 24 hours at 37°C in a 5% CO2/95% air atmosphere. 
Calcium phosphate transfections of HPV replication plasmids (pCMV-E2, pCMV-E1 and 
pOri16M / pTM1-E1, pCR3-E2 and pOri16M) or SV40 replication plasmids (pGL3 control / Chapter 2: Materials and Methods 
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pGL3 basic) took place the following day. Sixteen hours post transfection the calcium 
phosphate  and  medium  was    removed,  the  cells  were  washed  twice  with  PBS  and 
incubated in fresh medium  for a further 48 hour. The cells were then washed once with 
PBS and excess PBS was removed by a pasteur pipette. Cell were lysed in 800μl of Hirt 
solution (10mM EDTA pH???, 0.5% SDS) and scraped into a 1.5 ml Eppendorf tube. 200μl 
of  5M  NaCl  was  added  and  the  samples  were  left  at  4°C  overnight.  Samples  were 
centrifuged at 5000g for 30 minutes at 4°C, extracted twice with phenol:  chloroform: 
isoamyl alcohol (2.2.2.1) and precipitated with ethanol (2.2.2.2). The DNA pellet was dried 
and resuspended in 100μl of ddH2O and the samples were analysed by real time PCR 
(2.2.2.4).  
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2.2.3 Statistics 
 
2.2.3.1 Mean and standard error of the mean 
 
The mean ± the standard error of the mean (SEM) are shown in several experiments as a 
control for experimental reproducibility.  The standard error of the mean (SEM) gives a 
measure of the precision of the mean giving a representation of the spread of the data, 
indicating how far the mean of a sample is from the true mean. The SEM is calculated by 
dividing the standard deviation by the square root of the total number of samples used.  
This is calculated in Microsoft Excel using = STDEV/SQRT (COUNT(X,-Y)).  
Where STDEV (σ) =            
                                      
 
 
SEM = Standard Deviation  
      √ [Sample number (n)] 
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2.2.3.2 Statistical Significance 
 
Statistical significance for the data presented in this thesis was typically calculated using a 
Students-T-test to give a significance value (p). This was carried out using Microsoft Excel 
(T-TEST function). The cut off for all experiments was taken as 0.05, therefore if two sets 
of data return a p value of <0.05 there is a less than 5% chance that the result observed is 
due to chance, and the two groups are therefore statistically significantly different. 
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Chapter 3 – Results 
 
 
3.1 HPV E1-E2 mediated DNA replication is not arrested by DNA 
damage. 
 
The DNA from the high risk HPVs is often found integrated into the host cell DNA in high 
grade squamous cell carcinomas specimens (Cooper et al., 1991; Kristiansen et al., 1994; 
Alazawi et al., 2002; Peitsaro et al., 2002; Arias-Pulido et al., 2006; Pett et al., 2006.) Viral 
integration has been shown to be a factor in cell transformation from studies carried out 
in HPV positive cervical cancer specimens and in vitro model systems (Wentzensen et al., 
2004;  Dall  et  al.,2008.).  Integration  results  in  the  unregulated  expression  of  the 
oncogenes E6 and E7 which can lead to the development of cancer. Factors that may 
promote  viral  integration  include  replication  of  the  viral  genome  during  cellular  DNA 
damage. This would promote double stranded breaks in the viral and cellular DNA and 
increase the chance of integration through a DNA repair mechanism such as NHEJ (Ziegert 
et al., 2003). It has been suggested that replication of integrated viral DNA by E1 and E2 
may also cause genomic damage and this could lead to further integration events (Kadaja 
et al., 2007; Kadaja et al., 2009). Another dsDNA virus that has controversial findings 
regarding its replication status during an activated DNA damage response is the SV40 
virus.  Some  reports  suggest  that  SV480  infection  requires  an  activated  DNA  damage 
response  for  a  productive  life  cycle  (Shi  et  al.,  2005).  Whereas  there  is  evidence  to 
suggest that an activated DNA damage response inhibits SV40 replication (Miao et al., 
2003).  
 
The regulation of DNA replication is well described in the literature however the precise 
targets at the replication fork that respond to DNA damage pathways have not been 
clearly defined. There is evidence that the components of the cellular MCM2-7 helicase is 
targeted for phosphorylation by ATR/ATM in response to DNA damage  (Cortez et al., 
2004; Ishimi et al., 2003a; Ishimi et al., 2003b). Therefore targeting of the helicase by DNA Chapter 3: Results 
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damage pathways may inhibit DNA replication in the presence of DNA damage. E1, LT and 
MCM2-7 are all ATPases Associated with a variety of cellular Activities (AAA+) domain 
containing helicases. The 200-250 amino acid AAA+ domain contains conserved ATPase 
sequences that use the energy released from ATP hydrolysis to alter the structure of DNA 
during replication (White & Lauring, 2007).  
The large T antigen (LT) of SV40 initiates viral replication in a similar manner to HPV E1. 
Both proteins share structural homology in both the DNA binding and helicase domains 
and functional similarities (Luo et al., 1996; Enemark et al., 2000; Li et al., 2003; Meinke et 
al., 2006; Enemark & Joshua-Tor, 2006). LT is a viral origin binding protein that forms 
double  hexameric  rings  encircling  the  viral  DNA.  Similarly  to  E1  it  distorts  DNA  and 
initiates replication bidirectionally (Valle et al., 2000). The major mechanistic difference 
between E1 and LT is that LT does not require a viral loading factor to bind to the viral 
origin.  
 
In this study the replication of the papillomavirus origin replication was compared to SV40 
origin replication. The hypothesis is that HPV is able to replicate in the presence of DNA 
damage. To determine this hypothesis, the replication of HPV and SV40 origin containing 
plasmids by E1:E2 or LT is first examined using in vivo and in vitro replication assays. Both 
viruses contain double stranded circular DNA and replicate in a similar manner using host 
cell  replication  proteins  to  undertake  their  own  replication.  Therefore  SV40  origin 
replication  was  used  as  a  control  to  identify  any  differences  between  HPV  and  SV40 
replication that may help understand factors that can lead to HPV integration. Low risk 
and high risk (HPV11 and HPV16 respectively) replication was also compared. The low risk 
HPV11 can cause genital warts whereas the high risk HPV16 can cause cervical cancer. 
The high risk types can cause oncogenesis when the viral DNA becomes integrated and 
the E6 and E7 protein expression becomes unregulated. Comparing replication of HPV11 
and HPV16 may help to understand why some strains of papillomavirus can cause cancer 
and why some strains do not. Chapter 3: Results 
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3.1.1  HPV11  E1-E2  mediated  replication  in  vivo  is  not  arrested  by  DNA 
damaging agents. 
 
To investigate whether HPV11 E1–E2 mediated DNA replication is arrested following DNA 
damage, transient DNA replication assays were carried out in 293T cells using the real-
time PCR protocol developed in previously in our laboratory (Taylor and Morgan, 2003; 
Morgan  and  Taylor,  2005).  Initially  this  protocol  was  used  with  C33A  and  U2OS  cells 
however the combination of calcium phosphate transfection and drug treatment resulted 
in high amounts of cell death. Although 293T cells are not a cervical epithelial cell line 
they  were  chosen  due  to  their  high  transfectability  of  the  viral  protein  expressing 
plasmids and ability to withstand subsequent drug treatment. Briefly, plasmids containing 
HPV11 E1, HPV11 E2 and the HPV16 origin of replication were transfected into 293T cells 
using the calcium phosphate method of transfection (2.2.1.2). In these experiments, the 
pOri-16M  (designed  for  HPV16  replication)  can  be  used  to  investigate  HPV11  E1-E2-
mediated replication because the origin sequences are well conserved in mucosal HPVs. 
Cells  were  then  treated  with  a  DNA  damaging  agent  or  aphidicolin.  In  separate 
experiments etoposide and camptothecin were used as DNA damaging agents. Etoposide 
inhibits topoisomerase IIa, resulting in double strand DNA (dsDNA) breaks during the S 
phase  of  the  cell  cycle.  To  create  DNA  damage  a  relatively  high  concentration  of 
etoposide  was  used  (50μM).  This  concentration  has  been  shown  to  produce  dsDNA 
breaks  in  293T  cells  (Abramson  et  al.,  2010).  Camptothecin  inhibits  the  DNA  enzyme 
topoisomerase I and creates dsDNA breaks. It was used at 10μM as this concentration has 
previously been shown to cause dsDNA breaks and is tolerated by 293T (Reinhardt et al., 
2007; Fu et al., 2007). Cells were also treated with Aphidicolin (2.5μg/ml) as a control. 
Aphidicolin  inhibits  the  replicative  DNA  polymerase  (alpha/delta/epsilon)  inhibitor 
(Ikegami et al, 1978). Therefore aphidicolin treatment should arrest both cellular and viral 
(HPV  and  SV40)  DNA  replication.  A  previous  publication  had  used  aphidicolin  at  a 
concentration of 5μg/ml to arrest U2OS cells that stabley express HPV16 E2 (Johansson et 
al., 2009). Concentrations slightly above and below this value were tested and it was 
found that 2.5μg/ml could arrest HPV replication therefore this was the concentration 
used in these assays. Forty eight hours later the cells were lysed and DNA extracted using 
HIRT extraction (2.2.2.22). DNA was purified by phenol.chloroform extraction (2.2.2.1) 
and ethanol precipitation (2.2.2.2). Digesting DNA with DpnI and ExoIII resulted in freshly Chapter 3: Results 
 
92 
 
replicated origin plasmid DNA. The E.coli strains used for propagation of viral plasmid 
DNA  cause  methylation  of  the  plasmid  DNA using  DAM  methyltransferase.  The  Dpn1 
digests  DAM-methylated  (non-replicated)  DNA  and  ExoIII  digests  single  stranded  DNA 
overhangs. The amount of freshly replicated DNA which was then measured using Real 
Time PCR (2.2.2.4). 
 
The results obtained with HPV11 E1 and E2 replication in vivo are shown in Figure 3.3.1. 
In Figure 3.1.1.(a), origin plasmid replication is not detected in the non-transfected cells 
(lane 1), HPV origin plasmid transfected alone (lane 2) and HPV origin plasmid with E1 
expression plasmid (lane 3). Replication of the origin plasmid is detected when the E1 and 
E2  expression  plasmid  are  co-transfected  (lane  4).  After  treatment  with  the  DNA 
polymerase inhibitor aphidicolin, this replication signal is greatly reduced. The small level 
of  replication  detected  may  be  a  result  of  origin  plasmid  replication  prior  to  drug 
treatment (lane 6). There is a statistical difference between untreated and aphidicolin 
treated cells. When etoposide is added to the HPV plasmid transfected cells, there is an 
apparent  increase  in  origin  plasmid  DNA  replication  (lane  5).  However,  there  is  no 
significant  difference  between  HPV11  ori  replication  with  and  without  etoposide 
treatment.  In  Figure  3.1.1  (b)  again  no  DNA  replication  signal  is  detected  in  non-
transfected cells or when a plasmid containing the HPV origin is transfected alone or with 
an E1 expression plasmid (lanes 1–3). DNA replication is detected when the E2 expression 
plasmid  is  also  co  transfected  (lane  4).  When  the  cells  are  treated  with  aphidicolin 
following transfection there is a minimal level of replicated origin plasmid (lane 6). As 
p<0.05, there is a statistical difference between untreated HPV11 E1-E2-ori transfected 
and aphidicolin treated cells When the transfected cells are treated with camptothecin 
HPV11 E1-E2 mediated replication of the origin is not inhibited (lane 5). As p>0.05, there 
is  no  statistical  difference  between  HPV11  E1-E2-ori  transfected  untreated  and 
camptothecin treated cells. This result may be ascribed to one of the repeats showing an 
exceptionally large increase in origin replication when treated with camptothecin. Chapter 3: Results 
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Figure 3.1.1 HPV11 E1-E2 mediated replication in vivo is not arrested by DNA damaging 
agents. 
 
(a) HPV11 origin replication assay with etoposide treatment 
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(b) HPV11 origin replication assay with camptothecin treatment 
 
           
Figure3.1.1 (a) HPV11 E1-E2 mediated replication is not arrested by etoposide in vivo. 
293T cells were transfected with 100pg of pOriM (lanes 2–6), 5μg of pCMV11-E1 (lanes 3–
6)  and  2μg  of  pCMV11-E2  (lanes  4–6).  16  hours  after  transfection,  cells  were  left 
untreated  (lanes  1–4)  or  treated  with  50µM  of  etoposide  (lane  5)  or  2.5  μg/ml  of 
aphidicolin (lane 6). Forty-eight hours later low molecular weight DNA was harvested 
from the cells for transient replication assays. The results shown represent the summary 
of three experiments with mean and standard error of the mean shown. Results are 
shown as a fold difference (F.D) to lane 4 (ori, E1 &E2 with no drug treatment). Statistical 
significance by Student’s t-test is indicated as * (p < 0.05). (b) HPV11 E1-E2 mediated 
replication is not arrested by camptothecin in vivo. The replication assay was carried out 
as described in figure 3.1.1(a). 16 hours after transfection cells were treated with 10 µM 
of camptothecin (lane 5) instead of etoposide. The results shown represent the summary 
of  three  experiments  with  mean  and  standard  error  of  the  mean  shown.  Lane  4  is 
standardised to 1 and the results shown are a fold difference of this value.  Statistical 
significance by Student’s t-test is indicated as * (p < 0.05). Chapter 3: Results 
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3.1.2 SV40 virus LT mediated replication in vivo is arrested by etoposide. 
 
It was feasible that HPV replication during treatment with DNA damaging agents might be 
explained by a lack of DNA damage response in the 293T cells. Therefore another DNA 
virus was used to confirm that HPV replication during DNA damage was simply not a 
result of the 293T cells failing to sense and activate a DNA damage response pathway. 
The LT-mediated SV40 origin DNA replication was used to assess this in vivo (Figure 3.1.2). 
293T cells stably express SV40 LT therefore only the SV40 origin containing plasmid was 
required to be transfected into the cells. In 293T cells only, there is no replication signal 
detected  (lane  1).  A  control  plasmid  that  contains  the  luciferase  gene  but  does  not 
contain the sequence for the  SV40 origin (p-SV40 ori) does not produce a replication 
signal (lane 2). Transfection of a plasmid containing the SV40 origin sequence (p+SV40 ori) 
produces a replication signal in lane 3. In lane 5 the 293T cells have been transfected with 
p+SV40 ori and aphidicolin. In a similar trend to HPV E1 and E2 mediated replication, 
aphidicolin arrests LT mediated replication. The p value is calculated to be 5x10
-7. As 
p<0.05 there is a significant difference between p+SV40 ori replication with and without 
aphidicolin treatment. In a direct contrast to HPV E1-E2 mediated replication, etoposide 
treatment of p+SV40 transfected cells results in an arrest in LT mediated SV40 origin 
plasmid replication (lane 4). The p value is calculated to be 0.005. As p<0.05 then there is 
a significant difference between p+SV40 ori with and without etoposide treatment.  Chapter 3: Results 
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Figure 3.1.2 SV40 virus LT mediated replication in vivo is arrested by etoposide. 
 
          
 
Figure3.1.2 SV40 virus LT mediated replication in vivo is arrested by etoposide. 293T 
cells were transfected with 1ng of luciferase gene containing plasmid DNA (lanes 2–5). In 
lane  2,  the plasmid  contained no  SV40  origin of  replication  in  lanes 3–5 the  plasmid 
contained an SV40 origin of replication. One day post transfection, drug treatments were 
added in lane 4 (50μM of etoposide) and lane 5 (2.5 μg/ml of aphidicolin). The other lanes 
are  all untreated  (lanes  1-3).    Forty-eight  hours  later low  molecular weight  DNA  was 
harvested.  The  results  shown  represent  three  independent  experiments  and  are 
standardised to LT mediated p+SV40 replication without any drug treatment (lane 3). 
Statistical significance by Student’s t-test is indicated as * (p < 0.05). Chapter 3: Results 
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3.1.3  HPV16  E1-E2  mediated  replication  in  vivo  is  not  arrested  by 
etoposide. 
 
The ability of a HR-HPV to replicate during DNA damage was investigated. Replication 
during DNA damage of a HR-HPV could be a factor promoting viral integration that is 
often detected with cancer causing HPVs. Integration of the HPV16 genome into the host 
cell  chromosome  is  a  key  event  in  the  pathway  to  cervical  cancer  as  it  results  in 
unregulated expression of the viral oncoproteins E6 and E7 (Jeon et al., 1996; Romanczuk 
& Howley, 1992; Romanczuk et al., 1990). The low risk types do not cause cancer because 
they  do  not  express  oncoproteins.  To  investigate  whether  HPV16  E1–E2  mediated 
replication of the ori plasmid is arrested by DNA damage caused by etoposide transient 
DNA replication assays in 293T cells using the real-time PCR protocol as described in 3.1.1 
were  carried  out.  Fig.  3.1.3  represents  the  results  obtained  with  HPV16  E1  and  E2 
mediated replication in vivo. In lane 1 no DNA replication is detected in the untransfected 
cells. No replication is detected when a plasmid containing the HPV origin (pOri-16M) is 
transfected with or without an E1 expression plasmid (lanes 2–3). As anticipated, DNA 
replication is detectable when the E2 expression plasmid is co-transfected with pOri-16M 
and E1 (lane 4). When the cells are treated with aphidicolin following transfection E1-E2 
replication of the origin plasmid is inhibited (lane 6). The p value is calculated to be  
4x10
-7. As p<0.05 there is a significant difference between E1-E2 mediated replication of 
pOri-16M with and without aphidicolin treatment. HPV16 E1 and E2 replicate the origin 
plasmid in the presence of etoposide treatment (lane 5). The p value is calculated to be 
0.85. As p>0.05 there is no significant difference between E1-E2 mediated replication of 
pOri-16M with and without etoposide treatment. 
 
These  data  suggest  that  the  HR-HPV16  E1-E2  can  replicate  the  origin  plasmid  during 
etoposide treatment. However to definitively prove whether replication is a factor that 
may  contribute  to  viral  integration,  the  type  of  DNA  damage  caused  by  etoposide 
treatment should be assessed. A comet electrophoresis assay could be used to visualize 
and quantify double strand DNA breaks (Singh et al., 1988). Prior to electrophoresis the 
DNA is situated within the comet ‘head’. During electrophoresis undamaged DNA is too 
large  to  migrate  and  does  not  leave  the  “head”.  However  damaged  DNA  migrates 
towards  the  anode  creating  a  ‘tail’  which  can  be  clearly  seen  using  a  fluorescent Chapter 3: Results 
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microscope. Image analysis of the fluorescence intensity can be compared between the 
‘head’ and ‘tail’ to detect dsDNA breaks.   To further validate the presence of dsDNA 
breaks during etoposide treatment, H2AX phosphorylation could be examined in these 
samples. H2AX is phosphorylated on serine 139 in response to DNA double stranded 
breaks (Fernandez-Capetillo et al., 2004; Harper & Elledge, 2007). A simple western blot 
using a phospho-H2AX Ser 139 antibody may detect differences in DNA damage/repair in 
etoposide-untreated and treated cell lines.  Chapter 3: Results 
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Figure 3.1.3 HPV16 E1-E2 mediated replication in vivo is not arrested by etoposide. 
 
           
 
Figure 3.1.3 HPV16 E1-E2 mediated replication in vivo is not arrested by etoposide. 293T 
cells were transfected with 100pg of pOri-16M (lanes 2–6), 5μg of pCMV16-E1 (lanes 3–6) 
and 2μg of pCMV16-E2 (lanes 4–6). The day after transfection, cells were left untreated 
(lanes 1–4) or treated with 50µM of etoposide (lane 5) or 2.5 μg/ml of aphidicolin (lane 
6). Forty-eight hours later low molecular weight DNA was harvested from the cells for 
replication assays. The results shown represent the summary of three experiments and 
are standardised to E1+E2 without treatment (lane 4) equalling 1. Statistical significance 
by Student’s t-test is indicated as * (p < 0.05). Chapter 3: Results 
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3.1.4  In  vitro  results  show  that  LT  replication  arrest  is  inhibited  via  a 
checkpoint response, while E1–E2 replication is not 
 
In  Figures  3.1.1-3,  LT-mediated  replication  of  the  SV40  origin  plasmid  is  inhibited  in 
response  to  etoposide  treatment  whereas  HPV11  and  HPV16  E1  and  E2-mediated 
replication  of  the  HPV16  origin  replication  plasmid  is  not.  To  address  whether  these 
differences are a result of an activated DNA damage checkpoint response, the role of the 
DNA  checkpoint  kinases  (ATR/ATM/DNA-PK)  in  replication  control  was  investigated. 
Previous studies have shown that MCM2-7 helicase is targeted for phosphorylation by 
ATR/ATM in response to DNA damage (Cortez et al., 2004). It was therefore feasible that 
a checkpoint kinase may specifically target SV40 LT for phosphorylation and this may 
explain why replication of SV40 origin is inhibited during etoposide treatment.  in vivo 
experiments such as those in Figures 3.1.1-3, using either knockdown of DNA checkpoint 
kinases in 293T cells or the use of checkpoint kinases inhibitors were attempted. However 
the  combination  of  siRNA  oligonucleotides/checkpoint  inhibitors  with  etoposide 
treatment was highly toxic to the cells meaning that this approach was not feasible..  
   
To address this problem, in vitro viral DNA replication assays were utilized and carried out 
by John Fisk at the University of Buffalo. The protocol for studying in vitro HPV and LT 
replication has been previously established for HPV11, BPV1 and SV40 origin replication in 
293 cell extracts (Melendy et al., 1995; Narahari et al., 2006).  This protocol was adapted 
in  order  to  study  HPV/LT  origin  replication  during  an  activated  checkpoint  response 
(2.2.2.5). The pUC19 plasmid DNA was digested with RsaI enzyme. This produced linear 
DNA strands which mimic dsDNA breaks. The undigested or digested plasmid was added 
to the 293 cell extract to determine differences in HPV and SV40 origin replication in the 
presence of undamaged or damaged DNA. Checkpoint kinase inhibitors were used to 
establish whether an activated DNA damage response can regulate LT or E1 mediated 
replication in vitro (2.2.2.6). As a control, the same amount of undigested plasmid DNA 
was added. This DNA did not contain blunt DNA ends and therefore did not mimic DNA 
damage. The addition of undigested circular DNA  did not modify the DNA replication 
capabilities of LT or E1. Figure 3.1.4 (a) represents LT replication in vitro. When 50ng of 
undigested supercoiled pUC19 is added to the cell extract, it has no effect on LT origin 
replication.  Replication  intermediates  or  Cairns  structures  are  formed  during  the Chapter 3: Results 
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bidirectional replication of circular DNA molecules (Tapper & DePamphilis, 1977). There is 
no change in replication intermediate products between lanes 1 and 2. When 50ng of 
linearised DNA (mimics dsDNA breaks) is added in lane 4, there is a significant reduction 
in the production of LT replication intermediates. Form I and II DNA are the replicated 
progeny of replication intermediates. Form I DNA exists as supercoiled circular DNA and 
form II exists as circular DNA which has a nick in one of the strands. There appears to be a 
reduction in the quantity of form I and II DNA in lane 4 compared to the lanes that 
contain supercoiled uncut pUC19 DNA (lanes 2 and 3). DNA ends can therefore induce an 
arrest of LT mediated replication in vitro. 
 
Wortmannin  inhibits  the  phosphoinositide  3-kinase  related  kinase  (PIKK)  family  of 
proteins.  ATR,  ATM  and  DNA-PK  are  checkpoint  kinases  that belong to  this  family  of 
proteins. To determine whether the arrest in LT mediated SV40 origin replication was a 
result  of  an  activated  checkpoint  response,  wortmannin  was  included  in  the  assay. 
Wortmannin in the presence of super coiled DNA does not affect LT mediated replication 
(compare lane 3 to lane 2). On the contrary, wortmannin in the presence of DNA ends 
does effect LT mediated replication. In lane 4, linearised pUC19 DNA inhibits LT mediated 
replication. LT mediated replication was evident in the presence of linearised DNA and 
wortmannin (lane 5). Therefore wortmannin can relieve arrest in LT-mediated replication 
in the presence DNA ends suggesting that a PIKK protein is responsible for regulating LT 
mediated replication during the presence of DNA ends. 
 
To  determine  whether  HPV  replication  was  inhibited  by  the  addition  of  DNA  ends, 
identical experiments were carried out comparing the SV40 LT with HPV11 E1 in vitro 
(Figure 3.1.4 (b)). Similarly to the previous experiment, the addition of 50 and 100ng of 
digested pUC19 reduces the quantity of replication intermediates and replicated DNA 
suggesting  that  LT  mediated  replication  is  inhibited  by  DNA  ends  (lanes  2  and  3). 
However,  the  addition  of  linearised  DNA  does  not  inhibit  HPV11  E1  mediated  DNA 
replication  as  can  be  seen  by  presence  of  replication  intermediates  after  100ng  of 
digested pUC19 was added (lane 5). These in vitro results imitate the in vivo DNA damage 
replication  assay  results.  Therefore  LT  mediated  replication  is  sensitive  to  checkpoint 
kinase signalling via a PIKK pathway whereas E1 mediated replication is not.  
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By using PIKK inhibitors that prevent either ATM or DNA-PK activation, it was possible to 
investigate which of the kinases was responsible for the inhibition of LT induced DNA 
replication in vitro. As there is no specific ATR inhibitor, a process of elimination using the 
ATM and DNA-PK inhibitors could determine whether ATR was responsible (Figure 3.1.4 
(c)). As was seen previously in Figures 3.1.4 (a) and (b), the addition of RsaI digested 
pUC19 DNA resulted in a decrease in LT replication (down to around 38% compared to 
the control DMSO treatment) in lane 2. The addition of wortmannin in lane 3 results in LT 
mediated replication in the presence of DNA ends. When NU7026, a DNA-PK checkpoint 
inhibitor, or KU55933, an ATM specific checkpoint inhibitor, are added individually or 
together,  replication  remains  low  at  levels  similar  to  that  seen  with  the  addition  of 
digested  pUC19  DNA  (lanes  4,5,6  respectively).  Therefore,  through  a  process  of 
elimination,  it  can  be  hypothesised  that  ATR  checkpoint  kinase  is  responsible  for 
regulating LT mediated replication in the presence of DNA ends in vitro and this may 
serve as a model for LT mediated replication in vivo. In addition, the inhibitors for DNA-PK 
and ATM were tested in order to confirm their functional activity in these experiments. 
The  Promega  DNA-PK  assay  kit  (DNA-PK  inhibition)  and  NBS1  hyper-phosphorylation 
detection (ATM inhibition) were used to verify inhibition (data with Melendy laboratory, 
University of Buffalo).  Chapter 3: Results 
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Figure 3.1.4 In vitro results show that LT replication arrest is inhibited via a checkpoint 
response, while E1–E2 replication is not. 
 
 
 
 
Figure 3.1.4 In vitro results show that LT replication arrest is inhibited via a checkpoint 
response, while E1–E2 replication is not. a) In vitro SV40 DNA replication as described in 
2.2.2.5 was carried out in the presence of 0.1% DMSO (lane 1). Undigested pUC19 DNA 
(50ng) was added to the 293 cell extract prior to the assembly of replication reaction, 
either in the absence (lane 2) or presence of 20μM wortmannin (lane 3). Restriction-
enzyme digested pUC19 (50ng) was added to the 293 cell extract prior to the assembly of 
SV40 replication reaction either in the absence (lane 4) or presence of 20μM wortmannin 
(lane 5). b) Left panel: SV40 replication reactions were carried out in a similar method to 
(a). 0, 50 or 100ng of restriction enzyme digested pUC19 DNA was added as indicated. In 
the right panel: HPV11 DNA replication reactions were carried out as described in 2.2.2.5 Chapter 3: Results 
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using the same extract and reaction buffer as in the left panel. The only variant is the 
replication template DNA and the use of HPV11 E1 in place of SV40 LT. Zero or 100ng of 
restriction enzyme digested pUC19 DNA was added as indicated. c) The PIKK inhibitors 
(DNA-PKi=NU7026; ATMi=KU55933) were added to the 293 extracts on ice, 5 minute prior 
to  addition  of  template  and  replication  reaction  components  (concentrations  of  the 
inhibitors  given  are  final  concentration  in  the  reaction).  LT  replication  levels  were 
quantified as described in chapter 2.2.2.6. Results shown represent four independent 
experiments; error bars indicate the standard deviation. 
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3.1.5 LT is a substrate for DNA checkpoint kinases in vivo. 
 
During  an  activated  DNA  damage  response,  DNA  replication  is  inhibited  to  prevent 
replication  of  a  mutated  genome.  It  has  been  suggested  that  the  cellular  MCM2-7 
helicase is targeted by checkpoint kinases in response to DNA damage and this may result 
in the inhibition of DNA replication (Cortez et al., 2004; Ishimi et al., 2003a; Ishimi et al., 
2003b). The results in Figure 3.1.6 also suggest that ATR is the checkpoint kinase that 
regulates LT mediated replication in vitro. It was therefore possible that the checkpoint 
kinases  were  responsible  for  the  inhibition  of  LT-mediated  replication  of  the  origin 
plasmid  by  targeting  the  SV40  LT  helicase  during  DNA  damage.  Similarly  to  HPV 
replication, SV40 replication requires many of the same cellular replication proteins to 
initiate replication from the SV40 origin such as DNA pol α/δ and RFA (Replication factor 
A) (Muller et al., 1994; Melendy et al., 1995). Therefore an obvious difference between 
SV40 and HPV replication is the viral helicase. LT is the only viral protein that is required 
for SV40 replication whereas E1 in combination with E2 are the viral proteins required to 
carry out HPV origin replication. A previous study has shown that LT is phosphorylated at 
Ser120 by ATM in response to ionizing radiation treatment (Shi et al., 2005). Therefore, 
similar to phosphorylation of the MCM-2-7 helicase complex, the checkpoint kinases may 
target LT (and not E1) for phosphorylation and this may explain the differences in viral 
replication during DNA damage.  
 
To  investigate  whether  the  DNA  damaging  agent  etoposide  is  able  to  activate  a 
checkpoint kinase pathway the phosphorylation of a downstream target protein, Chk2 
was investigated in 293T cells. The phosphorylation of Chk2 protein is an indication of an 
activated DNA damage response (Matsuoka et al., 1998; Chaturvedi et al., 1999). In Figure 
3.1.5(a) 293T cells were treated with a range of concentrations of etoposide for two 
hours. The phosphorylation of Chk2 is evident at 10 and 50μM of etoposide (lanes 2 and 
3) but not in untreated 293T cells (lane 1)). Therefore phosphorylation of Chk2 protein 
demonstrates the activation of a checkpoint kinase pathway.  
 
To investigate whether LT is phosphorylated in a similar manner to MCM2-7 in response 
to checkpoint kinase activation, LT protein co-immunoprecipitation pull down with the 
protein  kinases  ATR  and  ATM  in  response  to  etoposide  treatment  was  investigated Chapter 3: Results 
 
106 
 
(2.2.2.8). 293T cells that stably express the LT protein were untreated or treated with 
50μM of etoposide. Cells were harvested and protein extracts were immunoprecipitated 
with a phospho-(Ser/Thr)-glutamine ATR/ATM substrate antibody (pS/Q antibody). This 
antibody  pulls  down  proteins  that  have  been  phosphorylated  on  serine/threonine 
residues  by  the  protein  kinases  ATR/ATM.  The  samples  were  subjected  to 
immunoblotting for LT (Figure 3.1.5 (b)). In the input lanes, 3 and 4, it is evident that the 
LT protein is not degraded by 30 minutes of etoposide treatment therefore ruling out the 
possibility of protein degradation. The pS/Q antibody co-precipitates a significant amount 
of LT protein after etoposide treatment (lane 2) whereas LT shows no pull down with the 
pS/Q antibody in untreated 293T cells (lane 1). This result suggests that, similar to MCM2-
7, the LT helicase is phosphorylated by either ATR or ATM in response to an activated 
DNA damage response in vivo.  
 
 
Figure 3.1.5 LT is a substrate For DNA checkpoint kinases in vivo. 
 
(a) 
      
 
 
(b) 
           
 
 
Figure 3.1.5 LT is a substrate For DNA checkpoint kinases in vivo. a) 293T cells were 
treated  with  0/10/50μM  of  etoposide  for  2  hours.  Cells  were  harvested  and  protein Chapter 3: Results 
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extracts  were  prepared  for  western  blot  analysis  using  a  phospho-Chk2  Threonine-68 
antibody to confirm ATR/ATM checkpoint activation.  (b) Cells were left untreated (-) or 
treated with 50μM of etoposide (+) for 30 minutes and protein extracts were prepared. A 
fraction of the protein extract was then immunoprecipitated with an S/Q antibody (lanes 
1 and 2). The precipitate was probed with LT antibody (pAb101).  Chapter 3: Results 
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3.1.6 E1 is not a substrate for DNA checkpoint kinases in vivo. 
 
Having  established  ATR  activation  with  etoposide  treatment  and  shown  that  LT  is  a 
substrate  for  ATR  phosphorylation  in  vivo,  it  was  hypothesised  that  E1  may  not  be 
targeted for phosphorylation by ATR/ATM in vivo in the presence of an activated DNA 
damage response. To investigate this HPV11 and HPV16 E1 protein was used in a similar 
experiment to Figure 3.1.5. 293T cells were transfected with an HA-tagged E1 plasmid 
(pMH1-11E1HA/pMH1-16E1HA), expressing either HPV11 or HPV16 E1 respectively and 
were then treated with 50μM of etoposide. Protein extracts were immunoprecipitated 
with  the  phospho-(Ser/Thr)-glutamine  ATR/ATM  substrate  antibody  (pS/Q  antibody). 
These extracts were then subjected to immunoblotting for E1 protein pull down. In Figure 
3.1.6 (a), cells were calcium phosphate transfected with 1μg of HPV11 HA-tagged E1 or an 
empty control plasmid of the same concentration. Forty eight hours post transfection, 
samples were left untreated or treated with 50μM of etoposide for 30 minutes prior to 
harvest and protein preparation. A fraction of the protein extract was incubated with the 
pS/Q antibody and extracts were then prepared for western blotting. The membranes 
were probed against E1 (HA). In lanes 1, 2, 5 and 6, there is no E1 present in these 
samples therefore they act as negative controls. There appears to be phosphorylation of 
E1 in the absence of DNA damage (lane 3). However, the pS/Q antibody fails to pull down 
E1 in the presence of DNA damage (lane 4). In lanes 7 and 8, the HA-tagged E1 plasmid is 
detectable in the input lanes. In lane 8, E1 is not degraded as a consequence of etoposide 
treatment  and  this  therefore  rules  out  any  suggestions  that  E1  is  simply  not  co-
immunoprecipitated with the pS/Q antibody because it has been degraded.  Studies on 
BPV E1 protein suggest that E1 is phosphorylated and this may regulate BPV replication 
(Lentz et al., 1993; Zanardi et al., 1997; Lentz et al., 2002). Therefore the phosphorylation 
of HPV11 E1 in undamaged cells may be a consequence of E1 regulation. A recent paper 
has also suggested that BPV1 E1 may contain an ATR phosphorylation site (Lentz et al., 
2006).  Further  evidence  is  required  to  confirm  this  hypothesis  however  the  result  in 
Figure 3.1.6 (a) suggests that either ATR or ATM phosphorylates HPV11 E1 in untreated 
cells, suggesting a regulatory role for the protein kinases.  
 
Figure 3.1.6 (b) shows the results obtained with HA-tagged HPV16 E1. This experiment 
was carried out in an identical manner to the experiment in 3.1.6 (a) with the exception Chapter 3: Results 
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of  transfection  of  a  HPV16  HA-tagged  E1  instead  of  HPV11.  Lanes  1  and  3  serve  as 
negative controls as they have not been transfected with E1. Unlike HPV11 E1 the pS/Q 
antibody appears not to pull down E1 in the absence of etoposide treatment (lanes 2). 
Similarly to HPV11, HPV16 E1 does not appear to be phosphorylated by ATR/ATM in 
response to etoposide treatment (lane 4).  E1 is detected in the input lanes (5 and 6). 
Therefore  the  results  from  our  checkpoint  activated  co-immunoprecipitation  assays 
demonstrate that the E1 protein of HPV11 and HPV16 is not targeted for phosphorylation 
by the ATR/ATM checkpoint kinases in response to DNA damage.  Chapter 3: Results 
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Figure 3.1.6 E1 is not a substrate for DNA checkpoint kinases in vivo. 
 
(a) 
     
 
 
(b)  
 
 
Figure 3.1.6 E1 is not a substrate for DNA checkpoint kinases in vivo. (a) Cells were 
transfected with 1μg of HPV11 HA-E1 (lanes 3, 4 and 7, 8) or 1μg of empty control vector 
(lanes  1,  2  and  5,  6).  Twenty-four  hours  later  the  cells  were  treated  with  50μM  of 
etoposide  for  30  minutes  (+)  or  left  untreated  (−)  as  indicated  and  protein  extracts 
prepared. A fraction of the protein extract was then immunoprecipitated with an S/Q 
antibody (lanes 1–4) and the resultant precipitate probed with an HA antibody to detect 
any immunoprecipitated E1 b) 293T cells were transfected with 1μg of HPV16 HA-E1 
(lanes 2, 4 and 5, 6) or 1μg of empty control vector (lanes 1, 3). Twenty-four hours later 
the cells were treated with 50μM of etoposide for 30 minutes (+) or left untreated (−) as 
indicated  and  protein  extracts  prepared.  A  fraction  of  the  protein  extract  was  then Chapter 3: Results 
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immunoprecipitated  with  an  S/Q  antibody  (lanes  1–4)  and  the  resultant  precipitate 
probed with an HA antibody.  Chapter 3: Results 
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3.1.7  LT  protein  levels  are  reduced  following  prolonged  etoposide 
treatment 
 
The DNA  replication  assay  results  in  Figures  3.1.1-3.1.3 are  extended over  a  48  hour 
period  following  etoposide  treatment.    To  investigate  the  levels  of  the  LT  protein 
following extended etoposide treatment, a time course of etoposide treatment followed 
by LT western blotting was carried out and the results are shown in Figure 3.1.7 (a). The 
level of LT protein begins to drastically decrease after 8 hours of etoposide exposure. 
After 24 hours there is a significant reduction in the LT proteins levels as it is barely 
detectable by western blotting. To confirm that etoposide had activated an ATR DNA 
damage  response,  a  phospho-Chk1  antibody  was  probed  against  these  extracts.  
Etoposide  treatment  clearly  phosphorylates  Chk1.  Chk1  is  a  substrate  for  activated 
ATR/ATM (Zhao and Piwnica-Worms, 2001). Chk1 phosphorylation persists over the 24 
hour period of the experiment. Gamma-tubulin levels are shown as a loading control.  
 
LT  RNA  levels  were  also  analysed  to  investigate  whether  LT  protein  reduction  after 
prolonged etoposide treatment was a post translational event, and not simply due to a 
reduction in LT mRNA levels (Figure 3.1.7 (b)). Although LT mRNA levels decreased by 24 
hours to around 36% of RNA levels without treatment (100%) this was not representative 
of the protein levels detected by western blot (2.2.1.15). Therefore LT mRNA reduction is 
not  fully  responsible  for  the  reduction  of  protein  levels  after  prolonged  etoposide 
treatment.  In addition, the in vitro experiments in Figure 3.1.4 demonstrate that the 
regulation of LT mediated DNA replication by DNA damaging agents is due to a direct 
regulation of the LT protein. Therefore although there is a reduction in LT RNA levels 
following etoposide treatment, this is unlikely to fully account for the inhibition of DNA 
replication  function.  When  aphidicolin  is  used,  an  immediate  arrest  of  LT  replication 
occurs (Figure 3.1.2). The replication signals after etoposide and aphidicolin treatment are 
very  similar  in  Figure  3.1.2,  suggesting  an  immediate  arrest  of  LT  mediated  DNA 
replication by etoposide.  
 
To determine whether part of the reduction of LT protein is due to proteosome mediated 
degradation,  the  proteasomal  inhibitor  MG132  was  used  in  the  LT-etoposide 
experiments. The result of this experiment is shown in Figure 3.1.7 (c). In lane 1, LT Chapter 3: Results 
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protein is detected in untreated 293T cells. Following treatment with etoposide, protein 
levels  decrease  (lane  2).  LT  protein  levels  appear  to  decrease  slightly  in  response  to 
MG132 treatment (lane 3). The LT protein can be easily detected by western blot when 
treated  in  combination  with  etoposide  and  MG132.  The  results  from  three  identical 
experiments were quantified using Image J software and graphed in Figure 3.1.7 (d). The 
addition of etoposide to 293T cells drastically reduces LT protein levels to around 5%  of 
that detected in untreated 293T cells. Treatment with MG132 also reduces LT levels to 
around 30% less than the untreated cells. MG132 is dissolved in DMSO. DMSO has been 
reported to affect protein stability therefore this may explain the reduction in LT protein 
levels (Tjernberg et al., 2006). 293T cells treated with etoposide and MG132 have around 
60% less LT protein than untreated cells. These results suggest that LT protein levels are 
reduced  by  long  term  etoposide  treatment  because  of  a  decrease  in  LT  RNA  levels, 
possibly due the health of the cells beginning to deteriorate, and by degradation of LT via 
the proteasome.  Chapter 3: Results 
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3.1.7 LT protein levels are reduced following prolonged etoposide treatment  
 
(a) 
       
 
(b) 
                  
 
(c) 
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(d) LT protein levels following etoposide and MG132 treatment.  
 
           
          
Figure 3.1.7 LT protein levels are reduced following prolonged etoposide treatment. a) 
293T cells were treated with 50μM of etoposide for the time periods shown and then 
protein extracts prepared.  These extracts were then western blotted for the proteins 
indicated.  Chk1  S317  serves  as  a  control  to  confirm  activation  of  the  DNA  damage 
response and gamma-tubulin as a loading control. b) 293T cells were treated with 50μM 
of etoposide for 24 hours. RNA extracted from the cells was converted to cDNA and levels 
of LT were detected using real-time PCR. The graph represents 3 experiments with results 
normalised  to  β-actin.  c)  LT  protein  levels  are  reduced  via  the  proteosome  following 
etoposide treatment. 293T cells were treated with 50μM etoposide (lanes 2 and 4) and/or 
100μM  MG132  as  indicated  and  protein  extracts  prepared  24  hours  later.  Western 
blotting was then carried out for LT and gamma-tubulin as a loading control. (d) Three 
replicates from 3.1.7 (c) were quantified using Image J software and gamma tubulin as a 
loading control. The results displayed show the mean and standard error of the mean.  Chapter 3: Results 
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3.1.8  HPV16  E1  protein  levels  are  not  reduced  following  prolonged 
etoposide treatment.  
 
Previously  it  was  shown  that  ATR  targets  LT  for  phosphorylation  as  a  result  of  DNA 
damage, and a consequence of long term exposure to DNA damage is a large reduction in 
LT protein levels (Figures 3.1.4 and 3.1.7 respectively). Therefore it was hypothesised that 
the ability of HPV  E1 protein to avoid phosphorylation by  the ATR checkpoint kinase 
would result in unchanged protein levels after long term etoposide exposure. The protein 
levels  of  the  HPV16  E1  helicase  were  investigated  following  long  term  exposure  to 
etoposide. In Figure 3.1.8 (a), 293T cells were calcium phosphate transfected with 1μg of 
HPV16 HA-tagged E1 plasmid. The following day cells were treated with etoposide for the 
time points indicated, and harvested for western blot analysis against E1 (HA), phospho-
Chk1 S317 (to show DNA damage checkpoint activation) and gamma tubulin  (loading 
control).  Lane 1 does not contain any transfected E1 plasmid and serves as a negative 
control. E1 is detected when transfected in lane 2. Figure 3.1.8 also demonstrates that 
calcium phosphate transfection does not activate a DNA damage response because no 
phosphorylated Chk1 is detected by western blot. Short term exposure (0.5 hours) with 
etoposide  does  not  alter  E1  protein  levels  during  the  activation  of  a  DNA  damage 
response  (lane  3).  In  contrast  to  the  LT  helicase,  E1  protein  levels  do  not  appear  to 
decrease after 24 hours of etoposide treatment. Results from three experiments were 
quantified using Image J software and gamma tubulin as a loading control (Figure 3.1.8 
(b)). Treatment with etoposide results in a doubling of E1 protein levels after 24 hours. E1 
protein levels appear to remain high after long term etoposide treatment. Treatment 
with etoposide may arrest the 293T cells in the S phase of the cell cycle (Chow & Ross, 
1987). E2 protein has been shown to be stabilised in S phase of the cell cycle and there 
may be a similar mechanism for E1 stabilisation (Johansson et al., 2009). E1 associates 
with cyclin E/Cdk2 and prevents E1 degradation via the proteosome (Cueille et al., 1998; 
Ma et al., 1999). Cyclin E/Cdk2 is a key regulator that initiates progression into the S 
phase of the cell cycle and therefore it is feasible that E1 may also be stabilised during s 
phase.  
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3.1.8 E1 protein levels are not reduced following prolonged etoposide treatment.  
 
(a) 
 
         
 
(b) 
 
             
 
Figure 3.1.8 E1 protein levels are not reduced following prolonged etoposide treatment. 
(a)  293T cells were transfected with 1μg of HPV16 HA-E1 plasmid and the following day 
cells left untreated (−) or treated with 50μM of etoposide (+) for 0.5 hours (lane 3) and 24 
hours (lane 4). Protein extracts were then prepared and western blotted for the proteins Chapter 3: Results 
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indicated.  Phospho-Chk1  S317  serves  as  a  control  to  confirm  activation  of  the  DNA 
damage  response  and  gamma-tubulin  is  used  as  a  loading  control.  (b)  Three  similar 
experiments  were  quantified  after  24  hours  of  etoposide  treatment  using  Image  J 
software  and  gamma  tubulin  as  a  loading  control.  The  results  show  the  mean  and 
standard error of the mean from three independent experiments.  
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3.1.9 Site directed mutagenesis of LT phosphorylation sites. 
 
LT is phosphorylated on serine and threonine sites by ATR in response to DNA damage 
(Figure  3.1.5).  ATR  is  known  to  target  serine/threonine  sites  that  are  followed  by  a 
glutamine  (SQ/TQ  sites)  (Traven  &  Heierhorst 2005).  Activities  of  LT  are  differentially 
regulated by phosphorylation  of  serine  and  threonine  residues  (Shi et  al.,  2005).  Site 
directed mutagenesis of LT at known S/Q or T/Q sites was carried out. The aim was to find 
the  specific  S/Q  site  that  is  phosphorylated  by  ATR  in  response  to  DNA  damage. 
Mutations were made in the LT plasmid using  the site directed mutagenesis protocol 
(2.2.2.11 & 2.2.2.12). The serine or threonine were mutated and replaced with an alanine 
(Figure 3.1.9).  
 
Figure 3.1.9 Site directed mutagenesis of LT phosphorylation sites. 
 
 
 
 
 
 
Figure  3.1.9  Site  Directed  Mutagenesis  of  known  LT  phosphorylation  sites.  Image 
showing the known S/Q and T/Q sites on LT. The sites highlighted were chosen to be 
mutated in wild type pLT using site directed mutagenesis. Chapter 3: Results 
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3.1.10 LT mutated plasmids are recognised by LT antibodies.  
 
To ensure that the LT epitope recognition site for the LT antibodies, pAb101 and pAb419 
was retained following mutation of the LT plasmid a simple co-immunoprecipitation was 
carried out in 293 cells. Using the GeneJuice method of transfection, either wild type LT 
plasmid DNA, or one of the mutant plasmid (pLTAg S120A, Q517A, S639A, S664/666A, 
S676A) were transfected into cells. Two days post transfection, cells were harvested and a 
fraction of the extract was immunoprecipitated with the LT antibody, pAb419. Samples 
were then prepared for western blot analysis and probed against the LT antibody pAb101 
(Figure 3.1.10). Unlike 293T cells, 293 cells do not stably express the wild type LT protein 
(lane 1). Wild-type (wt) LT was detected in the pull down (Lane 2). All but one of the 
mutants  (pLTAg  S664/666A)  were  pulled  down  with  the  wild  type  LT  antibody.  This 
mutant contained a double mutation due to the close proximity of the S/Q sites. It was 
therefore possible that this mutation was detrimental to the correct LT protein folding as 
the antibody could not recognise the epitope of the mutated plasmid. The mutants that 
were capable of pull down with wild type  LT antibody demonstrate that the epitope 
recognition site for the antibodies pAb101/419 on the mutated LT protein is maintained 
despite site directed mutagenesis.  
 
Figure 3.1.10 LT mutated plasmids are recognised by LT antibodies. 
 
 
Figure  3.1.10  LT  mutated  plasmids  are  recognised  by  LT  antibodies  293  cells  were 
transfected with 2μg of pLT or with 2μg of  one of the mutants; pLTAg S120A, Q517A, 
S639A, S664/666A, S676A. Forty eight hours post transfection, cells were harvested for 
immunoprecipitation. Protein extracts were immunoprecipitated with pAb419 (LT) and 
samples were prepared for western blot analysis probing against pAb101 (LT).  Chapter 3: Results 
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3.1.11 ATR targets LT SQ/TQ mutants for phosphorylation after etoposide 
treatment.  
 
To determine if ATR/ATM phosphorylates a specific LT SQ/TQ site during an activated 
DNA damage response, co-immunoprecipitation was carried out using the LT mutated 
plasmids. The mutant and wild type LT plasmids were transfected into 293 cells using the 
GeneJuice method of transfection (2.2.1.3). Two days later, cells were treated with 50μM 
etoposide for 6 hours. Cells were treated for 6 hours because previous results indicated 
that LT protein levels do not substantially decrease after this time and phosphorylation of 
Chk1, indicative of an activated checkpoint response is still detected (Figure 3.1.7). Cells 
were then harvested and protein extracts were made. A fraction of the extract was then 
immunoprecipitated  with  the  phospho-S/Q  antibody  that  had  been  used  previously 
(Figure 3.1.5 (b)). The extracts were then prepared for western blot analysis and the 
membranes  were  probed  with  the  LT  antibody  (pAb101).  If  a  LT  mutant  that  had 
previously shown pull down with the wild type LT but failed to co-immunoprecipitate with 
the  pS/Q  antibody,  it  would  reveal  a  specific  site  on  LT  that  is  phosphorylated  by 
ATR/ATM in response to DNA damage. In Figure 3.1.11 wild type LT is phosphorylated by 
ATR/ATM in response to etoposide treatment (lane 2). The pLTAg S664/666A mutant was 
not detected by co-immunoprecipitation (lane 6). This mutant previously failed to co-
immunoprecipitate with wild type LT and it was not detected in the input lanes therefore 
this mutation has resulted in loss of confirmation of the antibody recognition site. The 
remaining  LT  mutants  all  pull  down  with  the  pS/Q  antibody.  Therefore  none  of  the 
potential ATR/ATM target residues are individually responsible for phosphorylation of LT 
following DNA damage. At this point it was decided that proteomic studies would be 
more  effective  at  determining  the  phosphorylation  of  LT  following  DNA  damage. 
Proteomic studies would allow for the identification of post translational modification of 
phosphorylation sites on the LT protein after etoposide treatment.  Chapter 3: Results 
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Figure  3.1.11  ATR  targets  LT  SQ/TQ  mutants  for  phosphorylation  after  etoposide 
treatment. 
 
 
 
 
Figure  3.1.11  ATR  targets  SQ/TQ  LT  mutants  for  phosphorylation  after  etoposide 
treatment. 293 cells were transfected with 2μg of pLT or a pLTAg mutant. Two days post 
transfection cells were treated with 50μM of etoposide for 6 hours. Cells were harvested 
and protein extracts prepared. A fraction of the extract was immunoprecipitated with the 
phospho-S/Q  antibody  and  prepared  for  western  blot  analysis  against  pAb101.  Input 
extracts are also shown and gamma tubulin represents a loading control.  
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3.2  In  vitro  cell  extract  preparation  of  ATR  and  TopBP1  deficient  cell 
extracts 
 
In Chapter 3.1 replication assays showed that replication of the SV4O origin by the SV40 
helicase  LT  is  inhibited  in  vivo  after  treatment  with  etoposide  and  in  vitro  by  linear 
digested DNA plasmid. Further to this, in vitro data suggested that the ATR kinases are 
responsible for the activation of the checkpoint pathway that regulates replication by LT. 
Co-immunoprecipitation  using  an  antibody  that  binds  to  proteins  that  have  been 
phosphorylated by ATR/ATM suggested that LT is targeted by these proteins in response 
to etoposide treatment in vivo. Chapter 3.2 focuses on determining whether the ATR 
kinase  is  indeed  responsible  for  the  regulation  of  LT-mediated  SV40  origin  plasmid 
replication.  
 
 
3.2.1 ATR and TopBP1 are essential for activation of Chk1 protein kinase. 
 
The  in  vitro  results  in  Figure  3.1.4  suggest  that  ATR  is  responsible  for  regulating  LT 
replication. This result was extended in the in vivo co-immunoprecipitation assay where 
LT was shown to be targeted for phosphorylation by ATR/ATM in response to etoposide 
treatment (Figure 3.1.5). Attempts were made to generate protein extracts lacking in ATR 
activity.  The ATR
-deficient extract could then be used during in vitro replication studies to 
investigate  LT-mediated  replication  during  DNA  damage  without  ATR  activation.  This 
would validate the hypothesis that ATR is the protein kinase that regulates LT mediated 
replication.  Two  proteins  that  were  targeted  for  knockdown  were  ATR  and  TopBP1. 
TopBP1 plays the role of a sensor protein in the DNA damage response that is essential 
for  ATR  activation  (Kumagai  et  al.,  2006).  TopBP1  coordinates  activation  of  the  DNA 
damage checkpoint response by coupling the interaction of the 9-1-1 checkpoint clamp at 
sites of ssDNA. In return this activates the ATR-ATRIP checkpoint kinase complex (Chapter 
1.9.2).  The  activation  of  ATR  triggers  a  cascade  of  phosphorylation  events  which 
ultimately  leads  to  cell  cycle  arrest.  Owing  to  the  fact  that  previous  studies  have 
demonstrated  the  essential  nature  of  ATR  (making  it  unlikely  to  generate  sufficient 
amounts of ATR depleted cell extract for replication assays) the dual approach of TopBP1 Chapter 3: Results 
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and  ATR  knockdown  offered  a  greater  chance  of  success.  The  phenotype  of  TopBP1 
depleted cells is well defined.  
 
Oligonucleotides were designed against ATR and TopBP1 (siATR and siTopBP1). The siRNA 
oligonucleotides were transfected using the Lipofectamine 2000 protocol (2.2.1.4) into 
293T cells that were harvested forty eight hours later for western blot analysis (Figure 
3.2.1 (a)). Levels of knockdown were measured by probing the membranes for ATR and 
TopBP1. In lane 1 and 4, 293T cells were mock transfected. A control oligonucleotide 
(siLuciferase) was transfected into the cells in order to control for any protein knockdown 
due to the presence of an oligonucleotide targeting a non essential gene (lanes 2 and 3). 
In lane 3, ATR protein levels have greatly reduced confirming the knockdown by the siATR 
oligonucleotide. TopBP1 protein levels are also significantly reduced after transfection 
with siTopBP1 (lane 6). Transfecting siRNA oligonucleotides into cells can cause off target 
effects  such  as  the  silencing  of  non  specific  target  genes  and  reduced  protein  levels 
(Jackson  et  al.,  2003;  Snove  &  Holen,  2004;  Jackson  &  Linsley,  2004).  Studies  have 
demonstrated that the knock down of TopBP1 reduces the activation of ATR (Kumagai et 
al.,  2006;  Pedram  et  al.,  2009).  However  due  to  the  off  target  effects  or  siRNA 
oligonucleotides,  ATR  and  TopBP1  protein  levels  should  have  been  determined  after 
knockdown of TopBP1 and ATR (respectively). This would have been useful to determine 
whether knock down of TopBP1 could reduce DNA damage signalling independently from 
ATR.  
 
The effect of ATR and TopBP1 knockdown on the activation of the DNA damage response 
was  investigated  by  examining  Chk1  phosphorylation.  TopBP1  was  knocked  down  as 
described  above.  Twenty  four  hours  later  cells  were  treated  with  hydroxyurea  (HU) 
(Figure 3.2.1 (b)). Hydroxyurea has previously been shown to activate ATR DNA damage 
pathways  (Hammond  et  al.,  2003).  After  HU  treatment,  the  cells  were  harvested  for 
western  blot  analysis.  In  lanes  1  and  2,  cells  were  mock  treated.  In  lane  2  Chk1  is 
phosphorylated at S317 in response to HU treatment, indicating an activated checkpoint 
response.  In  lanes  3  and  4,  cells  were  transfected  with  the  control  oligonucleotide, 
siLuciferase. In lane 4, Chk1 is phosphorylated when cells are treated with HU. In lanes 5 
and 6 the cells were transfected with siTopBP1. Levels of phosphorylated Chk1 protein 
are activated upon HU treatment in lane 6, however these levels are much lower than Chapter 3: Results 
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those seen in lanes 2 and 4. This may be a result of a partial knockdown of TopBP1.  A 
pan-Chk1 antibody that detects the total amount of Chk1 in each protein extraction was 
used as a control for Chk1 levels, and gamma tubulin antibody was used as a loading 
control. These results indicate that TopBP1 knock down in 293T cells results in reduced 
Chk1 phosphorylation. ATR was knocked down and cells treated with hydroxyurea in a 
similar way to TopBP1 (Figure 3.2.1 (c)). In lane 1 and 2, cells were mock treated. In lane 2 
Chk1 is phosphorylated at S317 in response to HU treatment. In lanes 3 and 4, cells were 
transfected  with  the  control  oligo,  siLuciferase.  In  lane  4,  Chk1  is  phosphorylated  in 
response to HU treatment. In lanes 5 and 6 the cells were transfected with siATR. In lane 
6, siATR transfected-HU treated cells do not appear to contain any phosphorylated Chk1 
protein. A pan-Chk1 antibody that detects the total amount of Chk1 is each extraction 
was used as a control for Chk1 levels, and gamma tubulin antibody was used as a loading 
control. These results indicate that when ATR or TopBP1 are knocked down, DNA damage 
signalling  through  Chk1  kinase  is  significantly  inhibited  indicating  a  reduction  in  DNA 
damage signalling.  Chapter 3: Results 
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Figure 3.2.1 ATR and TopBP1 are essential for activation of Chk1 protein kinase. 
 
(a) 
 
         
 
(b) 
             
 
 
(c) 
             
 
 
Figure 3.2.1 ATR and TopBP1 are essential for activation of Chk1 protein kinase. (a) 293T 
cells  were  mock  transfected  or  transfected  with  oligonucleotides  against 
Luciferase/ATR/TopBP1 genes. The oligonucleotide efficiency for ATR/TopBP1 knockdown 
was analysed by western blotting using antibodies against ATR and TopBP1. (b) 293T cells 
were mock transfected (lanes 1 and 2), transfected with siLuciferase (lanes 3 and 4) or 
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siATR (lanes 5 and 6). Lanes 2, 4, and 6 are samples that were treated with 3mM of HU for 
4  hours.  Cells  were  then  harvested  and  analysed  for  western  blotting  for  antibodies 
against  phospho-Chk1  S317,  pan-Chk1  and  gamma  tubulin.  (c)  cells  were  mock 
transfected (lanes 1 and 2), transfected with siLuciferase (lanes 3 and 4) or siTopBP1 
(lanes 5 and 6). Lanes 2, 4, and 6 are samples that were treated with 3mM of HU for 4 
hours. Cells were then harvested and analysed by western blotting for antibodies against 
phospho-Chk1 S317, pan-Chk1 and gamma tubulin. Chapter 3: Results 
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3.2.2 Cell survival is diminished when ATR and TopBP1 are knocked down 
 
Having  established  that  siATR  and  siTopBP1  treatment  of  293T  cells  inhibited  DNA 
damage  response  signalling,  the  next  step  was  to  investigate  the  effects  of  ATR  and 
TopBP1 knockdown on cell growth. This would determine whether it was possible  to 
generate enough TopBP1/ATR knockdown extract for use in the in vitro DNA replication 
assays.  TopBP1  knockdown  in  293T  cells  has  previously  been  shown  to  result  in  no 
aberrant  changes  in  cell  growth  (Wright,  2007).  This  result  was  validated  using  the 
siTopBP1 oligonucleotide and cell growth during ATR knockdown was also investigated. A 
simple cell count assay was completed to investigate whether cells could replicate and 
grow in the absence of ATR/TopBP1 siRNA. HEK 293T cells were transfected with lipids, 
siLuciferase, siATR or siTopBP1  using the  Lipofectamine2000 protocol.  Two days after 
transfection cells were harvested, counted and 2 x 10
5 cells were replated in triplicate for 
each transfection. Every 2-3 days, cells were harvested, counted and replated (Figure 
3.2.2). These experiments were carried out in triplicate, with the standard error bars 
shown. In contrast to the findings from Wright, 2007 TopBP1 appears to be essential for 
normal 293T cell growth because transfected cells were unable to replicate efficiently. 
ATR is also essential for cellular replication. Since TopBP1 and ATR appear to be essential 
for normal cell growth in vivo, it would be very difficult to generate cell extracts depleted 
of ATR activity for in vitro replication assays.  
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Figure 3.2.2 Cell survival is diminished when ATR and TopBP1 are knocked down 
 
 
 
3.2.2 Cell survival is diminished when ATR and TopBP1 are knocked down. 293T cells 
were either untreated, or treated with siLuciferase/siTopBP1/siATR/mock. A cell count 
assay  was  performed  after  knockdown.  Day  0  is  representative  of  2  days  post 
transfection.  Cells  were  harvested  and  counted  at  the  time  points  indicated.  The 
experiments were carried out three times in triplicate and this data shows the standard 
error of the three experiments. Values are shown as a fold difference where day zero is 
standardised to 1.  Chapter 3: Results 
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3.2.3  Long  term  cell  survival  is  abolished  when  ATR  and  TopBP1  are 
knocked down 
 
To validate previous findings that TopBP1 and ATR are essential to cell survival crystal 
violet colony survival assays were carried out over fourteen days (2.2.1.6). In these assays 
TopBP1 or ATR were knocked down using TopBP1/ATR targeted siRNA and similarly to the 
previous cell count assays; siLuciferase and mock (lipofectamine only) controls were also 
used. The results for the colony survival assay are shown in Figure 3.2.3. This experiment 
was carried out three times in triplicate; this figure is representative of the triplicate 
plates from the same repeat experiment. It is visually very clear that knocking down 
TopBP1 or ATR expression has a profound effect on 293T cell growth over long periods of 
time. The results are clear that TopBP1 and ATR deficient 293T cells are unable to grow, 
ruling out the possibility of generating enough knocked down lysate for in vitro replication 
assays.  
 
3.2.3 Long term cell survival is abolished when ATR and TopBP1 are knocked down 
 
 
Figure 3.2.3 Long term cell survival is abolished when ATR and TopBP1 are knocked 
down. Photographs from 293T colony survival assay. These experiments were carried out 
three times in triplicate. The plates shown here are representative of those obtained for 
the three experiments. 293T cells were plated out and mock transfected, siLuciferase 
transfected,  siATR  transfected  or  siTopBP1  transfected.  All  colonies  were  visualized 
fourteen days following siRNA treatment using a 0.5% crystal violet solution. 
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3.3 HPV16 E2 is stabilised by E1 and etoposide 
 
In Figure 3.1.8, HPV16 E1 protein levels appear to increase in the presence of etoposide 
although the mechanism used to explain this observation was not investigated. The E1 
and E2 proteins interact during the virus life cycle  at the viral origin therefore it was 
feasible  that E2  protein  levels  may  also  increase  during  etoposide  treatment.  E2 is  a 
multifunctional protein and any changes in protein levels would affect many stages of the 
virus life cycle such replication and regulation of transcription.  Changes in E2 protein 
levels  will  affect  levels  of  virus  replication  therefore  the  levels  of  E2  protein  in  the 
presence of E1 was also investigated.  
 
 
3.3.1. HPV16 E2 is stabilised by prolonged etoposide treatment 
 
In  Figure  3.1.2,  the  HPV  viral  helicase  E1  avoids  phosphorylation  by  ATR  during  an 
activated DNA damage response.  This  result  may  explain  why  E1  protein  levels  were 
shown to increase after long term exposure to etoposide (Figure 3.1.8). The E2 protein is 
also  required  to  initiate  HPV  replication  therefore  the  consequences  of  prolonged 
etoposide treatment on E2 protein levels was also investigated. 293T cells were calcium 
phosphate transfected with HPV16 E2. Two days post transfection cells were untreated or 
treated  with  etoposide  for  2/4/6/8/16  and  24  hours.  Cells  were  then  harvested  and 
prepared  for  western  blot  analysis.  In  a  similar  trend  to  E1,  there  appears  to  be  an 
increase in E2 protein levels following long term etoposide exposure (Figure 3.3.1(a)). This 
result suggests a stabilisation of E2 following etoposide treatment. To determine whether 
the increase in E2 protein levels is a post translational event or simply due to increased E2 
RNA levels, E2 RNA was measured after 24 hours of etoposide treatment. E2 transfected 
293T cells were untreated or treated with 50μM of etoposide. Cells were harvested and 
RNA was extracted using Qiagen RNeasy kit and contaminating DNA removed using the 
DNA-free kit (2.2.2.15 & 2.2.2.16). Complimentary DNA was synthesised using SuperScript 
III reverse transcriptase kit (2.2.2.17). E2 levels were detected using real time PCR and 
standardised with a beta actin control (Figure 3.4.2. (b)). In the presence of etoposide, E2 
RNA levels increase to approximately 5 fold more, than untreated E2 transfected cells (p Chapter 3: Results 
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value >0.05). Therefore although there is an increase increase in E2 mRNA levels after 
prolonged etoposide treatment it is not a significant difference.  
 
Figure 3.3.1 HPV16 E2 is stabilised by prolonged etoposide treatment 
 
(a)  
          
 
(b)                        
 
                              E2 RNA levels increase after etoposide treatment 
                             
 
Figure  3.3.1  E2  is  stabilised  by  prolonged  etoposide  treatment  (a)  293T  cells  were 
transfected  with  2μg  of  HPV16  E2  plasmid.  48  hours  later  cells  left  untreated  (−)  or 
treated with 50μM of etoposide (+) for the times indicated. Cells were harvested and 
prepared  for  western  blot  analysis  and  probed  for  E2  (TVG261)  and  gamma  tubulin. 
Phosphorylated Chk1 S317 serves as a control to confirm activation of the DNA damage 
response.  (b) 293T cells were transfected with 2μg of HPV16 E2 plasmid and untreated or 
treated with 50μM of etoposide for 16 hours. RNA extracted from the cells was converted 
to cDNA and levels of E2 were detected using real-time PCR. The graph represents 3 
experiments with results normalised to beta actin. The values shown are representative 
of fold difference where E2 is equal to 1.  Chapter 3: Results 
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3.3.2 HPV16 E2 is stabilised by E1 through post translational modifications. 
 
The consequence of E1 and etoposide on E2 protein levels was next investigated. 293T 
cells were transfected with HPV16 E2, and either the HPV16 HA tagged E1 or an empty 
vector plasmid. Two days post transfection the cells were treated with 50μM etoposide 
for 24 hours or were left untreated.  The treated cells were then harvested and prepared 
for  western  blot  analysis  probing  with  antibodies  against  E2  (TVG261),  E1  (HA)  and 
gamma tubulin (Figure 3.3.2 (a)). E2 protein is detectable when transfected by itself (lane 
3). When co-transfected with the HA tagged E1 plasmid, E2 protein levels increase (lane 
4). In the presence of etoposide, E2 protein levels again increase. There appears to be an 
additive effect on E2 protein levels when both E1 and etoposide treatment are present 
(lane 6). The increase seen in E2 protein levels in etoposide treated cells is attributed to a 
rise in E2 mRNA (Figure 3.3.1). To investigate whether the changes in E2 protein levels in 
the  presence  of  E1  is  a  result  of  additional  E2  mRNA  or  due  to  post  translational 
modifications, E2 RNA levels were analysed (Figure 3.3.2 (b)). There is an increase in E2 
RNA in the presence of E1 by around two fold however this is not significantly different as 
the p value is >0.05.  Chapter 3: Results 
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Figure 3.3.2 HPV16 E2 is stabilised by E1 through post translational modifications. 
 
(a) 
          
(b) 
  HPV16 E2 RNA levels in the presence of E1 
              
 
Figure 3.3.2 HPV16 E2 is stabilised by E1 through post translational modifications. (a) 
Cells were transfected with 2μg of HPV16 E2 (+), 100ng HPV16 E1 HA tagged (+) and left 
untreated (-) or treated with 50μM etoposide (+) for 16 hours. Cells were then harvested 
and prepared for western blot analysis by probing for E2 (TVG261), E1 (HA) and gamma 
tubulin as the loading control.  (b) 293T cells were transfected with 2μg of HPV16 E2 
plasmid with or without 1μg of HPV16 E1 HA tagged. RNA extracted from the cells was 
converted  to  cDNA  and  levels  of  E2  were  detected  using  real-time  PCR.  The  graph 
represents 3 experiments with results normalised to beta actin. Chapter 3: Results 
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3.3.3 Etoposide arrests HPV16 E1 and E2 transfected 293T cells at the G2/M 
checkpoint 
 
Etoposide inhibits the cell cycle by creating double stranded DNA breaks. It has been 
shown that HPV16 E2 is stabilised in the S phase of the cell cycle in E2 stably expressing 
U2OS cells (Johansson et al., 2009). It was possible that the stabilisation of E2 observed 
with long term etoposide exposure and E1 co-transfection could be a consequence of an S 
phase arrest. Flow cytometry analysis was carried out to determine the cell cycle profile 
of E2 and E1 transfected 293T cells that were either untreated or treated with etoposide. 
Briefly, 293T cells were mock calcium phosphate transfected or transfected with HPV16 
E2 (with and without HA tagged E1). Two days post transfection the cells were treated 
with etoposide for 16 hours and prepared for flow cytometry analysis.  The profiles in the 
top row are untreated and the bottom row is the profiles of cells treated with etoposide 
(Figure 3.3.3). Mock transfected 293T cells treated with etoposide arrest the cells at the 
G2/M checkpoint (bottom row, left panel). Cells transfected with E2 have a normal cycle 
profile (top row, middle panel). When treated with etoposide these cells also arrest at the 
G2/M  checkpoint  (bottom  row,  middle  panel).  E2  and  E1  co-transfected  cells  have  a 
normal profile (top row, right panel). After etoposide treatment the cells arrest at the  In 
G2 phase (bottom row, right panel). Etoposide arrests E1 and E2 transfected 293T cells 
predominantly at the G2 phase of the cell cycle. Etoposide and E1 do not arrest cells in S 
phase and therefore E1 does not increase E2 protein levels by arresting the cell cycle in S 
phase.  Therefore  the  mechanisms  by  which  E1  increases  E2  protein  levels  were 
investigated further.  
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Figure  3.3.3  Etopsoide arrests  HPV16  E1  and E2  transfected  293T cells  at  the  G2/M 
checkpoint 
 
 
 
Figure  3.3.3  Etopsoide arrests  HPV16  E1  and E2  transfected  293T cells  at  the  G2/M 
checkpoint. 293T cells were either mock calcium phosphate transfected, transfected with 
2μg of HPV16 E2 or co transfected with E2 and 1μg of HA-tagged HPV16 E1. Forty eight 
hours later cells were left untreated or treated to 50μM of etoposide for 16 hours. Cells 
were  then  harvested  and  prepared  by  propidium  iodide  staining  for  flow  cytometry 
analysis. 
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3.4 HPV16 E2 has increased stability and function due to a direct 
interaction with the viral helicase E1. 
 
The results in Chapter 3.3 indicated that HPV16 E1 increases E2 protein levels through 
post translational mechanisms. E2 RNA analysis showed that there was an increase in 
RNA by E1 to around 2 fold higher, however this was not significantly different (Figure 
3.3.2 (b)). Cell cycle analysis revealed that E1 transfected cells were not arrested in S 
phase ruling out this mechanism to explain E2 stabilisation (Figure 3.3.3). This chapter 
investigates the E1.E2 interaction, the effects it has on E2 protein stability and possible 
mechanisms  that  E1  uses  to  alter  the  levels  of  E2  protein  within  the  cell.  E2  is  a 
multifunctional  protein  within  the  virus  life  cycle  and  therefore  the  functional 
consequences of this interaction were also investigated.  
 
3.4.1 HPV16 E1 increases E2 protein levels. 
 
 
It  became  obvious  that  E2  protein  levels  were  higher  in  the  presence  of  E1  whilst 
investigating the effect that etoposide had on both proteins stabilisation (Figure 3.3.2(a)). 
In the western blot, E2 protein levels increased in the presence of the HA-tagged E1 
expression vector. As further evidence of stronger E2 expression in the presence of E1 a 
different E1 expressing vector was used in Figure 3.4.1. HPV16 E2 (pCMV-E2) and the 
alternative HPV16 E1 plasmid (pCMV-E1) were calcium phosphate transfected into 293T 
cells. Forty eight hours post transfection, cells were harvested, and protein was extracted 
and prepared for western blot analysis. There is no antibody for HPV16 E1 however the 
E1 protein expressed from this plasmid is functional as it is able to replicate HPV16 origin 
plasmid in the presence of an E2 expressing plasmid (King et al., 2010).  E2 protein bands 
appear to be stronger in the presence of the alternative E1 plasmid. This result supports 
previous evidence that E1 can increase E2 protein levels.  
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Figure 3.4.1 HPV16 E1 increases E2 protein levels. 
 
                    
 
 
Figure 3.4.1 HPV16 E1 increases E2 protein levels. 293T cells were transfected with 2µg 
of E2 and either 0/5/10µg of the alternative E1 plasmid. Forty eight hours later the cells 
were  harvested  and  prepared  for  western  blot  analysis  to  probe  for  E2  and  gamma 
tubulin. There is no available antibody available for the alternative HPV16 E1 plasmid. Chapter 3: Results 
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3.4.2 HPV16 E1 can alter E2 chromatin affinity 
 
HPV16 E2 that interacts with chromatin is more stabilised than E2 that does not have a 
high affinity for chromatin (Donaldson et al., 2007). During salt extraction assays, E2 is 
shown to be detectable in soluble cell extracts with a high salt concentration more than 
low salt concentration extracts. From this previous work it was hypothesised that E1 may 
increase E2 protein levels by shifting E2 onto chromatin. Salt extractions were carried out 
in 293T cells to investigate this hypothesis. HPV16 E2 and HPV16 E1 tagged with HA were 
co-transfected into the cells and forty eight hours post transfection the cell lysate was 
serially extracted in increasing concentrations of NaCl in CSK (0.15/0.2/0.4/0.6/0.8/1.0M 
salt) (2.2.2.20). The extractions were prepared for western blot analysis and probed with 
antibodies against E1 (HA) and E2 (TVG261) (Figure 3.4.2(a)). The results from Figure 3.4.2 
(a) are representative of three independent experiments. Visually there appears to be a 
slight shift in E2 towards the 1.0M salt extraction whilst in the presence of E1. To confirm 
this  by  densitometry  the  blots  were  quantified  using  Image  J  software  and  graphed 
showing a percentage of the total amount of E2 from all the extractions (Figure 3.4.2 (b)). 
There is a significant difference between E2 at 1M in the absence or presence of E1. The 
remaining extracts (0.15-0.8) did not show a significant difference between E2 levels with 
and without E1 (p>0.05).  Chapter 3: Results 
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Figure 3.4.2 HPV16 E1 can alter E2 chromatin affinity 
 
(a) 
 
 
 
 
 
(b) 
               E1 causes association of E2 with less-soluble biochemical fractions 
 Chapter 3: Results 
 
140 
 
 
Figure 3.4.2 HPV16 E1 can alter E2 chromatin affinity. 2µg of HPV16 E2 with or without 
1µg of HPV16 E1HA were transfected into 293T cells. Proteins were serially extracted 
using Triton-X lysis buffer with salt concentration ranging from 0.15 to 1M. The E2 and E1 
proteins were detected using western blot analysis using the TVG261 antibody for E2 
detection and HA antibody for E1 detection. Statistical significance by Students t-test is 
indicated as * (p<0.05). (b) Three repeats were quantified using Image J software. The 
graph displays the mean  and the standard error of the mean for each extraction. The 
value  for  E2  was  calculated  as  a  percentage  of  the  total  amount  of  E2  for  all  the 
extractions (0.15-1.0M).  
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3.4.3. HPV16 E2 is stabilised by E1.  
 
E2 protein levels increase in the presence of E1. E1 may therefore increase the half-life of 
E2 by increasing the stability of the protein. Cycloheximide (CHX) drug treatment was 
used to investigate whether E1 extends E2 protein stability as this drug is known to inhibit 
protein biosynthesis. HPV16 E2 was transfected in 293T cells with and without HA tagged 
E1 expression plasmid. The transfected cells were treated with  100μM of the protein 
synthesis CHX for either 0/1/2/3/4 or 6 hours. The cells were then harvested and protein 
was extracted for western blot analysis using antibodies against E1 (HA) and E2 (TVG-
261). In Figure 3.4.3(a) E2 protein levels are reduced as a result of CHX treatment. This 
reduction  is  less  obvious  when  E1  is  co-transfected  with  E2.  Three  repeats  were 
quantified using Image J software using gamma tubulin as a loading control (Figure 3.4.3 
(b)).  The  graph  shows  the  mean  and  the  standard  error  of  the  mean  from  three 
independent experiments. E2 protein half life was calculated using the Microsoft Excel 
programme.  This  programme  predicted  the  best  fit  line  for  each  data  set  and  the 
equation of this line was used to calculate the half life at 50% of E2 protein level without 
CHX  treatment.  The  half  life  of  E2  alone  was  calculated  to  be  2.6  hours  and  in  the 
presence of E1 it increases to 3.5 hours.  Chapter 3: Results 
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Figure 3.4.3 HPV16 E2 is stabilised by E1. 
 
(a)  
 
                                  
 
(b) 
 
                           E2 half life increases in the presence of E1 
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Figure 3.4.3 HPV16 E2 is stabilised by E1. (a) 293T cells were transfected with 50ng of E1-
HA and 1 µg of E2. Forty eight hours post transfection the cells were treated with 100μM 
CHX for the time points indicated and cells were then harvested for western blot analysis 
for E2 (TVG261) and E1 (HA). (b) Protein bands were quantified using E2 levels relative to 
pre-CHX treatment and the gamma tubulin signal was used for normalisation of each 
band.  The  graph  represents  the  mean  and  standard  error  of  the  mean  for  three 
independent experiments. Image J software was used for quantification of the protein 
bands and therefore made it possible to estimate the half life of E2.  
 
 Chapter 3: Results 
 
144 
 
3.4.4 HPV16 E2 E39A mutant does not interact with HA-tagged E1 
 
E1 and E2 have been shown to interact at glutamic acid 39 on HPV16 E2. A mutant E2 
expression  plasmid  harbouring  a  glutamic  acid  to  alanine  substitution  at  amino  acid 
position 39 is unable to support HPV replication but does not loose its transactivation 
function (Sakai et al 1996). This mutation was synthesised into the HPV16 E2 expression 
plasmid used throughout this thesis by Mary Donaldson using site directed mutagenesis 
(2.2.2.11 & 2.2.2.12).. The mutated E2 expressing plasmid was then utilized to investigate 
whether E1 stabilisation of E2 is a result of a direct interaction between both proteins. To 
test whether E2 expressed from the mutated plasmid had lost its ability to interact with 
E1 protein, co-immunoprecipitation experiments were carried out in 293T cells. The E39A 
E2  mutant  or  E2  wild  type  expressing  plasmids  were  co-transfected  with 
0/0.1/1/10/100ng of E1-HA expression plasmid. Two days post transfection the cells were 
harvested and proteins were extracted. Protein lysates were incubated with an antibody 
against HA to detect E1 (Figure 3.4.4). E2 wild type and E39A mutant pull down was 
determined using the E2 antibody, TVG261. The western blot shows that the E2 wild type 
co-immunoprecipitates with E1. No pull down was detected with the E39A mutant. Input 
lanes also show that wild type E2 protein bands  appear to  increase in intensity with 
increasing amounts of transfected E1. On the contrary E39A mutant show no change. This 
result suggests the E39A mutant may not be stabilised by E1. Future work was focused on 
testing this theory.  
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3.4.4 HPV16 E2 E39A mutant does not interact with HA-tagged E1 
 
 
 
3.4.4  HPV16  E2  E39A  mutant  does  not interact  with  HA-tagged  E1.  293T  cells  were 
transfected with a concentration range of E1-HA plasmid (0.1/1/10/100ng) and either 2µg 
of E2 wild type or 2µg of E39A E2 mutant. Cell lysates were harvested forty eight hours 
later  and  protein  extracted.  To  detect  E2/E39A  interaction  with  E1,  lysates  were 
immunoprecipitated with the anti-HA antibody. Samples were then prepared for western 
blot  analysis  and  immunoblotted  with  antibodies  against  E2  (TVG  261),  E1  (HA)  and 
gamma  tubulin  as  a  loading  control.  The  image  shown  is  representative  of  three 
independent experiments. Chapter 3: Results 
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3.4.5 HPV16 E2 stabilisation by E1 is a result of a direct E1.E2 interaction 
 
E1 and E2 interact during the virus life cycle to mediate replication from the viral origin. 
Therefore E1 may stabilise E2 to enhance viral replication during the viral life cycle. This 
may be important during viral vegetative replication in the differentiating epithelial cells. 
E1  may  increase  the  stability  of  E2  as  a  result  of  the  proteins  interacting  directly. 
Therefore the ability of E1 to stabilise the E2 E39A mutant was assessed next (Figure. 
3.4.5 (a)). This figure is representative of three independent experiments. E2 E39A and E1 
transfected  293T  cells  were  treated  with  100μM  of  the  protein  synthesis  inhibitor 
cycloheximide (CHX) for the indicated time points. The cells were then harvested and 
prepared for western blot analysis and probed for E2 (TVG 261) and E1 (HA). The E2 E39A 
protein bands appear to lose intensity after 2 hours of CHX treatment. In the presence of 
E1, E39A protein levels show only a slight increase in intensity compared to E39A alone at 
2 hours. The actual E39A half life was calculated from three independent experiments 
using ImageJ software (Figure 3.4.5 (b)). This figure represents the quantified results with 
associated mean and standard errors of the mean.  The half life of E39A was calculated as 
2.8 hours. In the presence of E1, the half life was marginally increased to 2.9 hours. This 
result suggests that the E1.E2 interaction is essential for the increase in E2 stability by the 
E1 protein. 
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Figure 3.4.5 HPV16 E2 stabilisation by E1 is a result of a direct E1.E2 interaction  
 
(a) 
                               
 
 
(b)  The E39A E2 mutant does not show increased stabilisation by E1 
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Figure 3.4.5 HPV16 E2 stabilisation by E1 is a result of a direct E1.E2 interaction a) 293T 
cells were calcium phosphate transfected with 2µg of E39A plasmid and 50ng of either 
E1-HA or an empty vector plasmid DNA. Two days post transfection, cells were treated 
with CHX (100μM) for the time points indicated and harvested for western blot analysis. 
E39A was detected using the TVG261 antibody. E1 was detected using the HA antibody. 
(b) E39A half life in the absence and presence of E1 was calculated using densitometry. 
Protein bands were quantified using E39A levels relative to pre-CHX treatment and the 
gamma tubulin signal was used for normalisation of each band. The graph represents the 
mean and standard error of the mean from three independent experiments. Image J 
software was used for quantification of the protein bands and therefore made it possible 
to estimate the half life of E39A. Chapter 3: Results 
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3.4.6  HPV16  E1  enhances  E2 functional activity as a result  of the E1.E2 
interaction.  
 
Studies have demonstrated that chromatin adaptor protein, Brd4, can alter E2 protein 
stability and functional activity therefore it was hypothesised that a consequence of the 
direct interaction between E1 and E2 would be a change in E2 transcriptional activity 
(Schweiger et al., 2006; Lee & Chiang, 2009; Gagnon et al., 2009; Zheng et al., 2009). To 
investigate  any  changes  that  E1  may  influence  on  E2  transcriptional  activity, 
transcriptional assays were undertaken that use the tk6E2 plasmid containing six HPV16 
E2 binding sites, a downstream thymidine kinase promoter and a luciferase reporter gene 
(Vance, 1999). The HPV16 E2 expression plasmid (1/10/100ng) and tk6E2 plasmid was 
transfected into 293T cells with and without HPV16 E1-HA (Figure 3.4.6 (a)). Luciferase 
activity was normalised using the tk6E2 plasmid only (normalised to 1) and the values 
shown are represented as fold differences (n-fold). At all concentrations of E2, luciferase 
expression increased with increasing amounts of E2 and there was no trans-repression at 
the  highest  amount  of  E2  used  (blue  bars).  The  effect  of  an  E1-E2  interaction  was 
investigated by co-transfection of the HA-tagged E1 with HPV16 E2 plasmids (red bars). 
There is an approximate 8 fold increase in transcriptional activation in the presence of E1 
compared to E2 alone when 1ng of E2 plasmid is co-transfected with HA-tagged E1 (p 
value  <  0.05).  There  is  an  approximate  9  fold  increase  when  10ng  of  E2  plasmid  is 
transfected with E1 expression plasmid (p value < 0.05). E1 results in an approximate 4 
fold increase with 100ng of E2 plasmid. However because the p value is 0.007, there is no 
significant  difference between these  data  sets.  Compared  to 1ng  and 10ng  of  E2,  E1 
enhancement of E2 transcriptional activation at 100ng of E2 is reduced. This may be 
attributed to E2 binding site saturation.  
 
The increase in E2 transcription by the presence of E1 may be attributed to a direct 
interaction between these proteins. To test this hypothesis, the E2 mutant plasmid that 
has reduced interaction with E1 was used in a similar experiment to Figure 3.4.6 (a). The 
only deviation between the experiments was the use of E2 E39A mutant in place of E2 
wild type expression plasmid, all plasmid concentrations were kept the same (Figure 3.4.6 
(b)). At the concentrations 1/10/100ng, luciferase expression of E2 E39A mutant is higher 
than  with  the  reporter  plasmid  alone,  demonstrating  that  this  mutant  retains Chapter 3: Results 
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transcriptional functions comparable to wild type E2. The transcriptional activity of wild 
type E2 and E2 E39A expression plasmids are very similar. For all concentrations of E39A 
(1/10/100ng) there is only a small rise detected in E2 transcriptional activation when E1 is 
present (red bars). The 2 fold increase in E2 transcription and small increase in E2 E39A 
protein half life seen previously in the presence of E1 (Figure 3.3.3) may be a result of a 
weak E1 and E2 interaction that was not detected by western blot (Figure 3.4.4). In Figure 
3.3.2 (b) E2 RNA is increased by almost two fold when co-transfected with HA-E1 plasmid. 
The E2 and E39A ORFs are cloned into the same plasmid so contain the same promoter 
and enhancer sequences. Therefore any increase in transcription or half life may reflect 
the increase in RNA levels seen previously. The data presented shows evidence that a 
direct  interaction  between  E1  and  E2  is  accountable  for  an  increase  in  E2  functional 
activity.  Chapter 3: Results 
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Figure 3.4.6 HPV16 E1 enhances E2 functional activity as a result of the E1.E2 
interaction. 
 
 
(a)                Transcriptional function of E2 is enhanced by E1 
 
           
* *
* *
 
  
(b)                Transcriptional function of E39A is not enhanced by E1 
 
            
  
 
Figure  3.4.6  HPV16  E1  enhances  E2  functional  activity  as  a  result  of  the  E1.E2 
interaction. (a) One microgram of the tk6E2 reporter plasmid was co-transfected with Chapter 3: Results 
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increasing amounts of HPV16 E2 in the absence (blue bars) or presence (red bars)  of 50ng 
HPV16 E1HA. Cells were harvested 48 hours post transfection and assayed for luciferase 
activity (Promega). Luciferase activity for the lysate containing tk6E2 only (black bar) is 
normalized to 1 and other activities are calculated as a fold difference (n fold). The results 
shown are an average of three independent experiments with mean and standard error 
of the mean bars displayed. Statistical significance by Students t-test is indicated as * 
(p<0.05).  (b)  One  microgram  of  the  tk6E2  reporter  plasmid  was  co-transfected  with 
increasing amounts of HPV16 E39A mutant in the absence (blue bars) or presence (red 
bars) of 50ng of HPV16 E1. Cells were harvested 48 hours post transfection and assayed 
for luciferase activity. Luciferase activity for the lysate containing tk6E2 only (black bar) is 
normalized to 1 and other activities are calculated as a difference (n fold). The results 
shown are an average of three independent experiments showing the mean. Standard 
error of the mean are also displayed. Chapter 3: Results 
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3.4.7 Functional activity of the transcriptionally defective HPV16 R37A E2 
mutant in the presence of E1  
 
Previous work has shown that a mutated E2 (R37A) was able to bind to E1, retained 
reasonable replication function but had greatly reduced transactivation function (Sakai et 
al., 1996). It was later discovered by the same group that this mutation severely impeded 
E2 and Brd4 interaction (Schweiger et al 2006). The Brd4-E2 interaction was therefore 
deemed essential for mediating E2 transcriptional function. It was considered whether E1 
could  stimulate  E2  R37A  mutant  transcriptional  activity  and  therefore  whether  E1 
contributes directly to transcriptional activation. 293T cells were transfected with the 
tk6E2 reporter plasmid, with increasing amount of E2/R37A in the presence or absence of 
HA tagged E1. The R37A mutant was constructed in the E2 plasmid that is used in this 
particular experiment, by Peter Howley’s group (Harvard, Boston). Both wild type and 
mutant plasmids are identical with the exception of the arginine to alanine mutation at 
amino acid position 37. 
 
Forty eight hours post transfection duplicate samples were harvested and prepared for a 
transcription assay. Luciferase activity for the tk6E2 plasmid was normalised to 1, and 
activities from other samples were calculated as a fold difference (n-fold). The values 
shown represent an average of three independent experiments. As can be seen in Figure 
3.4.7 (a), the new E2 plasmid mimicked our previous results in shown in Figure 3.4.6. As 
E2 concentration is increased, the luciferase signal from tk6E2 activation increases (blue 
bars). This demonstrates that the E2 expression plasmid shows expression of increasing 
E2. When E1 is present, again an enhancement of E2 function is observed (red bars). At 
10ng  of  E2,  E1  increases  activation  by  approximately  2  fold,  at  100ng  of  E2  this 
enhancement  increases  to  around  10  fold  and  at  1μg  of  E2,  E2  activity  increases  by 
approximately  4  fold.  These  results  are  similar  to  the  previous  observations  of  E1 
stimulated  E2  functional  activity  however  the  p  values  for  each  concentration  where 
>0.05 so it cannot be said that there is a significant difference.    
 
The ability of E1 to increase the R37A mutant transcriptional activity was investigated in 
Figure 3.4.7 (b). Preparation of the transcription assay was carried out in a similar fashion 
to Figure 3.4.7(a) with the only variation being the transfection of R37A and not wild type Chapter 3: Results 
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E2.  Previous  work  with  R37A  mutant  has  demonstrated  severely  diminished 
transcriptional functions of this plasmid compared to wild type E2. Our results are not 
reflective of this observation. R37A appears to be transcriptionaly active with the tk6E2 
reporter plasmid. At 10ng of R37A, the signal is 3 fold higher compared to tk6E2 alone, at 
100ng  this  signal  is  5  fold  higher  and  at  1μg  of  R37A  this  signal  is  10  times  higher. 
Therefore the R37A mutant is functionally active with the tk6E2 reporter plasmid. The 
disparities in the results may be a consequence of differences in reporter plasmids. The 
previous study used chloramphenicol acetyltransferase (CAT) reporter plasmids and this 
study used luciferase reporter plasmids.  
 
Figure 3.4.7 Functional activity of the transcriptionaly defective HPV16 R37A E2 mutant 
in the presence of E1 
 
 
(a)         HPV16 E2 transcription in the presence of E1 
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(b) HPV16 E2 R37A mutant transcription in the presence of E1 
 
         
 
Figure 3.4.7  Functional activity of the transcriptionaly defective R37A E2 mutant in the 
presence of E1 (a) One microgram of the tk6E2 reporter plasmid was co-transfected with 
increasing amounts of HPV16 E2 in the absence (blue bars) or presence (red bars) of 50ng 
of  HPV16  E1HA.  Cells  were  harvested  48  hours  post  transfection  and  assayed  for 
luciferase activity (Promega). Luciferase activity of lysate containing tk6E2 only (black bar) 
is normalized to 1 and other activities are calculated as a difference (n fold). The results 
shown are an average of three independent experiments with standard error of the mean 
displayed.  (b)  One  microgram  of  the  tk6E2  reporter  plasmid  was  co-transfected  with 
increasing amounts of HPV16 R37A mutant in the absence (blue bars) or presence (red 
bars)  of  50ng  of  HPV16  E1HA.  Cells  were  harvested  48  hours  post  transfection  and 
assayed for luciferase activity. Luciferase activity of lysates containing tk6E2 only (black 
bar) is normalized to 1 and other activities are calculated as a difference (n fold). The 
results shown are an average of three independent experiments with standard error of 
the mean displayed. Chapter 3: Results 
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3.4.8 HPV16 E1 increases E2 stability in a cervical cancer cell line.  
 
The data shown in Chapter 3.4 has been carried out in the HEK 293T cell line. The biggest 
threat to human health caused by HPV16 is its ability to cause cancer in cervical epithelial 
cells. Similar experiments were therefore carried out  in a cell line that mimicked the 
oncogenic environment that HPV may encounter during tumourigenesis in the cervix. The 
C33A cell line is a HPV-negative, human cervical carcinoma cell line. This cell line was used 
to  investigate  the  consequences  of  the  E1  and  E2  interaction.  Protein  half  life 
experiments were completed using cycloheximide as an inhibitor of protein synthesis to 
investigate whether E1 can increase E2 stability in a cervical cancer cell line. HPV16 E2 
was transfected with or without HPV16 E1 HA tagged plasmid. The cells were treated with 
CHX two days after transfection for the time points indicated (Figure 3.4.8 (a)). C33A cells 
were then harvested for western blot analysis to detect E2 (TVG261), E1 (HA) and gamma 
tubulin (loading control). The image is representative of three independent experiments. 
At 1 hour of CHX treatment, the intensity of the E2 protein band appears significantly less 
with E2 alone, compared to E2 in the presence of E1. Densitometry is used in Figure 3.4.8 
(b) to estimate the half life of E2 in C33A cells. The quantitated results show the average 
of  three  independent  experiments  with  associated  means  and  standard  error  of  the 
mean. Using the Microsoft Excel programme to calculate the equation of the best fit line 
for each data set the half life was calculated. E2 has a calculated half life of 3.6 hours in 
C33A  cells.  The  half  life  increases  substantially  to  5.7  hours  in  the  presence  of  E1. 
Therefore in a cervical carcinoma cell line, E1 is able to increase E2 stability by increasing 
the protein’s half life.  
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Figure 3.4.8 HPV16 E1 increases E2 stability in a cervical cancer cell line. 
 
(a)  
 
                         
 
 
 
(b)     HPV16 E1 increases E2 stability in C33A cells 
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Figure 3.4.8 HPV16 E1 increases E2 stability in a cervical cancer cell line. (a) C33A cells 
were  transfected  with  2µg  HPV16  E2  with  or  without  2µg  E1-HA.  Two  days  post 
transfection, cells were treated with 100μM of CHX for the time points indicated and 
harvested  for  western  blot  analysis  using  TVG261  (E2)  HA  antibody  (E1)  and  gamma 
tubulin  as  a  loading  control.  (b)  E2  half  life  in  the  absence  and  presence  of  E1  was 
calculated using densitometry. Protein bands were quantified using E2 levels relative to 
pre-CHX treatment and the gamma tubulin signal was used for normalisation of each 
band. The graph represents the average percentage of protein with standard error of the 
mean of three independent experiments. Image J software was used for quantification of 
the protein bands and therefore made it possible to estimate the half life of E2 in C33A 
cells. Chapter 3: Results 
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3.4.9 E2 transcriptional activity in a cervical cancer cell line. 
 
A previous observation in the 293T cell line demonstrated that E2 stability is improved by 
a direct interaction with E1 and a functional consequence of this interaction is increased 
E2 transcriptional activity (Figure 3.4.6). Therefore the effect E1 has on E2 transcriptional 
activity was also investigated using the C33A cell line. Figure 3.4.9 (a) shows the results of 
the E2 transcription assay in C33A cells. Luciferase expression from the tk6E2 reporter 
plasmid increases with increasing amounts of transfected E2 (blue bars). There was no 
signal repression at the highest amount of E2 used. All signals were stronger than the 
tk6E2 plasmid alone (black bar) and this demonstrates that E2 is capable of activating the 
tk  promoter  in  C33A  cells.  The  effect  of  E1-E2  interaction  was  investigated  by  co-
transfection of 50ng of E1 and 10/100/1000ng of E2 (red bars). At 1ng E2, there is an 
approximate 12 fold increase in transcriptional activation in the presence of E1 compared 
to E2 alone. At 10ng E2 there is an approximate 6 fold increase and at 100ng E2, there is 
an approximate 3.5 fold increase. However these increases are not significantly different 
because the p value was greater than 0.05 at each concentration of E2 used.  
 
To determine whether the increase in E2 transcription function is a consequence of an E1-
E2 interaction the E39A mutant was used in place of wild type E2 (Figure 3.4.9 (b)). The 
values and standard errors shown are an average of three independent experiments. At 
all concentrations of E39A (blue bars) used, luciferase expression was higher than the 
tk6E2 reporter plasmid (black bar), demonstrating that this mutant retained normal E2 
transcriptional functions in C33A cells. Luciferase expression increases from 1ng to 100ng 
E39A  (blue  bars).  The  red  bars  represent  samples  where  E39A  and  E1  have  been  co 
transfected.  At  1ng  E39A,  there  is  an  approximate  3  fold  increase  in  transcriptional 
activation  in  the  presence  of  E1  compared  to  E39A  alone.  At  10ng  E39A  there  is  an 
approximate 2 fold increase and at 100ng E39A, there is an approximate 1.2 fold increase 
in the presence of E1. The p values was greater than 0.05 at each concentration of E39A 
therefore there is no significant difference between E39A mutant with and without E1. 
This result may reflect some residual binding between E1 and the E39A mutant or an 
increase  in  E39A  RNA  levels  as  mentioned  previously.  The  enhancement  of  E39A 
mediated transcription in the presence of E1 is much smaller compared to E2 wild type.  
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Figure 3.4.9 E2 transcriptional activity in a cervical cancer cell line. 
 
 
(a)              HPV16 E2 transcriptional activity in the presence of E1 
 
            
 
 
(b)            HPV16 E2 E39A mutant transcriptional activity in the presence of E1 
 
         
 
Figure 3.4.9 E2 transcriptional activity in a cervical cancer cell line. (a) One microgram of 
the tk6E2 reporter plasmid was transfected alone (black bar) or with increasing amounts 
of HPV16 E2 in the absence (blue bars) or presence of 50ng of E1HA (red bars). C33A were Chapter 3: Results 
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harvested  48  hours  post  transfection  and  assayed  for  luciferase  activity.  Luciferase 
activity  of  lysates  containing  tk6E2  only  is  normalized  to  1  and  other  activities  ware 
calculated as a fold difference (n fold). The values and standard errors of the mean are 
shown and are an average of three independent experiments. (d) One microgram of the 
tk6E2  reporter  plasmid  was  transfected  alone  (black  bar)  or  with  increasing  amounts 
(1/10/100ng) of the E39A mutant in the absence (blue bars) or presence of 50ng E1HA 
(red bars). C33A were harvested 48 hours post transfection and assayed for luciferase 
activity. Luciferase activity of lysate containing tk6E2 plasmid only is normalized to 1 and 
other activities are calculated as a fold difference (n fold). The values and standard error 
of the mean are shown and are an average of three independent experiments. Chapter 3: Results 
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3.5 Summary of Chapter 3 
 
 
The data presented in this chapter shows the ability of E1 and E2 to replicate the HPV 
origin in the presence of DNA damage despite the activation of checkpoint kinases. In 
contrast, SV40 LT mediated replication is arrested in response to treatment with DNA 
damaging agents. Evidence from in vitro replication assays suggest that it is ATR that 
targets LT and prevents replication during DNA damage. Further evidence supporting this 
hypothesis was hampered because ATR/TopBP1 knock down cells were unable to grow.  
 
In vivo, ATR/ATM phosphorylates LT in response to DNA damage and a consequence is LT 
degradation by the proteosome. Mutational work of predicted ATR/ATM targeted sites in 
LT failed to indicate an individual  site responsible for phosphorylation. In comparison 
activated ATR/ATM does not target E1 for phosphorylation in vivo and this may explain 
the differences between HPV E1-E2 and SV40 LT mediated replication.  
 
Analysis  of  the  E1.E2  interaction  in  293T  and  C33A  has  shown  that  E1  stabilises  E2 
through post translational modifications. E1 does not alter the cell cycle but does alter E2 
affinity for chromatin. E2 shows a higher affinity for chromatin in the presence of E1.  
Functional  analysis  using  a  reporter  plasmid  that  contains  six  E2  binding  sites  has 
demonstrated the ability of E1 to significantly enhance E2 transcriptional functions in the 
293T cell line. These results will be discussed in detail in Chapter 4.      Chapter 4: Discussion 
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Chapter 4- Discussion 
 
4.1 E1-E2 mediated HPV origin replication is not inhibited in response to DNA damage 
HPV is the causative agent of cervical cancer and the integration of viral DNA into the host 
genome can enhance malignant transformation (Pett & Coleman, 2007). Deletions in both 
E1
 and E2 genes are often observed during integration with the maximum number of 
losses  observed
  within the  E2  gene  region  (zur  Hausen,  2002).  Loss  of  E2  expression 
results in unregulated transcription of the E6 and E7 oncogenes, predisposing the cell to 
genomic instability.  
 
Factors promoting HPV integration may include the ability of the virus to replicate at the 
same time as DNA breaks in the cell genome. Figures 3.1.1 & 3.1.3 demonstrate the 
ability of the replication proteins E1 and E2 to replicate the HPV origin of replication 
under conditions of DNA double strand breaks therefore increasing the chances of viral 
integration. Etoposide and camptothecin cause DNA damage however other factors that 
may promote naturally occurring DNA breaks are endogenous factors such as the female 
hormone estrogen. Estrogen is an important issue in cervical cancer research because 
many women take the estrogen-containing contraceptive pill.  Some studies have shown 
that  woman  who  use  estrogen  as  a  contraceptive  pill  have  higher  rates  of  cervical 
dysplasia than those who do not (Moulten & Le, 1991; Moreno et al., 2002; Smith et al., 
2003; McFarlane-Anderson et al., 2008; Vanakankovit & Taneepanichskul, 2008). Data 
from one multicentre study showed that use of the oral contraceptive increased the risk 
of developing cervical cancer in a duration-dependent manner compared to women who 
did not use the pill. The risk increased by 2.72 fold for women using the contraceptive for 
5-9 years.  Women that used the contraceptive pill for ten or more years had a 4.48 fold 
increase in cervical cancer rates (Moreno et al., 2002). A separate study of 12531 cases of 
cervical  cancer  also  showed  an  increase  in  cervical  cancer  rates  with  increasing     Chapter 4: Discussion 
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contraceptive pill duration (reviewed in Smith et al., 2003). Women who tested positive 
for HPV DNA and used the contraceptive pill for 5-9 years had increased rates by 1.3 fold 
and for 10 years or more of use showed increased rates of 2.5 fold compared to woman 
who did not take contraceptive pill. The same study also suggests that the incidence rate 
of  cervical  cancer  decreased  after  the  oral  contraceptive  stopped  being  used.  Later 
studies have also linked long term use of the oral contraceptive with increased rates of 
cervical  cancer  (McFarlane-Anderson  et  al.,  2008;  Vanakankovit  &  Taneepanichskul, 
2008).  Estrogen  has  also  been  shown  to  contribute  to  the  onset,  persistence  and 
malignant  progression of  cervical  cancer  in  HPV-transgenic  mouse  models)  and  cause 
resistance to apoptosis in cervical cancer cells (Arbeit et al., 1996; Brake and Lambert, 
2004; Chen et al., 2004). 
 
Further  to  this,  several  estrogen  metabolites  can  cause  DNA  damage  through  redox 
cycling  processes  that  produce  reactive  radical  species  (Yager  &  Liehr,  1996).  Redox 
cycling  of  estrogen  quinone  in  cells  generates  free  radicals,  which  induce  DNA  single 
strand breaks in estrogen-sensitive breast cancer cells (Nutter et al., 1991; Nutter et al., 
1994). ATR is the predominant Ser/Thr kinase that is activated in response to single strand 
breaks. 17-βestradiol substantially blocks ATR by reducing the enhanced association of 
ATR and TopBP1 proteins that follows after DNA damage (Pedram et al., 2009). This study 
showed that 17-βestradiol inhibits ATR activation through rapid PI3K/AKT signalling in 
breast  cancer  cells.  AKT  phosphorylates  TopBP1  thereby  preventing  the  enhanced 
interaction of ATR with TopBP1 after DNA damage. 17-βestradiol also inhibited claspin 
and Chk1 protein association therefore preventing Chk1 signalling to the G2/M checkpoint 
(Pedram et al., 2009). Inactivation of ATR signalling could result in HPV replication in the 
presence of DNA breaks therefore increasing the risk of viral integration.  
 
Taken together with our findings a hypothetical model can be built. HPV replicates in 
estrogen-sensitive  cervical  cells.  The  presence  of  estrogen  potentially  results  in  DNA     Chapter 4: Discussion 
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damage. As HPV replication is not inhibited by DNA damage pathways, the virus replicates 
in the presence of DNA breaks and this increases the chances of viral integration into the 
host genome. Recurrence rates after treatment for CIN I are estimated to be around 10% 
(Flannelly et al., 1997). Part of this recurrence may be attributed to estrogen.  Future 
work should focus on studying integration rates of HPV DNA in the presence and absence 
of estrogen and to consider the effects of anti-estrogen therapy in combination with 
current treatments to reduce HPV recurrence ultimately to reduce cervical cancer rates. 
 
4.2 SV40 LT is targeted for phosphorylation by activated ATR 
HPV E1-E2 mediated replication is not inhibited despite the activation of a DNA damage 
response, whereas SV40 LT mediated origin replication was (compare Figures 3.1.1 and 
3.1.3  with  3.1.2).  The  findings  in  this  thesis  suggest  that  ATR  is  the  protein  kinase 
responsible for this inhibition in vitro and after etoposide treatment ATR/ATM was also 
shown  to  target  LT  for  phosphorylation  in  vivo  (Figure  3.1.4  &  3.1.5  respectively).  
Previous studies on SV40 infection have demonstrated that the DNA damage response is 
activated in the infected cells and that the replication functions of LT are regulated by 
consequent  phosphorylation.  In  particular,  phosphorylation  of  serine  120  results  in  a 
stimulation of LT mediated replication (Shi et al., 2005). SV40 infected cells alter the host 
DNA  damage  response  by  targeting  the  MRN  complex  for  degradation  via  the 
proteosome (Digweed et al., 2002; Zhao et al., 2008). Large T Antigen interacts with the 
Nbs1 component of the MRN complex to disrupt DNA replication control and therefore 
enhancing  SV40  replication  (Wu  et  al.,  2004).  Therefore  the  host  cell  DNA  damage 
response is re-programmed by SV40 infection to promote viral DNA replication. 293T cells 
used in this study retain the ability to signal via the DNA damage signalling kinases despite 
stably expressing LT (Shirata et al., 2005). In contrast, DNA damage signals can suppress 
SV40 DNA replication in mammalian cells via activation of the DNA damage signalling 
kinases  (Miao  et  al.,  2003).  The  replication  functions  of  LT  are  regulated  by 
phosphorylation,  where  low  levels  of  phosphorylation  appear  to  promote  LT  origin     Chapter 4: Discussion 
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binding and replication, and high levels of phosphorylation inhibit replication (Wang et 
al., 1993).  
The results described in this thesis agree with the previous studies demonstrating arrest 
of LT-mediated DNA replication following DNA damage (Miao et al., 2003). It appears that 
treatment with DNA damaging agents (which activate damage signalling pathways but 
suppress  replication)  may  be  related  to  differential  modification  of  LT  in  different 
circumstances.  Phosphorylation  of  serine  120  results  in  stimulation  of  LT  replication 
function  following  viral  infection  and  it  is  possible  that  following  exposure  to  DNA 
damaging agents LT is differentially modified resulting in replication repression (Shi et al., 
2005). The LT mutation studies of hypothesised ATR phosphorylation target sites did not 
reveal a single SQ/TQ site that was responsible for ATR phosphorylation (Figure 3.1.11). 
Future  work  should  focus  on  proteomic  studies  as  it  is  possible  that  the  ATR  kinase 
targets multiple sites on LT for phosphorylation in response to exogenous DNA damage. A 
suggestion  as  to  how  the  proteomic  studies  could  be  carried  out  is  to  use  the  pS/Q 
antibody to enrich for LT sequences that have been phosphorylated by ATM/ATR after 
etoposide  treatment.  Alterations  in  the  LT  amino  acid  sequence  indicative  of  post 
translational modification could be identified using sequencing of the known LT SQ/TQ 
sites and by mass spectrometry.  
 
Upon activation of the DNA damage response DNA replication is stalled (Abraham, 2001; 
Bartek  &  Lukas,  2003;  Harper  &  Elledge,  2007).  Protein  kinase  activation  and  signal 
transduction pathways have been clearly defined, however what is not clear is which 
targets at the replication fork result in the inhibition of DNA replication. Previous work 
has demonstrated that following DNA damage SV40 DNA replication control mimics that 
of cellular DNA replication (Miao et al., 2003). The results presented in this thesis support 
the hypothesis that the replicative helicase is a direct target for phosphorylation by the 
DNA damaging signalling kinases. The cellular replicative helicase complex consisting of 
the MCM2-7 proteins becomes phosphorylated in response to DNA damage (Cortez et al., 
2004;  Ishimi  et  al.,  2003a,  b).  Phosphorylation  of  the  helicase  proteins  appears     Chapter 4: Discussion 
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fundamental in the arrest of DNA replication following DNA damage. Future work should 
focus on determining what sites of  LT are targeted for phosphorylation by ATR upon 
activation of DNA damage kinases as this will be a useful model for studying eukaryotic 
DNA replication. LT plasmids could be synthesised harbouring mutations in the known 
ATR target sites. The mutated plasmids could then been utilized in checkpoint kinase 
transient replication assays. The results will support evidence that activated ATR directly 
targets the DNA helicase for phosphorylation therefore inhibiting replication during DNA 
damage.  
 
4.3 E1 is not a substrate for ATR kinase in response to DNA damage.  
An  important  result  to  consider  is  that  neither  HPV11  nor  HPV16  E1  proteins  are 
substrates for DNA damage kinases upon activation of ATR (Figure 3.1.6). Similar to SV40, 
recent  work  has  demonstrated  that  HPV  can  activate  DNA  damage  signalling  kinases 
during their life cycle (Moody and Laimins., 2009). However in contrast to SV40, HPV E1-
E2 mediated replication does not arrest in response to DNA damage (King et al., 2010).  
The  findings  from  this  thesis  suggest  for  the  first  time  that  in  the  presence  of  DNA 
damage the E1 helicase is not targeted for phosphorylation despite the activation of ATR, 
whereas the LT helicase (model for MCM complex) is. Therefore the difference in the DNA 
replication  response  of  LT  and  E1–E2  is  likely  related  to  either  the  differential 
phosphorylation of LT and E1 following DNA damage or to differential interactions of the 
viral helicases with cellular factors phosphorylated by DNA damage response pathways. 
 
The  consequences  of  this  in  relation  to  the  virus  life  cycle  should  be  taken  into 
consideration. Regulation of cellular replication limits genomic duplication to once per 
cell cycle. However in the differentiating layers of the epithelium the papillomavirus is 
able  to  replicate  despite  the  fact  that  differentiating  cells  exit  the  cell  cycle 
(amplificational replication). Work carried out in the Laimins laboratory has shown that 
HPV  activates  components  of  the  ATM/ATR  pathways  and  this  is  required  for  viral     Chapter 4: Discussion 
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genome  amplification  in  differentiating  cells  (Moody  &  Laimins,  2009).  The  findings 
described in this work also imply that HPV uses checkpoint kinase activation in order to 
carry out its replication. These observations suggest that the ATR/ATM kinase pathway 
may be a potential therapeutic target to inhibit HPV replication. ATR is essential for cell 
survival (Figure 3.2.2 & 3.3.3) therefore the inhibition of ATR signalling using downstream 
components of this pathway may be a better antiviral target than ATR itself (e.g Chk1 
kinase).  
 
Long term exposure to the DNA damaging agent etoposide results in the degradation of 
LT by the proteosome (Figure 3.1.7). This degradation is unlikely to explain the inhibition 
of LT DNA replication reported in Figure 3.1.2. Treatment of cells with aphidicolin results 
in an immediate arrest of DNA replication because it inhibits the DNA polymerase α and 
δ. LT mediated replication shows similar trends in replication of the SV40 origin plasmid 
for aphidicolin and etoposide arrested replication, suggesting an immediate arrest of LT 
replication following etoposide treatment. In contrast, HPV E1 protein is not degraded 
after long term etoposide exposure. This evidence suggests that by avoiding downstream 
targeting by DNA damage kinases HPV is able to replicate in the presence of DNA damage. 
 
4.4 TopBP1 is essential for DNA replication and cell survival 
In Chapter 3.2, attempts to create ATR-deficient cell lysate in order to carry out in vitro 
SV40  checkpoint  kinase  replication  assays  were  unsuccessful.  The  task  of  generating 
enough ATR deficient lysate was always going to be a challenge because ATR is essential 
for completion of the cell cycle. ATR deficiency in mice is found to be lethal to embryonic 
development (Brown & Baltimore, 2000; de Klein et al., 2000). Seckel syndrome, ATR 
deficiency  in  humans,  is  characterized  by  growth  retardation,  microcephaly,  mental 
retardation  and  craniofacial  abnormalities  (O'Driscoll  et  al.,  2004).  The  lack  of  ATR-
deficient cells is an obstacle to functional studies of this protein. Therefore it was deemed 
feasible to knock down TopBP1 because this protein is involved in ATR activation. Further     Chapter 4: Discussion 
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to this, previous reports have suggested that TopBP1-deficient 293T cells can grow for a 
short period of time (Wright, 2007). TopBP1 KD cells prevent ATR inactivation (Figure 
3.2.1) however cell growth was severely diminished in cells transfected with TopBP1 or 
ATR siRNA oligonucleotides (Figure 3.2.2 and 3.3.3). Therefore TopBP1 deficient 293T 
cells were unable to grow ruling out the possibility of ATR knock down in vitro replication 
assays.  
 
4.5 A consequence of the E1-E2 interaction is increased E2 stability 
E2 is a multifunctional protein which has numerous roles in the papillomavirus lifecycle. It 
is involved in the regulation of viral transcription, viral genome segregation during mitosis 
and it anchors E1 to the viral origin of replication to initiate viral replication (McBride, 
2008). Therefore the regulation of E2 function is important to the virus lifecycle because 
E2 has the potential to disrupt the viral life cycle at several steps. The activities of E2 
within a cell are likely to be affected by the amount of available E2 protein and one way 
of controlling this is to regulate the turnover of this protein. In Chapter 3.3, HPV16 E2 
protein levels appear to increase when treated with etoposide and when co-transfected 
alongside E1 (Figure 3.3.2). Previous work reports that E2 protein levels increase within 
the S phase of the cell cycle (Johansson et al., 2009). Therefore it was considered whether 
the DNA damage induced by etoposide was causing the E2 transfected cells to arrest in S 
phase and this would explain E2 stabilisation. Flow cytometry analysis shows that E2 
transfected cells were arrested in G2/M phase after etoposide treatment and not S phase 
therefore  this did  not explain  the  rise  in  E2 protein  levels  after  etoposide  treatment 
(Figure 3.3.3). E2 RNA levels were examined in the presence of etoposide because it was 
possible that the increase in E2 protein levels was a result of increased CMV promoter 
activity from the E2 plasmid. Real-Time PCR measuring HPV16 E2 mRNA confirmed that 
etoposide increased the CMV promoter activity in the HPV16 E2 plasmid. Therefore E2 
stabilisation by etoposide is not a post translational event. 
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Worthy of great consideration from Chapter 3 is the ability of HPV16 E1 to stabilise E2 in 
response  to  CHX  treatment  (Figure  3.3.2).  Further  analysis  of  E2  RNA  levels  in  the 
presence  of  E1  revealed  that  the  stabilisation  is  a  post  translational  event.  Further 
evidence using an alternative E1 plasmid to increase E2 protein levels is demonstrated in 
Figure 3.4.1. One hypothesis that may explain the increase in E2 stability in the presence 
of E1 protein is the ability of E1 to alter the cell cycle. E1 may alter the cell cycle to favour 
an S phase environment which is suitable for HPV replication. A previous study in this 
laboratory highlighted HPV16 E2 stabilisation in the S phase of the cell cycle (Johansson et 
al., 2009).  However E1 and E2 transfected 293T cells were shown to have a normal 
cycling profile and therefore this does not explain the stabilisation of the E2 protein in the 
presence of E1 protein (Figure 3.3.3).  
 
Another  post  translational  modification  that  may  explain  the  mechanism  behind  E2 
increased stability by E1 is the ability of E1 to shift E2 onto chromatin. Previously, in 
TopBP1 depleted cells, E2 was shown to have a higher affinity for chromatin and this 
subsequently resulted in higher levels of E2 protein compared to TopBP1 containing cells 
(Donaldson et al., 2007). It was therefore possible that E1 interacts with E2 encouraging 
its  affinity  for  chromatin.  The  results  in  Figure  3.4.2  suggest  that  E1  results  in  E2 
redistributing into the chromatin pellet. In the viral life cycle the virus genome associates 
with  the  host  chromatin.    E2  ensures  accurate  segregation  of  the  replicated  viral 
episomes to the daughter cells during host cell division by interacting with host mitotic 
chromosomes (Skiadopoulos and McBride, 1998; Florence and Faller, 2001; Dey et al., 
2003;  Van Tine et al., 2004; You et al 2004; Zheng et al., 2005; Baxter et al 2005; Dai et al, 
2006; Schweiger et al., 2006; Parish et al, 2006; Oliveira et al., 2006; Donaldson et al 
2007; Poddar et al., 2008; Poddar, 2009). The data presented in this thesis suggest that 
the E1 protein enhances E2 interaction with chromatin and therefore E1 may have a role 
in viral genome segregation. E1 may stabilise E2 and enhance its tethering function with 
the chromatin. This finding is in disagreement with a previous study. This study carried 
out in the Botchan laboratory suggested that wild type BPV1 E1 protein could relocate E2     Chapter 4: Discussion 
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from  mitotic  chromosomes  therefore  interfering  with  its  tethering  functions 
(Voitenleitner & Botchan, 2002). However these studies were carried out in BPV1 and not 
HPV16.  The  proteins that  papillomavirus  E2  uses  in  chromatin tethering  and  genome 
partitioning  vary  between  different  papillomavirus  types  (McPhillips  et  al.,  2006). 
Therefore differences between the results presented here and those reported previously 
may  be  explained  by  the  use  of  different  papillomavirus  types.  Future  work  should 
consider the E1.E2 interaction at varying points during the cell cycle using different types 
of papillomavirus. This could be achieved using fluorescence microscopy of both E1 and 
E2  proteins  and  examining  the  interaction  of  E2  with  chromatin  during  mitosis  and 
cytokinesis. E2 protein half life in the presence of E1 protein should also be examined in 
chromatin (high salt) pellets. This would confirm whether E1 stabilises E2 that is in close 
proximity to cellular chromatin.  
 
Previous studies on E2 regulation have shown that the E2 proteins of HPV16, HPV18 and 
BPV1  are  ubiquitinated  at  the  amino  terminal  and  subsequently  targeted  by  the 
proteosome for degradation (Bellanger et al., 2001; Penrose and McBride, 2000; Taylor et 
al., 2003).  E2 has a  relatively short half life and measurements from this  laboratory 
approximate it to be 45 minutes (Taylor et al., 2003). However in a natural HPV infection, 
E2 does not exist as an isolated viral protein, but it is expressed with other HPV proteins 
during  the  virus  lifecycle.  Therefore  it  is  important  to  consider  E2  turnover  in  the 
presence of other HPV proteins. Viral proteins have been previously reported to alter E2 
turnover and function. Studies have demonstrated that E4 can influence the stability and 
function of the E2 protein (Davy et al., 2009). The N terminal domain of E2 directly binds 
the HPV16 E1^E4 protein altering E2 solubility and decreasing turnover. In the presence 
of E1^E4 E2 protein becomes less soluble. Therefore the E1^E4 protein may influence E2 
activity by altering its cellular location. Through a direct interaction E2 and E6 proteins are 
both capable of regulating each other’s activity resulting in changes in E6 targeting of 
PDZ-containing  substrates  and  the  functional  activities  of  E2.  In  the  presence  of  E6, 
transcriptional activity of E2 is elevated whilst viral DNA replication is inhibited (Grm et     Chapter 4: Discussion 
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al., 2005).  The L2 capsid protein may regulate the transcriptional functions of E2 without 
affecting its ability to interact with the E1 protein during replication (Okoye et al., 2005).  
 
In this thesis the results have demonstrated that via a direct interaction, HPV16 E1 can 
regulate the stability of E2 and is also capable of enhancing E2 transcription functions. 
Previous  work  from  this  laboratory  has  shown  that  HPV16  E2  is  degraded  via  the 
proteosome following ubiquitinylation (Taylor et al., 2003). It was hypothesised that E1 
stabilises E2 by preventing its turnover via the proteosome. Brd4, a major binding protein 
for E2, binds the N terminal transactivation domain of E2 and co-localizes with E2 on 
mitotic chromosomes. Besides tethering the viral episome to mitotic chromosomes the 
E2-Brd4 interaction also plays important roles in E2 turnover. Recent studies demonstrate 
that expression of the Brd4 C terminal domain blocks the interaction between E2 and the 
cullin-3 complex of the proteosome therefore preventing E2 degradation (Zheng et al., 
2009). Tax1BP1 has been shown to interact with E2 from HPV16, HPV18 and BPV1. In 
BPV1  the  C  terminal  region  of  Tax1BP1  interacts  with  the  N  terminal  transactivation 
domain of E2. This protein functions as an essential component of an A20 ubiquitin-
editing complex (Valck et al., 1999; Shembade et al., 2007; Iha et al., 2008) and has been 
shown to plays a role in the regulation of E2 by regulating its proteasomal degradation 
(Wang et al., 2009) 
 
The work carried out in this thesis investigated some of mechanisms that may explain the 
increase in E2 stability by E1 and found it was not simply due to an increase in E2 RNA 
levels or modulation of the cell cycle (Figures 3.3.2 & 3.3.3).  It is therefore possible that 
E1  acts  in  a  similar  manner  as  Brd4  and  Tax1BP1  by  blocking  E2  degradation. 
Alternatively, additional modifications of E2 may occur following interaction with E1 that 
contribute to protein stabilisation and function. Sumoylation counteracts ubiquitinylation 
and subsequent proteasomal degradation via competition with the same lysine residue of 
substrates (Hoege et al., 2002; Bergink & Jentsch, 2009). E2 interacts with components of     Chapter 4: Discussion 
 
173 
 
the SUMO family of proteins resulting in increased E2 stability (Wu et al., 2008; Wu et al., 
2009). The SUMO conjugating protein, Ubc9 and SUMO1 have been shown to interact 
directly with E1 from BPV1, HPV11 and HPV16 although the functional consequences are 
not yet completely defined (Rangasamy and Wilson, 2000; Fradet-Turcotte et al., 2009). 
Mutational analysis of the E1 protein at serine 330 was shown to be defective for Ubc9 
interaction and this lead to a loss of replication capabilities (Yasugi et al., 1997). It is 
therefore  possible  that  the  sumoylation  of  the  E2  and  E1  proteins  is  involved  in  the 
regulation of E2 protein turnover.  E1 may recruit Ubc9 to an E1.E2 complex, therefore 
preventing E2 degradation through SUMOylation.  
 
The life cycle of HPV is closely linked with the differentiation of epithelial cells. As cells 
migrate and begin to differentiate, maintenance replication switches to amplificational 
replication, and the factors that trigger this switch are unknown. It has been shown that 
the level of E2 increases during the epithelial differentiation process (Burns et al., 2010; 
Xue et al., 2010). E2 is essential for the regulation of HPV replication therefore the factors 
that regulate E2 may ultimately be contributing to the ‘switch’ in viral replication modes. 
This report demonstrates that the regulation of E2 protein turnover should be analysed in 
the presence of E1 because these proteins are often co-expressed in the HPV life cycle. It 
will be interesting to study the mechanisms involved in E1 stabilisation of E2 as this will 
provide targets and strategies for viral life cycle intervention.  
 
4.6 E1 enhances E2 transcriptional function 
The work in this thesis also demonstrates that, via a direct interaction, E1 is capable of 
enhancing E2 transcriptional functions in 293T cells (Figure 3.4.6). There have been many 
studies involving the regulation of E2 transcription function. The E1 protein of BPV1 has 
been  shown  to  activate  and  repress  E2  transcriptional  function  (Ferran  and  McBride, 
1998; Le Moal et al., 1994; Parker et al., 2000; Sandler et al., 1993). Variation in results 
may be a consequence of the reporter plasmid/cell line used in these studies. The work in     Chapter 4: Discussion 
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this thesis supports evidence that E1 enhances E2 transcriptional function and this is in 
concordance with previous HPV studies (Piccini et al., 1995; Demeret et al., 1998). E1 is 
shown  to  enhance  E2  transcriptional  function  in  HPV16  and  HPV18  chloramphenicol 
acetyltransferase (CAT) transcription assays (Piccini et al., 1995; Demeret et al., 1998). 
Similar to transcription assays carried out in this thesis, the reporter plasmids in the HPV 
studies all contained a thymidine kinase promoter.  
 
In Figure 3.4.6 E2-mediated transcription activation is greatly stimulated by E1 to levels 
that  suggest  the  involvement  of  additional  factors.  Activation  of  thymidine  kinase 
requires the modification of chromatin. HPV18 E1 protein has been shown to activate 
transcription when targeted to DNA by fusion of the full length protein with the BPV1 E2 
C terminal dimerization/DNA binding domain (Demeret et al, 1997). This suggests that E1 
is a transcriptional activator and that it can recruit chromatin modification complexes to 
promoters. These studies highlight the close association between the mechanisms used in 
HPV replication and gene transcription.  
 
E1 may also aid E2-recruitment of cellular transcription factors. Studies involving BPV1 E1 
mediated  increased  E2  transactivation  suggest  that  when  E1  interacts  with  the  E2 
activation domain it acts as an allosteric activator and that the E1.E2 interaction may 
stabilise a particular structure of E2, increasing its transcriptional functions (Parker et al, 
2000).  E1  modification  of  E2  structure  may  mediate  the  interaction  of  E2  with 
transcriptional co-factors such as Brd4 (Lee and Chiang, 2009; You et al., 2004), BRCA1 
(Kim et al., 2003), Tax1BP1 (Wang et al., 2009), TopBP1 (Boner et al., 2002) and p300 
(Peng et al., 2000). The virus uses the host chromatin remodelling proteins to promote 
viral  transcription  (Kumar  et  al.,  2007).  E2-activated  transcription  is  enhanced  by  its 
interaction with the Brahma (Brm) containing SWI/SNF chromatin remodelling complex 
(Kumar et al., 2007). It would be interesting to investigate whether  E1 enhances this 
interaction.      Chapter 4: Discussion 
 
175 
 
 
Papillomavirus  transcription  is  controlled  by  E2  binding  sites  and  multiple  regulatory 
elements within the virus LCR. E1 mediated enhancement of E2 transcriptional function 
may be attributed to a combination of increased E2 stability, improved E2 interaction 
with  transcriptional  co-factors  and  enhanced  recruitment  of  chromatin  modification 
complexes.  The  exact  molecular  mechanisms  by  which  HPV16  E1  influences  the 
transcriptional activity of E2 are still to be identified. Future studies should aim to identify 
the substrates of the E2/E1/DNA complex. E2 interaction with transcriptional co-factors 
and chromatin modifying complexes should be investigated in the presence and absence 
of E1 using co-immunoprecipitation techniques. The E2 mutant that does not interact 
with E1 (E2 E39A) would be a useful control in determining whether E1 enhances E2 
interaction with the cellular transcription proteins.     Chapter 4: Discussion 
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4.7 Conclusions 
This thesis had three main aims identified in Chapter 1. Efforts have been made to draw 
possible conclusions to each aim and are as follows: 
 
(i) To assess HPV E1/E2 mediated replication in the presence of DNA damage and an 
activated cellular DNA damage response. 
HPV origin replication in the presence of DNA damage suggests that this may be factor 
that will contribute to viral integration. This thesis shows the ability of HPV origin plasmid 
to replicate during DNA damage and an activated DNA damage response. Future work 
should investigate HPV integration rates in the absence and presence of DNA damaging 
agents.  It  would  also  be  useful  to  look  at  the  entire  HPV  genome  replication  in  the 
presence of DNA damage. The W12 cell line is derived from human cervical keratinocytes 
grown from a CIN I lesion that expresses episomal HPV16 (Stanley et al., 1989). The use of 
these cells would allow for investigations into papillomavirus replication in response to 
DNA damage whilst in the presence of all viral proteins. The cellular factors that can cause 
DNA damage will contribute to viral integration during a HPV infection. Anti-estrogen 
therapy has been discussed as a potential cofactor for cervical cancer treatment. 
 
(ii) To identify the downstream targets of DNA damage response pathways. 
The activation of DNA damage pathways is well described in the literature however the 
downstream targets at the replication fork are less well defined. Our findings suggest that 
the SV40 LT helicase  is a substrate for ATR during DNA damage. This result supports 
evidence  that  the  MCM2-7  cellular  helicase  is  a  target  for  ATR/ATM  in  response  to 
checkpoint activation. Future work should aim to generate LT plasmids that are mutated 
at known ATR/ATM target sites. In vivo checkpoint replication assays using the mutated 
LT plasmids will identify whether activated ATR/ATM inhibits LT replication. This will be a 
useful model for studying cellular replication.     Chapter 4: Discussion 
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(iii) To assess the regulatory and functional consequences of the E1.E2 interaction. 
Papillomaviruses encode the E1 and E2 proteins to carry out replication at the viral origin 
of replication. The regulatory and functional consequences of the E1.E2 interaction are 
controversial.  The  work  in  this  thesis  supports  evidence  that  E2  stability  and 
transcriptional activation is enhanced by E1 via a direct protein-protein interaction. This 
will have consequences for E2 functions in the viral life cycle as both these proteins may 
be co-expressed. Future work should aim to determine what factors E1 uses to enhance 
E2 stability and functions as it will lead to the identification of novel therapeutic targets. 
E1 is a functional interacting partner for HPV16 E2 in DNA replication. Evidence from this 
thesis suggests that E1 regulates the association of E2 with chromatin. Therefore E1 may 
have a role in enhancing the genome segregation functions by stabilising the association 
of E2 with mitotic chromosomes. 
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